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SUMMARY
The challenge of drug discovery is the finding of potent molecules against relevant
targets that exhibit no or, in comparison to the benefit, tolerable adverse effects on
the health of patients. Costs for a new drug can be approximated to US$1 billion and
the overall process can last up to 12 years. For such a long-term investment, early
elimination of compounds with a poor outlook contributes significantly to cost and
time efficiency. Hence, it is fundamental to understand and predict pharmacological
as well as toxicological properties of potential drug candidates at early steps during
development.
After implementation of high-throughput screening in the 1990s the amount of
screened compounds per validated pharmacological target increased dramatically.
But higher throughput did not automatically result in larger numbers of new
molecular entities. A possible explanation is that current thinking and the
methodologies used in drug discovery mainly focus on equilibrium aspects of drug
binding (KD, IC50,…). In contrast, many successful drugs act in a non-equilibrium
way caused by very slow complex dissociation, covalent bond formation or based on
biochemical target properties e.g. a two-state model prolonging the binary complex
residence time. Whereas target properties are preset, the complex dissociation time
based on ligand properties is modifiable and drawing increasing interest among drug
researchers.
Despite the emerging use of techniques to determine interaction kinetics, no
consistent correlation between structural properties of ligands and kinetics was
published. This lack of knowledge complicates modification of lead structures
towards favourable kinetic properties. Currently, measuring kinetics only provides
the possibility to differentiate between e.g. slow and fast dissociating leads.
The topic of the thesis was to implement surface plasmon resonance (SPR) based
biosensors to determine equilibrium binding constants, kinetic rate constants and
enthalpic/entropic contributions of ligands binding to the myelin-associated
glycoprotein (MAG). In an interdisciplinary environment with chemists, biologists,
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NMR and molecular modelling specialists, interaction data was required to support
the finding of new leads and ligands exhibiting advanced binding properties.
The SPR-based biosensor was validated on a model system for carbohydrate/protein
interactions. A diagnostic anti-sialyl Lewisa (sLea) antibody (GSLA-2) used in tumor
diagnostic was investigated. High selectivity of GSLA-2 towards the sLea epitope
was found and a close interaction with STD-NMR finally enabled an exact
description of the binding epitope. Additionally, the influence on interactions caused
by hydrophobic labels attached to a ligand was described.
For the myelin-associated glycoprotein, comparison of several immobilization
approaches displayed specific differences important for the characterization of
drug/target interactions. On all surfaces, reproducible results were obtained in good
agreement with data from a hapten inhibition assay. Interesting though unusual was
the occurrence of negative sensorgrams on surfaces with oriented immobilization
(capturing and enzymatic). These were only observed for sialic acid derivatives, a
certain class of MAG ligands. Larger molecules like the ganglioside GT1b or second-
site ligands displayed positive signals. Supporting experiments proved the negative
signals to be specifically derived from ligand binding. The most reasonable
explanation was a ligand-induced conformational change caused by sialic acid
derivatives.
Whereas capturing led to a baseline drift, enzymatic immobilization improved the
assay format significantly. Implementation of enzymatic immobilization provided a
highly reliable technique. Practicability for very low protein concentrations (4 µg/ml)
facilitated a direct immobilization of secreted proteins out of cell culture supernatant
delivering a gentle procedure.
All sialic acid-based ligands displayed fast association and dissociation rate constants
with a complex half-life in the range of 1-2 seconds. Therefore, future search for new
leads exhibiting slower dissociation appears promising. Interactions of sialic acid
derivatives with MAG were found to be mainly enthalpy driven. A decent correlation
between structural modifications and their enthalpic/entropic contribution was found.
Furthermore, it was possible to support and even expand data published on signal
deviations related to drug-like molecules.
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The non-availability of the crystal structure of the myelin-associated glycoprotein
complicated rational ligand design but was successfully compensated by a
combination of SPR-based biosensor data, STD-NMR and homology modeling. Even
though a crystal structure would significantly simplify ligand design, a detailed
picture of the interaction process including important kinetic data could be obtained.
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ABBREVIATIONS
ADMET Absorption, Distribution, Metabolism, Elimination, Toxicity
ASGP-R Asialoglycoprotein receptor
AUC Analytical ultracentrifugation
BIA Biomolecular Interaction Analysis
BSA Bovine serum albumin
cAMP cyclic adenosine monophosphate
CD Circular dichroism
CMD Carboxymethyl dextran
DMSO Dimethyl sulfoxide
CNS Central nervous system
DRG Dorsal root ganglia
DTT Dithiothreitol
EC50 50% effective concentration
FDA Food and drug administration (U.S.)
FPLC Fast protein liquid chromatography
FTIR Fourier transform infrared spectroscopy
GDP Guanosine diphosphate
GTP Guanosine triphosphate
hAGT O6-alkylguanine-DNA-alkyltransferase
HIV Human immunodeficiency virus
HTS High-throughput screening
IC50 50% inhibition concentration
ITC Isothermal titration calorimetry
KA Equilibrium association constant
KD Equilibrium dissociation constant
Ki Inhibition constant
kon Association rate constant
koff Dissociation rate constant
Lem Lemieux spacer
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MAG Myelin-associated glycoprotein
MDI Myelin-derived inhibitor
MW Molecular weight
NC Nitrocellulose
NCE New chemical entity
NgR Nogo receptor
NME New molecular entity
NMR Nuclear magnetic resonance
Omgp Oligodendrocyte myelin glycoprotein
P20 Polysorbate-20 (Tween-20)
PAGE Polyacrlyamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PND Post-natal day
PNS Peripheral nervous system
PTM Post-translational modifications
ROCK Rho Kinase
RT Room temperature
RU Resonance units
Req Equilibrium response
Rmax Maximum response
rIP Relative inhibitory potency
SAR Structure-activity relationship
SCI Spinal cord injury
SDS Sodium dodecylsulfate
Siglec Sialic acid binding Ig-like lectin
SKR Structure-kinetics relationship
sLea Sialyl Lewisa
sLex Sialyl Lewisx
SNAP hAGT mutant
SPR Surface plasmon resonance
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STD Saturation transfer difference
TIR Total internal reflection
TNF Tumor-necrosis factor
OUTLINE
11
1 INTRODUCTION.................................................................................. 15
1.1 Drug discovery ....................................................................................... 15
1.2 Myelin-associated glycoprotein (MAG) as drug target ........................ 18
1.2.1 Signal transmission by neurons .............................................................................................18
1.2.2 Failure of axonal regeneration in adult mammalian CNS.....................................................19
1.2.3 Myelin derived inhibitors (MDI) ...........................................................................................21
1.2.4 Structure and function of MAG .............................................................................................22
1.2.5 Sialic acid specificity of MAG...............................................................................................27
1.2.6 Overview of neurite outgrowth inhibition targets .................................................................36
1.2.7 Hapten inhibition assay for ligand screening ........................................................................38
1.3 Biacore biosensors for advanced interaction analysis .......................... 40
1.3.1 Measuring biomolecular interactions in drug discovery.......................................................40
1.3.2 Biacore technology.................................................................................................................47
1.3.3 Experimental setup .................................................................................................................54
1.3.4 Immobilization of protein on biosensor surfaces ..................................................................59
1.4 Expression of target proteins................................................................. 67
1.4.1 Baculovirus infected insect cells as expression system ........................................................68
1.4.2 Mammalian cells as expression system .................................................................................69
1.5 Aim of the thesis ..................................................................................... 70
2 MATERIAL AND METHODS ............................................................. 71
2.1 GSLA-2 as a model system for carbohydrate-lectin interactions ........ 71
2.1.1 Biacore instrumentation and materials ..................................................................................71
2.1.2 Biosensor experiments with GSLA-2....................................................................................71
2.1.2.1 Immobilization of GSLA-2 with amine coupling .................................................................72
2.1.2.2 Binding assays with GSLA-2.................................................................................................72
2.2 Myelin-associated glycoprotein (MAG) as drug target ........................ 74
2.2.1 Immobilization of Fc-MAG(d1-3) with amine coupling ......................................................74
2.2.1.1 Amine coupling of Fc-MAG(d1-3)........................................................................................74
2.2.1.2 Validation of coupled Fc-MAG(d1-3)...................................................................................75
2.2.2 Immobilization of Fc-MAG(d1-3) on a protein A surface ...................................................75
2.2.2.1 Immobilization of protein A with amine coupling................................................................75
2.2.2.2 Capturing of Fc-MAG(d1-3) on the protein A surface .........................................................76
OUTLINE
12
2.2.2.3 Validation of the capturing assay...........................................................................................76
2.2.2.4 Evaluation of negative sensorgrams ......................................................................................77
2.2.2.5 DMSO tolerability..................................................................................................................78
2.2.2.6 Sialic acid derivatives.............................................................................................................79
2.2.2.7 Detailed thermodynamic analysis ..........................................................................................80
2.2.3 Ligand optimization using second site screening..................................................................82
2.2.3.1 Characterization of second generation ligands......................................................................82
2.2.3.2 Competition experiments with sialic acid derivatives ..........................................................82
2.3 Expression of MAG(d1-3)-SNAP .......................................................... 84
2.3.1 Insect cells as expression system ...........................................................................................84
2.3.1.1 Growth and culture of bacterial cells (E. coli) ......................................................................84
2.3.1.2 Preparation of competent cells...............................................................................................88
2.3.1.3 Transformation .......................................................................................................................89
2.3.1.4 Analyses for plasmid DNA ....................................................................................................89
2.3.1.5 Cloning of MAG(d1-3)  into pSS26b ....................................................................................91
2.3.1.6 Cloning of MAG(d1-3)-SNAP / SNAP into pFastBac-S......................................................96
2.3.1.7 Growth and culture of insect cells .......................................................................................100
2.3.1.8 Isolation and analysis of bacmid DNA................................................................................101
2.3.1.9 Transfection of bacmid DNA into insect cells ....................................................................102
2.3.1.10 Amplification of P1 viral stock............................................................................................103
2.3.1.11 Evaluation of insect cell lines for espression ......................................................................103
2.3.1.12 Purification of FLAG-tag Proteins ......................................................................................103
2.3.1.13 Buffer exchange and sample concentration.........................................................................104
2.3.1.14 Western blot of FLAG-tagged proteins ...............................................................................105
2.4 Mammalian cells as expression system ............................................... 106
2.4.1 Cloning of MAG(d1-3) into pcDNAIII-SNAP ...................................................................109
2.5 Enzymatic immobilization ................................................................... 113
2.5.1 Evaluation of immobilization conditions ............................................................................113
2.5.1.1 Testing of different SNAP substrates ..................................................................................113
2.5.1.2 Testing of different SNAP concentrations...........................................................................113
2.5.1.3 Testing of different substrate immobilization times ...........................................................114
2.5.1.4 Preparation of a BG-PEG12 sensor chip...............................................................................115
2.5.1.5 Comparison of SNAP and MAG(d1-3)-SNAP ...................................................................115
2.5.1.6 MAG(d1-3)-SNAP expressed in mammalian cells .............................................................116
3 RESULTS AND DISCUSSION ........................................................... 117
OUTLINE
13
3.1 GSLA-2 as a model system for carbohydrate/lectin interactions....... 117
3.1.1 Biosensor experiments with GSLA-2..................................................................................117
3.1.1.1 Immobilization of GSLA-2 with amine coupling ...............................................................117
3.1.1.2 Binding assays with GSLA-2...............................................................................................119
3.2 Myelin-associated glycoprotein (MAG) as drug target ...................... 124
3.2.1 Amine coupling of Fc-MAG(d1-3)......................................................................................125
3.2.1.1 Immobilization of Fc-MAG(d1-3).......................................................................................126
3.2.1.2 Validation of coupled Fc-MAG(d1-3).................................................................................128
3.2.2 Immobilization of Fc-MAG(d1-3) on a protein A surface .................................................131
3.2.2.1 Immobilization of protein A with amine coupling..............................................................131
3.2.2.2 Capturing of Fc-MAG(d1-3) on the protein A surface .......................................................132
3.2.2.3 Validation of captured MAG)..............................................................................................132
3.2.2.4 Evaluation of negative sensorgrams ....................................................................................138
3.2.2.5 DMSO tolerability................................................................................................................141
3.2.2.6 Sialic acid derivatives...........................................................................................................142
3.2.2.7 Detailed thermodynamic analysis ........................................................................................151
3.2.3 Ligand optimization using second site screening................................................................161
3.2.3.1 Characterization of second generation ligands....................................................................162
3.2.3.2 Competition experiments with sialic acid derivatives ........................................................167
3.3 Expression of MAG(d1-3)-SNAP ........................................................ 169
3.3.1 Insect cells as expression system .........................................................................................171
3.3.1.1 Cloning of MAG(d1-3) into pSS26b ...................................................................................171
3.3.1.2 Cloning of MAG(d1-3)-SNAP / SNAP into pFastBac-S....................................................173
3.3.1.3 Isolation and analysis of bacmid DNA................................................................................174
3.3.1.4 Evaluation of insect cell lines for Expression .....................................................................175
3.3.1.5 Purification of FLAG-tag Proteins ......................................................................................176
3.3.2 Mammalian cells as expression system ...............................................................................177
3.3.2.1 Cloning of SNAP into pcDNAIII-Strep ..............................................................................177
3.3.2.2 Cloning of MAG(d1-3) into pcDNAIII-SNAP ...................................................................178
3.4 Enzymatic immobilization ................................................................... 180
3.4.1 Evaluation of immobilization conditions ............................................................................181
3.4.1.1 Testing of different SNAP substrates ..................................................................................181
3.4.1.2 Testing of different SNAP concentrations...........................................................................185
3.4.1.3 Testing of different substrate immobilization times ...........................................................186
3.4.1.4 Comparison of SNAP and MAG(d1-3)-SNAP ...................................................................188
OUTLINE
14
3.4.1.5 MAG(d1-3)-SNAP expressed in mammalian cells .............................................................192
4 CONCLUSIONS AND OUTLOOK.................................................... 194
5 LITERATURE..................................................................................... 201
INTRODUCTION
15
1 INTRODUCTION
1.1 Drug discovery
Drug discovery is a challenging and extensive process. In the development of a
successful drug, specialists from numerous areas (pharmacology, biology, chemistry,
medicine, computational sciences, system engineering, marketing,...) are involved. In
a multidisciplinary process, they all have to focus on one goal, a potent and safe drug
that finally creates a return on investment. Pharmaceutical companies worldwide
spend $ 50 billion per year on the drug discovery process.1 The entire development
for one final drug costs approximately $ 800 million. Lately, especially safety issues
requested by the regulatory authorities have substantially grown.2 If successful, the
drug turns out to be a blockbuster, representing a yearly turnover of $ 1 billion.
Considering the human body with all of its still unknown biochemical pathways,
construction of a drug that fulfils today’s safety guidelines provides an explanation
for such high cost. Furthermore, pharmaceutical companies try to avoid unexpected
side effects in the post-marketing phase to prevent huge compensation payments and
a loss of image by voluntary safety efforts. Due to the relation “the safer, the costly”
expenditures on drugs continue to rise to estimated worldwide drug sales of US $570
billion in 2007.3
Traditional drug discovery can be structured in 5 major steps (figure 1).
Figure 1. The drug discovery process on a progression scale from early target finding to clinical trials in men.
The process is rather circular then linear where failure leads to a return to an earlier step.
Target
Validation
Lead
Discovery
Lead
Optimization
Pharmako-
kinetics
Clinical
Studies
Toxicology
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First a target is identified and validated. Targets are considered defined mediators of
biochemical processes that influence pathophysiological functions like proteins,
nucleic acids, lipids or carbohydrates.
Key questions for target validation include:
• Is there a medical need?
• Is there a market worth the investment?
• Is the target fundamental for the pathological outcome?
• Is the target drugable? Druggability can be described as the existance of
protein folds that favour interactions with drug-like chemical compounds.4,5
• Who are the competitors and how far are their projects developed?
After target validation, small molecules are explored. Usually, high-throughput
methods are applied to screen huge libraries.6 In a subsequent optimization process
medicinal chemists modulate leads towards higher binding affinity and drug-like
properties.7-9 Along with affinity, selectivity for the target is a major task. To avoid
unwanted drug actions, the compound should only affect the target at clinically
relevant concentrations. Finally, after pharmacokinetic and toxicological studies,
clinical trials are conducted in men. These steps are not defined sharply and the
process between target validation and clinical trials is rather iterative than linear.
As indicated, reliable information on in vivo efficacy and safety are of huge interest
already at early stages. Therefore, today’s lead selection criteria should include safety
as much as potency and efficacy. In order to prevent failure in later steps e.g. clinical
trials an accurate prediction of these parameters is needed.
When planning a new drug discovery project, success is most likely with a G-protein-
coupled receptor (GPCR), a nuclear receptor or an ion channel as a target. More than
50% of all FDA approved drugs act on these classes even though there are many
other protein families (figure 2).1
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Figure 2. Analysis of the gene-family distribution of current drugs per drug target.1
But why is that? One interesting hypothesis focuses on current methods of interaction
analysis. The major statement is that the binary ligand/target residence time
influences drug success significantly. A detailed explanation is provided in 1.3.1.
Summing up, the major challenge of drug discovery is to discover potent drugs
against relevant targets that exhibit no or, in comparison to the benefit, tolerable
adverse effects on the health of patients. Early safety and efficacy predictions for
drug candidates are a major concern of pharmaceutical companies.
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1.2 Myelin-associated glycoprotein (MAG) as drug target
1.2.1 Signal transmission by neurons
Neurons are a major class of cells in the nervous system. Their main role is to process
and transmit information. Morphologically, a prototypical neuron is composed of a
cell body, a dendritic tree and an axon (figure 3). In the classical view of the neuron,
the cell body and dendritic tree receive inputs from other neurons, and the axon
transmits output signals.
Figure 3. Shape of a neuron containing myelin sheets wrapped around the axon allowing rapid signal
transduction
In the central nervous system (CNS) and peripheral nervous system (PNS), many
axons are wrapped concentrically and tightly by a multilamellar sheath of myelin
(figure 3 and 4), which is produced by oligodendrocytes in the CNS and Schwann
cell in the PNS.10 The myelin behaves as an insulator and is essential for rapid nerve
conduction, as evidenced by debilitating demyelinating diseases in the CNS and PNS
such as multiple sclerosis and the Guillain Barré syndrome.11 The myelin sheath is
interrupted regularly by the nodes of Ranvier that are small, unmyelinated regions of
axons (figure 4).
Axon wrapped by myelin sheets
Cell body Dendritic treeNodes of Ranvier
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Figure 4. Axon wrapped with myelin sheets.
In the axonal membrane at these nodes, voltage-gated sodium channels are highly
concentrated, thus allowing for the saltatory propagation of the action potential down
the length of myelinated axons (figure 5-A).12 The rapid impulse conduction that
results from the focal position of sodium channels along the axon has facilitated the
evolution of complex nervous system.
1.2.2 Failure of axonal regeneration in adult mammalian CNS
In contrast to the PNS and the embryonic CNS, regeneration of the adult brain and
spinal cord after lesions is extremely limited. Damage to the CNS of higher
vertebrates, including humans, often results in devastating and persistent functional
deficits. Therefore, patients with spinal cord injuries (SCI) or neurodegenerative
diseases like Alzheimer and multiple sclerosis suffer permanently from the loss in,
e.g. movement, body functions, sensation, and thinking. In the case of SCI, only a
controversial option of pharmacotherapeutic treatment is available and the need for
effective drugs is obvious.13 According to the American Association of Neurological
Surgeons, approximately 34,000 new spinal cord injuries in the major pharmaceutical
markets occur each year. In the U.S., related costs are estimated to $14.5 billion per
year.14
Although injured axons can sprout spontaneously, this regeneration attempt is
transitory and no significant re-growth occurs over long distances.15 However, this
failure is not due to an intrinsic or irreversible lack of the ability of the CNS neurons
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to regenerate, but rather to the non-permissive nature of the CNS environment.16 This
was demonstrated by studies where many types of CNS neurons extended long axons
either by grafting pieces of peripheral nerves onto a lesion site,17,18 or by isolating
neurons and growing them in culture.19 Furthermore, neurons such as dorsal root
ganglia (DRG) possess axons in both the CNS and PNS, but can only regenerate
peripheral damage. Unlike the Schwann cells in the PNS, oligodendrocytes continue
to express myelin proteins, including inhibitors, after injury and they do not engulf
myelin debris. Such an inhibitory environment is considered being a summary of
several factors. A lack of neurotrophic factors, a glial scar and inhibitory proteins
within myelin debris were described to play a significant role.
The glial scar appears as a physical barrier against axon outgrowth that is formed by
reactive astrocytes and extracellular matrix molecules such as chondroitine sulphate
proteoglycans (figure 5-C).20 In addition, these scar-associated proteoglycans were
revealed to be potent inhibitors of axon growth in vitro themselves.21 The glial scar
was found to mature within weeks depending on location but can be regarded as the
final step in prohibiting nerve regeneration.22-24 Nevertheless, directly after a lesion,
lack of neurotrophic factors and presence of myelin-derived inhibitors (MDIs) seem
to be accountable for the major impediment of neurite outgrowth (figure 5-B).
Therefore, inhibition of MDIs and/or administration of neurotrophic factors are
assumed to induce neurite outgrowth in vivo before maturation of the glial scar.
Combination therapies for successful treatment of SCI and neurodegenerative
diseases appear promising.
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Figure 5. Lesion of a functional neuron and its subsequent inhibition states that are responsible for neurite
outgrowth inhibition: A functional neuron transmits the signal via its nodes of Ranvier (A). After lesion, an
inhibitory environment at the site of the rupture limits neurite outgrowth (B). Finally, reactive astrocytes create
a physical barrier that prohibits any future outgrowth (C).
1.2.3 Myelin derived inhibitors (MDI)
The three major MDIs were described to be the myelin-associated glycoprotein
(MAG), the oligodendrocyte myelin glycoprotein (Omgp) and Nogo (table 1).
Table 1. Myelin derived inhibitors (MDI) present at the site of lesion.
MDI Source Axonal receptor
NogoA Residual myelin NgR family
Omgp Residual myelin NgR family
MAG Residual myelin NgR family
Gangliosides
functional
lesioned
blocked
A
B
C
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Nogo was the first MDI reported in literature. It was identified as an antigen to an
antibody (IN-1) that was isolated due to its ability to neutralize myelin based neurite
outgrowth inhibition in vivo.15,25-27 Three isoforms of Nogo (Nogo-A, -B and -C) are
generated by alternative splicing and promoter usage. Nogo consists of two inhibitory
domains: a unique amino-terminal region (amino-Nogo) on Nogo-A and a 66 amino
acid loop (Nogo-66) that is common to all three variants.28
The second inhibitor, oligodendrocyte myelin glycoprotein (Omgp), is a glycosyl
phosphatidylinositol GPI-anchored protein that contains a leucine-rich repeat (LRR)
domain.29 Omgp is found in the CNS as well as in the PNS.30
The third MDI is the myelin-associated glycoprotein (MAG) that is located in both
CNS and PNS like Omgp.
1.2.4 Structure and function of MAG
MAG belongs to the family of the I-type lectins. These are carbohydrate-binding
proteins within the immunoglobulin superfamily that are determined by their IgSF-
like amino acid sequence.31,32 The selective binding of sialylated carbohydrate
structures by MAG further places it into the Siglec (sialic acid binding Ig-like lectin)
subfamily.33 A few other IgSF member lectins have been identified that recognize
non-sialylated carbohydrate structures like PECAM, ICAM-1, N-CAM and CD48.
Within the group of Siglecs, several members have been depicted and numbered
sequentially (table 2).34 All Siglecs share common features like an N-terminal
variable type domain (v-type) and one or more constant type domains (c-type) that
are located extracellularly and a transmembrane domain. Most Siglecs function as
signal transduction molecules and occur predominately within the immune system.
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Table 2. Human siglecs with its alternative names and the tissue distribution.34
Siglec Alternative name Tissue/Cell type distribution
Siglec-1 Sialoadhesin Macrophages in spleen, lymph nodes,
and bone marrow
Siglec-2 CD22 B cells
Siglec-3 CD33 Myeloid cell lineage
Siglec-4 MAG Peripheral and central nerve system
Siglec-5 CD33-related Granulocytes and monocytes
Siglec-6 CD33-related B cells
Siglec-7 CD33-related NK cells and monocytes
Siglec-8 CD33-related Eosinophils
Siglec-9 CD33-related Granulocytes and monocytes
Siglec-10 CD33-related B cells, eosinophiles and monocytes
Siglec-11 CD33-related Macrophages
The cluster of differentiation (CD) is used for the identification of cell surface molecules on leukocytes. CD33-
related Siglecs share two conserved immunoreceptor tyrosine-based inhibitory motif.
MAG is a 100 kDa integral membrane protein comprising five extracellular Ig-like
domains with 8 or 9 potential glycosylation sites.35,36 The carbohydrate moiety
represents approximately 30% of the entire molecular weight of MAG.37 The first N-
terminal Ig domain is of a variable (v)-type and domains 2-5 are of homologous
constant (c)-type (figure 6). MAG represents 1% and 0.1% of the total myelin protein
in the CNS and PNS, respectively, and it is mostly located in the inner loop in the
CNS.38,39 As the result of alternative splicing, two isoforms of MAG, S- and L-MAG,
are produced, differing only by their cytoplasmatic domain.40
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Figure 6. Structure of MAG with the extracellular N-terminal v-type domain and the subsequent four c-type
domains. The first two N-terminal domains fold towards each other building an interdomain disulfide bridge.
Recent studies have shed light on the function and structure of the cytoplasmatic
domains of MAG (MAGct). The S-MAGct has a random coil structure in solution.41
It binds zinc, which induces a change in the surface hydrophobicity of the protein,42
but apparently, no folding occurs upon Zn binding.41 It is likely that the main function
of the S-MAGct is related to interactions with the Schwann cell microtubular
cytoskeleton, and that an unfolded structure is essential for these interactions.
Secondary structure predictions and circular dichroism measurements of synthetic
peptides indicate that the L-MAGct, on the other hand, probably folds into a structure
containing both helices and sheets.43 Evidence also exists on a tendency of L-MAGct
to homodimerise, which may be important in myelin-related signal transduction
C-terminus
N-terminus
extracellular part
intracellular part
v-type domain 1
c-type domains 2-5
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events. MAG is exclusively expressed by myelinating glial cells specifically
oligodendrocytes in the CNS and Schwann cells in the PNS.44
One interesting feature of MAG is its bi-functionality that is similar to other axon
guidance molecules.45,46 When cultured on MAG-expressing DRG neurons older than
post-natal day 4 (PND4), neurites extended shorter than when cultured on control
cells. In contrast, MAG promoted neurite outgrowth from DRG neurons from animals
younger than PND4. The response switch, which is also observed in retinal ganglia
and Raphe nucleus neurons, is concomitant with a development decrease in the
endogenous neuronal cAMP levels.47 It was shown, that artificially increased cAMP
levels in older neurons before spinal cut can alter their growth-state and induce
axonal growth even in the presence of MDIs. Both cAMP analogous and priming
with neurotropic factors to increase cAMP levels promoted axonal regeneration after
lesion.48,49
For MAG, a subsequent signalling cascade needed to be involved to transfer the
outgrowth inhibition signal into the neuron. In search for such a cascade, it was found
that neurons from a p75NTR-knockout mouse displayed no inhibition of neurite
outgrowth even though a direct interaction between MAG and p75NTR was absent.50
The p75NTR is a member of the tumor-necrosis factor (TNF) receptor family involved
in apoptosis. In additional experiments, p75NTR was precipitated by all three MDIs
(MAG, Nogo-66 and Omgp) and the Nogo receptor (NgR) was present in the
precipitate of each.51,52 It was concluded that all MDIs interact with the glycosyl-
phosphatidylinositol-anchored (GPI-anchored) NgR to elicit inhibition of neurite
outgrowth. Because NgR contains no transmembrane domain, signal-transduction is
elicited via the co-receptor p75NTR. Additionally, stimulation of the Rho-ROCK
pathway by such formed trimeric receptor complexes was described.50,52
Even before these receptor complexes were known, members of the Rho family of
small GTPas proteins had been implicated in myelin’s inhibitory effects.53
RhoGTPases, a subfamily of the Ras superfamily of GTPases, function as molecular
devices that control multiple signalling pathways in a very precise and coordinated
way by switching between a biochemically inactive (GDP-bound) and a active (GTP-
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bound) state.54,55 In the active, GTP-bound state, RhoGTPases activate numerous
downstream effectors like the Rho Kinase (ROCK).
ROCK is a serine/threonine (Ser/Thr) protein kinase that was identified about ten
years ago as a RhoGTP-binding protein.56,57 A variety of evidence indicated that
injury to brain and spinal cord results in a strongly activated RhoA-ROCK
pathway.58-61 Inhibition of ROCK by three different molecules (fasudil, Y-27632 and
p21CIP1/WAF1) enhanced nerve-fibre growth in mouse and rat spinal-cord injury
models.62-66.
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1.2.5 Sialic acid specificity of MAG
MAG was depicted to specifically bind to sialo-glycoproteins and sialo-glycolipids
(gangliosides), preferably when the sialic acid residue is attached by a α(2,3)-O
linkage.33 Nerve cell surface gangliosides like GD1a and GT1b were identified as such
specific ligands (figure 7).67-70
Figure 7: Molecular structure of the major two brain gangliosides GD1a (A) and GT1b (B).
Interestingly, MAG-mediated neurite outgrowth inhibition was reversed by blocking
ganglioside biosynthesis.67 In addition, nerve cells from mice lacking complex
gangliosides weren’t inhibited by MAG. This was strong evidence for an additional
inhibitory cascade based on such a ganglioside/MAG interaction.
The sialic acid binding site on MAG was mapped to Arg118 by mutation studies.71 In
a soluble form of mutated MAG, sialic acid binding capacity as well as its ability to
inhibit neurite outgrowth was completely lost (figure 8-B). Hence, the ganglioside
binding site must be located in the N-teminal (Ig)-like v-domain of MAG.
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Figure 8. Neurons were grown on a neurite promoting substrate and soluble wild-type or mutated Fc-MAG
was added. Soluble Fc-MAG(d1-3) inhibited outgrowth by 50% (A). Mutation of Arg118 to alanine or aspartic
acid (B) abolished inhibition completely.71
Interestingly, Arg118-mutated MAG presented to neurons through expression on
CHO cells showed no loss of inhibitory potential (figure 9-B). These contradictory
results where explained by compensation of lost sialic acid binding activity by other
cell adhesion molecules (CAMs) on the cell surface.16
Figure 9: MAG was expressed on CHO cells as wild-type or mutated (R118A, R118D). Neurite outgrowth
was inhibited though the sialic acid binding site was absent in the mutated MAG.71
Surprisingly, other experiments showed that clustering of gangliosides by antibodies
led to activation of Rho and subsequent outgrowth inhibition even without
A B
A B
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involvement of MAG or NgR.50,67,72,73 Probably this was due to a direct interaction of
GT1b and p75NTR. Binding to gangliosides like GD1a and GT1b is likely to potentate and
augment the inhibitory effects of MAG by inducing clustering of the signalling
molecules.16 It is possible that gangliosides clusters act as MAG receptors where
direct MAG/ganglioside interaction finally activates the Rho-ROCK cascade.74 In
general, such clusters of carbohydrate epitopes were shown to mediate cell adhesion
and/or signal transduction and are referred to as glycosynapses.75
Moreover, the found neurite outgrowth inhibition of Arg118-mutated MAG led to the
conclusion that an additional inhibition site must be present. This observation was in
agreement with the discovered NgR inhibition cascade.76,77
Figure 10. Absence of the extracellular domains 4 and 5 resulted in complete elimination of the inhibitory
potency of MAG. Therefore, the sialic acid independent inhibition site must be located in these domains.71
Due to the fact that soluble truncated MAG (N-terminal domains 1-3) bound to
neurons in a sialic acid–dependent manner, but only full-length MAG inhibited
neurite outgrowth, the NgR binding site on MAG must be located on the 4th and 5th
Ig-like domain (figure 10).
The importance of gangliosides for neurite outgrowth inhibition was further
underlined by in vivo experiments. Treatment with a sialidase enhanced spinal axon
outgrowth into implanted peripheral nerve grafts in a rat model of brachial plexus
avulsion.78 Besides, it was noticed that cleavage of Omgp and Nogo receptors did not
result in beneficial regeneration. Outgrowth inhibition was therefore stated to be
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primarily MAG mediated. Gangliosides were also shown to contribute to the long-
term axon-myelin stability.79 An exact picture of the function of MAG and the
physiological importance of ganglioside binding is still missing. High affinity
inhibitors for the sialic acid binding site are required to clarify the function and
pharmacological relevance of MAG.
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The entire inhibition cascade of MDIs including both the NgR and the ganglioside
cascade is summarized in figure 11.
Figure 11 (by courtesy of A. Vögtli): Simplified cascade of neurite outgrowth inhibition caused by myelin-
derived inhibitors. Activation of two different pathways joins up into a final growth cone collapse.
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The specificity of MAG towards different gangliosides was analyzed at an early
stage.70,80 Adhesion of MAG transfected COS cells to wells coated with different
gangliosides were studied. In these experiments it was found that the Chol-1
ganglioside GQ1bα exhibited the highest affinity followed by the two major brain
gangliosides GD1a and GT1b (figure 12). Chol-1 gangliosides are quantitatively minor
structures that are expressed exclusively on cholinergic neurons.81,82 The functional
significance of GQ1bα for MAG is still unclear.
Figure 12. Ganglioside binding specificity of MAG. High affinity is observed for the major brain gangliosides
GT1b and GD1a.
The higher affinity of GQ1bα compared to GT1b or GD1a must be derived from the
α(2,6)-O-linked sialic acid moiety. The structure activity relationship (SAR) profile
was further refined by numerous synthetic contributions dealing with neuraminic acid
derivatives and ganglioside fragments.68,83-85 These results led to the identification of
Neu5Ac-α(2→3)Gal-β(1→3)[Neu5Ac-α(2→6)]GalNAc as the major carbohydrate
binding epitope (figure 13-A). Moreover, the terminal α(2,3)-linked sialic acid was
described to contribute significantly to binding to MAG. Several important functional
groups were identified (figure 13-B) e.g. the carboxylic group that was known to
interact with Arg118 on MAG.
GD1a: Cer
GT1b:
Cer
GQ1bα: Cer 4 pmol/well
30 pmol/well
30 pmol/well
CerGM3: no adhesion
Key:
     Glucose                GalNac
     Galactose             2,3-Sialic acid
     2,6-Sialic acid       2,8-Sialic acid
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Figure 13. Carbohydrate binding epitope of MAG (A) and the α(2,3)-linked sialic acid with its contributing
functional groups highlighted in purple (B).
In figure 14 the α(2,3)-linked sialic acid of GT1b that was found to contribute
significantly to binding is highlighted in red.
Figure 14: GT1b with its terminal α(2,3)-linked sialic acid highlighted in red. This sialic acid moiety is mainly
responsible for MAG binding.
On the carbohydrate epitope, STD-NMR experiments revealed a number of
hydrophobic contacts (figure 15). A strong interaction was found for the methyl
moiety on N-Ac of the α(2,3)-linked sialic acid.
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Figure 15. STD-NMR signals obtained for the carbohydrate binding epitope of MAG (unpublished results).
Structure-activity relationship (SAR) studies were aggravated by the fact that no
crystal structure of MAG was available. For analysis of the binding mode a
homology model based on sialoadhesin (Siglec-1) co-crystallized with methyl 9-
benzamido-9-deoxy-Neu5Ac was available (unpublished results).
Recently, ligands based on the described carbohydrate epitope were tested for their
ability to reverse MAG mediated inhibition of axon outgrowth from rat cerebellar
granule neurons in vitro. Interestingly, these ligands enhanced axon regeneration in
proportion to their MAG binding affinities.86 Axon outgrowth was significantly
enhanced after addition of high affinity ligands (figure 16-B) compared to untreated
neurons (figure 16-A). The highest inhibition potency was found for the binding
epitope Neu5Ac-α(2,3)Gal-β(1,3)[Neu5Ac-α(2,6)]GalNAc (table 3).
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Table 3. Correlation of axon outgrowth with MAG binding affinity.86
These findings encourage further exploration of carbohydrate mimics as potential
MAG inhibitors. Especially the α(2,3)-linked sialic acid seemed to be optimal as lead
structure due to its low molecular weight (262.47 g/mol) and the structure activity
relationship (SAR) revealed. Unfortunately, no in vivo results for such mimetics were
available.
A B
Figure 16. Axon outgrowth monitored for
neurons without addition of MAG ligands (A)
and with 10 µM ligand 3 present (B).
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1.2.6 Overview of neurite outgrowth inhibition targets
After revealing parts of the inhibition cascade, the range of possible therapeutic
strategies for the treatment of spinal cord injury and related diseases broadened
significantly (table 4). On several targets promising progresses were achieved
whereas others have drawn little interest.
A first success story is Cethrin, a rho GTPase antagonist invented by BioAxone
Therapeutic. In December 2005, Cethrin was approved orphan drug status by the
FDA for treatment of acute thoracic and cervical spinal cord injuries.
Table 4. Overview of potential targets for the development of a spinal cord injury treatment.
Target Strategy Company
(compound)
Ref
MAG Block interaction with NgR GlaxoSmithKline
(mAB)
87,88
Nogo Block interaction with NgR Novartis
(mAB IN-1)
15,89,90
Omgp Block interaction with NgR - -
NgR Block interaction with MDIs Biogen 91
Rho Inhibit GTPase activity BioAxone
(Cethrin)
FDA approval
ROCK Inhibit Kinase activity Asahi Kasei
(Fasudil)
62-65,66
cAMP level Block Phosphodiesterase 4 Meiji Seika Kaisha
(Rolipram)
see below
cAMP level cAMP analogues see below
cAMP level adenylyl cyclase activator forskolin see below
As described, elevation of cAMP levels was shown to overcome inhibition of MAG
and myelin. An increase is either achieved by injection of cAMP analogues, adenylyl
cyclase activator (forskolin), phosphodiesterase inhibitors or neurotrophines.48,49
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Rolipram, a phosphodiesterase 4 (PDE4) inhibitor was shown to surmount inhibition
by MAG and myelin in culture. Additionally, neurons from animals treated with
rolipram were nott inhibited for various periods by MAG or myelin, indicating a
post-lesion effect. Importantly, when rolipram was delivered 2 weeks after a
hemisection lesion, along with embryonic spinal cord tissue implanted at the injury
site at the time of lesion, there was not only a significant increase in axon growth and
in functional recovery, but also an attenuation of the glial scar.
Rolipram was developed as an antidepressant and was used in clinical trials but
because of side effects (emesis, nausea) in some patients, the trials were stopped. It
has also been shown to exhibit immunosuppressive and anti-inflammatory effects.
However, treatment of depression requires long-term administration. For spinal cord
injuries, rolipram may only need to be delivered for a limited period of time, during
which time side effects would be tolerable. A further attraction of rolipram for
treating spinal cord injury is that it readily crosses the blood-brain barrier. Therefore,
subcutaneous delivery would avoid intervention at the site of injury.92
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1.2.7 Hapten inhibition assay for ligand screening
The affinity of MAG ligands was predominately determined in a hapten inhibition
assay.68 A microtiter plate, pre-coated with sialic acid (figure 18-A), is incubated with
a ligand (figure 18-B). In general, an Fc-MAG(d1-3) construct (figure 17-B)
containing the three N-terminal extracellular domains of MAG was employed. The
crystallizable fragment (Fc region) is part of an antibody composed of two heavy
chains that each contributes two to three constant domains, depending on the class of
the antibody (figure 17-A).93
Figure 17. The Fc and Fab fragments of antibodies (A). The Fc-MAG(d1-3) construct is composed by the Fc
fragment and two MAG(d1-3) domains (B).
Fc-MAG(d1-3) (figure 17-B) and a polyclonal goat anti-human IgG antibody coupled
to an alkaline phosphatase are added to the wells. The Fc-MAG(d1-3) and the
polyclonal antibody form a complex as indicated in figure 18-C. Binding of the
ligand to MAG will inhibit binding of Fc-MAG(d1-3) to the sialic acids on the plate
competitively (figure 18-D). Ligand affinity will therefore be correlated with the
amount of Fc-MAG(d1-3) bound to the plate. Afterwards, unbound Fc-MAG(d1-3) is
removed by washing (figure 18-E). The amount of Fc-MAG(d1-3) is then detected by
addition of substrate for the alkaline phosphatase to the wells.
A B
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Figure 18. Setup of the hapten inhibition assay: Sialic acids bound to the surface are displayed in orange (A)
and the ligand measured in blue (B). The Fc-MAG(d1-3) and a polyclonal goat anti-human IgG antibody
coupled to an alkaline phosphatase are added to the wells (C). The higher the ligand affinity the less Fc-
MAG(d1-3) binds to the surface (D). After washing (E), a fluorescent substrate is added to the wells and the
amount of bound MAG is determined (F).
A B
C D
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1.3 Biacore biosensors for advanced interaction analysis
1.3.1 Measuring biomolecular interactions in drug discovery
For pharmaceutical companies it is fundamental to understand pharmacological as
well as toxicological properties of potential drug candidates at early stages of
development. Besides, such molecules should preferably be orally available. In
general, the later task is partly accomplished by taking the Lipinski rules of five into
account.9,94 This finally allows administration of the drug as a solid formulation like a
tablet what is considered economically beneficial due to simple administration and
storage.
To cope with the demand for potent drugs without adverse effects no general rule is
applicable. At least in the case of toxicity, problematic chemical structures e.g. nitro-
group are known and can be avoided. In a traditional drug discovery process, a large
set of small molecules (300 Da) is screened against a validated target to discover new
leads compounds. The process is well known as high throughput screening (HTS) and
is carried out in a static assay format.6 High affinity is employed as selection criteria
for new lead structures.95 Unfortunately, testing increasing numbers of compounds at
faster and faster rates did not turn out to be as productive as anticipated.96
Lead compounds should preferably be of lower molecular complexity97, have a
smaller number of rings and rotatable bonds98, a lower MW and be more polar99 than
actual drugs. Afterwards, medicinal chemists increase affinity by adding and/or
exchanging functional groups on such lead molecules based on 3-dimensional
informations on the target e.g. x-ray based. The process is known as structure-based
drug-design.100 Finally, in vivo experiments and clinical trials are carried out with
drug candidates. Failure at this late state is economically undesired and much effort is
conducted to avoid such loses.
In biological systems representing open systems, levels of physiological ligands
change within milliseconds via rapid release and clearance. Consequently,
equilibrium with receptors or enzymes is often not reached. Besides, drug
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concentrations vary over time if not applied intravenously. In such an environment,
the kinetics of interactions ought to play an important role.
Structure-based drug design is typically developed in a competitive mode were a
molecule has to compete with a physiological ligand or substrate. Unfortunately,
accumulation of substrate or ligand can diminish efficacy and potency of competitive
inhibitors or antagonists.101 Based on this finding, David C. Swinney stated that the
biochemical mechanism of drug action has to be taken into account to avoid failure.
His hypothesis was that most effective drugs utilize non-equilibrium transitions to
enhance activity (table 5). These can either be based on the drug (covalent bond
formation, very slow dissociation) or the target (two-step model). In a two-step
model, an initial equilibrium binding event is followed by a transition to an non-
equilibrium system. Receptors displaying such a mechanism include GPCRs, ion
channels and nuclear receptors that are targets for 50% of all drugs approved by the
U.S. food and drug administration (FDA).1 The success of drug research seems to be
dependent on the mentioned biochemical mechanism and the ability to select based
on the mechanisms.
The importance of the biochemical mechanism of drug action can already be derived
from two famous statements. Paul Ehrlich stated that a substance would not work
unless it is bound “Corpora non agunt nisi fixata”. This is in close agreement with
the above mentioned biochemical mechanism. Even earlier, Paracelsus postulated
that alone dosage makes the poison “Sola dosis facit venenum”. Prolonged drug-
target dissociation times enable dosage reduction what is an effective gain for drug
safety.
Swinneys hypothesis was further supported by biosensor studies where biological
potency was better described by the dissociation rate constant than by equilibrium
binding affinity.102,103
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Table 5. Successful drugs and its non-equilibrium mechanisms of drug action.101
Drug Target Mechanism koff
Aspirin COX-1 Irreversible Irreversible
Omeprazole H+, K+ ATPase Irreversible Irreversible
Clavulanic acid β-lactamase Irreversible Irreversible
Rivastigmine Acetylcholinesterase Pseudo-Irreversible > 48 h
Candesartane AT-2-receptor Insurmountable 112 min
Deslortadine H1 receptor Insurmountable > 6 h
Verapamil Ca2+ channel Use-dependent 0.25 s
Casodex Androgen Receptor Induced degradation -
Copeland et al. further discussed the biochemical mechanism with an emphasis on
kinetic behaviour of drugs.104 They proposed that one of the most crucial factors for
sustained drug efficacy in vivo is not the apparent affinity of the drug for its target per
se, but rather the residence time of the drug molecule on its molecular target. The
residence time is defined as the binary complex residence time meaning the period
for which the receptor is occupied by the drug. It is only dependent on the drug/target
complex dissociation. Therefore, they agreed with Swinney on the importance of
including kinetic data, especially on the residence time, into drug discovery
decisions.
On the other hand, safety issues were elucidated by kinetic data of drugs. In the case
of roxifian, slow dissociation was shown to be the reason for severe
thrombocytopaenia.105,106 In some cases, however, there might be a temporal
distinction between desired effect and toxicity, such that rapid binding and
dissociation of a ligand results in the desired pharmacology, whereas sustained
residence leads to adverse effects. This has been suggested for D2 receptor blockers
that act as atypical antipsychotics.107 It was found that a rapid dissociation rate was
the only feature to distinguish between typical and atypical antipsychotic drugs.
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Concluding, high affinity in a static assay as a validation tool for drug candidates
might therefore not be sufficient to predict potency and safety. Hence, techniques that
provide information about biochemical mechanisms e.g. kinetics have great potential
for drug discovery.
SPR-based biosensors enable determination of kinetic parameters and have been in
use for over 20 years. The technique is mainly provided by Biacore AB (GE
healthcare) and has revolutionized the field of binding analysis. It is nowadays
commonly applied in research and pharmaceutical industry.108 In the pharmaceutical
industry it is mostly used as a secondary screen for validation of HTS hits.
The technique is surface-based, meaning that one interaction partner is immobilized
on a solid support. For drug discovery, a target protein usually has to be immobilized
to screen ligands. A disadvantage is that immobilization could lead to restrictions in
rotational freedom and accessibility of the protein, which can finally influence
binding parameters e.g. affinity and kinetics.109 Even though many HTS assays are
surface-based, this led to scepticism against the biosensor technique at first.
Therefore, several attempts were conducted to prove its comparability to solution-
based assay formats. It was demonstrated that kinetic, binding equilibrium and
thermodynamic results were in close agreement with methods like isothermal titration
calorimetry (ITC), analytical ultracentrifugation (AUC) and stopped-flow
fluorescence (SFF).110-112 Moreover, a high degree of reproducibility was observed in
studies with multiple users.112,113 Although these comparison studies led to positive
results, the most critical step for surface-based techniques remains to be
immobilization. All comparison studies where performed with carbonic anhydrase II
and results are likely to deviate for other proteins. Hence, the assay setup has to be
designed properly for all surface-based methods.
To finally implement kinetic data into the drug development process, the influence of
structural properties on kinetics, structure kinetics relationship (SKR), has to be
elucidated. Rules, how to retard dissociation, would simplify a yet iterative process.
Unfortunately, no such general rules are available though attempts were conducted to
clarify the situation.114,115 Probably, the relative importance of the association and
dissociation rates is a unique property of a certain drug target. Nevertheless, a
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selection of human immunodeficiency virus (HIV) 1 protease inhibitors displayed
kinetic differences (figure 19) based on their core structures.103,116,117 While a slow
association rate could be compensated by higher concentrations, slow dissociation
rates must be achieved by optimizing the ligand. For drug development, these
findings are of substantial importance. Kinetic data obtained in a first screening
would allow lead selection based on dissociation behaviour.
Figure 19. A kon, koff scatter plot of HIV protease inhibitors displaying the clustering of core structures.
Additional biosensor studies with HIV-1 protease inhibitors revealed fascinating
details on the interaction processes and underlined its specific advantages.
Thermodynamic analyses were performed with selected compounds.118 It was
possible to disclose the entropic and enthalpic influence on the association as well as
the dissociation rate. In this case, the energy barrier for complex formation was
dominated by large association enthalpy changes whereas for dissociation equal
contributions were found. Experiments with HIV-1 protease mutants, known to
mediate clinical drug resistance, revealed that resistance correlated with faster
complex dissociation.119,120 Other experiments indicated that association and
dissociation rates were influenced differently by pH changes.121 Combining these
results increases the understanding of the interaction process between HIV-1 protease
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and its inhibitors significantly. Knowledge about energy barriers of association and
dissociation phases and drug resistance are likely to become of great value for
pharmaceutical companies.
Analyses of conformational changes of proteins were reported as an additional
feature of SPR-based biosensors. It was found that unfolding or a change from
compact helical to extended structures like β–sheets decreased the signal
intensity.122,123 For ligand-induced conformational changes, a decrease of signal
intensity for maltose binding protein and an increase for human cytomegalovirus
protease were described.124,125 In the case of receptors, transduction of a physiological
signal upon ligand binding is predominately elicited via a conformational change.
The possibility to screen for such conformational changes would allow differentiating
between agonists (appropriate changes) and antagonists (no or inappropriate
changes).
Beside the SPR-based biosensor technique, a wide range of methods is available to
determine parameters like affinity, kinetics and thermodynamics of biomolecular
interactions (table 6). They all possess their specific advantages and disadvantages.
Technique specific artefacts might occur and therefore validation of obtained results
with other methods is highly recommended. Hence, other techniques should not be
considered competitive but rather complementary to such biosensors. Only a
combination of results from different methods will provide an accurate description of
the interaction process.
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Table 6. Techniques to characterize lead or drug/target interactions.
Affinity Kinetics ΔH, ΔS Stochio-
metry
Conf.
changes
Label
free
Epitope
mapping
SPR √ √ √ (√) (√) √
CD √ √ √
ITC √ √ √ √
MPA √ (√)
NMR √ √ √
MS √ (√) √ √
SFS √ √ √
AUC √ √ √ √
DPI √ √ √ √ √
CD: circular dichroism, ITC: isothermal titration calorimetry, MPA: microtiter plate assay, SFS: stopped-flow
spectroscopy, AUC: analytical ultra-centrifugation, AFM: atomic force microscopy, DPI: dual polarization
interferometry
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1.3.2 Biacore technology
The detection principle of Biacore is based on a phenomenon called surface plasmon
resonance (SPR). It arises as an electron charge density wave that was first described
in the late 1950s.126 Around 30 years later Pharmacia Biosensor AB launched a
commercially available SPR detection system. The company had a close relation to
the pharmaceutical industry what was represented in the company name. In 1996, the
the name was changed into Biacore AB and finally it was merged with GE healthcare
in 2006.
The SPR-phenomenon is based on total internal reflection (TIR), an evanescence
electric field (E), and surface plasmon waves. A light beam that propagates through
two non-absorbing media of different refractive index will be totally reflected at the
interface when exceeding a critical incidence angle (Θ). The reflected light beam
keeps its net energy upon reflection but an electric field intensity called evanescence
wave (E) leaks into the medium of lower refractive index. The amplitude of the
evanescent wave decreases exponentially with distance from the surface, and the
effective penetration depth is about half the wavelength of the incident light.127 By
usage of a thin metal film at the interface, surface plasmons are excited when the
p-polarized component of the evanescence field penetrates this layer. This results in
an enhancing of the evanescent wave. Surface plasmons are waves of oscillating
surface charge densities in a conducting metal and are equivalent to photons in the
case of light. A non-magnetic metal like gold is normally used for these layers.128-130
Since both photons and surface plasmons are a form of electromagnetic energy, they
can be fully described only by quantum physics. However, their properties can be
explained in a simplified manner as vector quantities. The light photon momentum at
the interface can be resolved into two vector components (parallel and perpendicular
to the interface). The magnitude of these incident light vectors (ilv) directly depends
on the light angle. The surface plasmon wave can be similarly described as a vector,
which depends on a number of factors (metal properties, layer thickness, surrounding
media). Resonance occurs only when the energy and momentum of the incident light
vector corresponds to the one of the surface plasmon vector (spv). In this case, the
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energy is converted from photons into plasmons what consequently leads to a drop in
the intensity of the reflected light (figure 20-D). Under non-resonance conditions no
such conversion arises and the light is fully reflected (figure 20-C).
Figure 20 (by courtesy of D. Ricklin). Principles of SPR. A: Total internal reflection (solid line) and
refraction (dashed line) of a light beam in dependence of the incidence angle Θ at the interface of two different
media (n1, n2). B: Evanescence field wave (E) leaking through a thin metal film (m). C, D: SPR in the gold
surface. If the incident light vectors (ilv) have another value than the surface plasmon vector (spv) light is fully
reflected (C). Only a specific angle leads to a matching of the two vectors and a resulting resonance (D).
In an experimental setup, metal nature and thickness as well as the properties of one
medium are kept constant. Resonance conditions are therefore only dependent of the
angle of the incident light and the refractive index of the second medium. Therefore,
refractive index changes in the second medium can be monitored by adjusting the
incident light angle until a dip in light intensity (resonance) is detectable.128-130
For Biacore experiments, sensor chips that carry a thin gold layer (50 nm) on a glass
support are applied. The gold surface is in direct contact with a flow cell and a prism
follows the glass side. A monochromatic, p-polarized light beam at a wavelength of
760 nm is focused in a wedge on the gold surface and the total internal reflection for
all angles is monitored on a diode array. The described evanescence field wave
penetrates into the flow cell and enables detection of the refractive index to a distance
of about 700 nm from the surface.
Biomolecular interaction measurements with SPR are based on the fact that binding
of molecules to the surface alters the refractive index. Such a change is recorded as a
change in the incidence light angle and converted into a response signal (figure 21).
The response signal is measured in resonance units (RU) that correspond to a shift in
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the resonance angle of approximately 10-4 °.129 Since the mass of the molecules
directly influences the refractive index, SPR biosensors are often referred to as mass
detectors. Such a correlation between sensor signal and mass increase was
experimentally determined for proteins (Equation 1).131
1 RU = 1 pg/mm2 Equation 1
This correlation is almost constant for molecules with high protein and low lipid and
carbohydrate content.129 The relationship can be extrapolated to other molecules such
as nucleic acids, carbohydrates, lipids or conjugate molecules. Hence, binding of
nearly all molecules to the sensor chip can be detected though sensitivity is likely to
vary for different types of ligands.130 On the other side, sensitivity is dependent on the
distance from the surface due to the exponential decay of the evanescent wave.
Consequently, distribution of the molecules within the matrix will influence signal
intensity. Additional, effects occurring around the interface, e.g. electrostatic
attraction or conformational changes, will further influence signals.132
Figure 21 (by courtesy of D. Ricklin). Detection of biomolecular interaction by SPR. A, B: Sensor surface
before and after interaction of two molecules. C: Shift of light intensity dip upon interaction.
In a typical Biacore experiment, one binding partner e.g. a receptor is immobilized on
the sensor chip and the other is injected. A direct surface-attachment of e.g. proteins
to a solid (gold) support often leads to loss in biological activity and a potential for
unspecific binding events. To overcome this problem, a special surface chemistry was
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developed involving a ‘protecting polymer’, which carries functional groups to
simplify immobilization. On commercially available biosensor chips, thiolated
carboxymethyl dextran chains are directly attached to the gold surface via the sulfur
atom. This provides a hydrophilic environment and immobilized biomolecules are
kept in a quasi-solvent environment.133 Especially for labile proteins such
physiological conditions increase stability. Inclusion of carboxyl groups in the
dextran matrix enables immobilization via well-defined chemistry. To suppress
electrostatic artefacts in experiments caused by remaining carboxyl groups and
sample contaminants routine addition of salts e.g. 150 mM NaCl to the buffer is
performed.129 Other reagents such as EDTA or polysorbate are highly recommended
to further limit non-specific signals. A schematic overview of the entire experimental
setup is visualized in figure 22.
Figure 22 (by courtesy of A. Vögtli). Schematic overview of the experimental setup of the Biacore 3000.
Precise sample delivery is conducted by the integrated fluidic cartridge (IFC). Binding of a ligand to an
immobilized target is monitored in real-time by the SPR-based detection system.
In stationary systems, mass transport of molecules to the surface is governed by
diffusion and convection processes. To ensure reliable results, incubation times of
several hours are necessary, which is not suitable for real-time systems. A flow
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system in a micro-flow cell offers a continuous transport of sample to and from the
surface, what minimizes diffusion and convection effects. Therefore, an integrated
fluidic cartridge was developed which reduced sample consumption and sample plug
dispersion after injection.129
As described, the shift in resonance angle is monitored in real-time and plotted in
dependence of time. In such a signal versus time plot, called sensorgram, the different
stages of a binding event are visualized (figure 23). Running buffer flowing over the
surface leads to a stable baseline. During continuous injection of sample, ligand binds
to the target in a distinct association phase (figure 23-A). Already at that stage,
dissociation occurs and influences the shape of the curve. Depending on the ligand,
steady state is reached after a specific injection time, where binding and dissociating
molecules are in equilibrium (figure 23-B). As soon as the injection is stopped,
running buffer flows over the surface and the pure dissociation phase becomes visible
(figure 23-C). In case of very slow dissociation, a regeneration step might be required
to remove all ligand and reach the baseline (figure 23-D).
Figure 23 (by courtesy of A. Vögtli). A typical sensorgram obtained for a standard interaction measurement.
Ligand from a sample starts to bind to the target (A) until a steady state is reached (B). After changing to pure
buffer, dissociation of the ligand is visible (C). In case of remaining ligand a subsequent regeneration step is
required (D)
A
B
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Kinetic parameters like the association and dissociation rate constants (kon, koff) are
derived from the sensorgram. The equilibrium dissociation constant (KD) can be
directly calculated from the kinetic rate constants using equation 2 or from steady
state signals at different concentrations using a saturation binding plot. Steady state
affinity is calculated based on equation 3, where Req is the equilibrium response
signal, KA is the equilibrium association constant, C the concentration, Rmax the
maximum possible response, and n a steric interference factor.
€ 
KD =
koff
kon
   [M]   and   
€ 
KA =
kon
koff
 [M-1| [Equation 2]
€ 
Req =
KA ⋅C ⋅Rmax
1+ KA ⋅C ⋅ n
   [RU] [Equation 3]
The effect of different kinetics on sensorgrams can easily be displayed by an in silico
experiment where eight concentrations (200 – 0.25 µM) of four virtual compounds
(A-D) are injected. Even though the affinity (KD) is identical (table 7), a clear kinetic
difference is visible in the sensorgrams (figure 24).
Table 7. Data describing the virtual compounds A, B, C and D.
Compound KD (µM) kon (M-1•s-1) koff (s-1)
A 10 10000 0.1
B 10 1000 0.01
C 10 500 0.005
D 10 100 0.001
For compound B, C and D, a steady state affinity analysis is already complicated
because steady state for the lower concentrations is not reached within injection time.
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Figure 24. Importance of kinetics demonstrated by a simulation with four virtual compounds (A, B, C and D)
all displaying a KD of 10 µM.
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1.3.3 Experimental setup
As mentioned, one of the interacting molecules has to be fixed on a sensor chip
surface. The immobilized molecule is named target and the free one is referred to as
ligand (figure 25). This nomenclature deviates from the original one introduced by
Biacore but is convenient for pharmaceutical purposes, where different compounds
(ligands) are screened against a defined target.
Figure 25. Experimental setup of a Biacore experiment. A target is immobilized onto a biosensor chip and a
ligand is injected.
In general, it is recommended to plan experiments in a way that a simple 1:1-binding
event is obtained. Therefore, multivalent binding partners should preferably be
immobilized on the chip. A careful selection of the immobilization method is
necessary and comparison of several strategies might be beneficial (see p. 58). In the
case of proteins, the immobilized amount can be estimated by the relationship that 1
RU corresponds approximately to a surface concentration of 1 pg/mm2.
For binding studies, the maximum response for a SPR signal can be approximated
using equation 4. Because the relation is only exact for proteins, calculated Rmax
values for other molecules e.g. carbohydrates or drug-like molecules will deviate.
Target
Ligand
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€ 
Rmax =
MWanalyte
MWt arg et
⋅ densityt arg et ⋅valency [Equation 4]
Drug discovery applications often require immobilization of the larger molecule
(receptor, enzyme, etc.). Small ligands (300-500 Da) are then screened resulting in
low signal intensity due to the somehow mass dependency. Several 1000 RU of
immobilized target protein result in Rmax values of around 10-100 RU and partial
deactivation further decreases the intensity. Molecules down to a molecular weight of
100 Da and a Rmax value of 1 RU were measured on Biacore S51 successfully.134
Even binding of Ca2+ was determined under special circumstances where potential
conformational changes were involved.125 If necessary, signal intensity problems with
small ligands can be circumvented by several approaches.
• By attaching the low molecular weight molecule to the surface, the protein itself
can be injected resulting in large signals. Unfortunately, protein consumption is
high and for each ligand a new surface has to be prepared. To immobilize such
molecules, a clear picture of the binding mode is needed to define the attachment
site.
• A competitive assay format provides another solution. First, usage of a high
molecular weight competitor can enhance the signal.135 Second, a standard
competitor can be immobilized and the small molecule is injected together with
the protein. Again high protein consumption complicates its usage.136
Nevertheless, both formats allow screening of several small molecules on the
same surface. For competition experiments, determination of association and
dissociation rate constants is complicated due to overlaying kinetics. A
competitor with a slow association rate needs longer injection times to establish
equilibrium.
Both the direct and the competition assays are sensitive to non-specific binding due to
the detection principle. While all three formats are suitable for ranking experiments,
only the direct assay can provide equilibrium and kinetic data of high-quality.133
As with all surface-based analysis methods, mass transport is a complicating factor.137
This phenomenon might occur when the interaction between ligand and target is
comparable or faster than the diffusion of ligand from bulk solution to the surface.
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Mass transport is dependent on the flow rate, cell dimensions, diffusion coefficient
and surface capacity.138,139 For a given ligand, only the variation of flow rate and the
surface capacity is possible. High flow rates (50-100 µl/min) at low surface densities
are recommended for the reduction of mass transport limitation. However, the flow
rate is often limited by the sample consumption or the required injection time. In
addition, the influence is relatively small since km is proportional to the square root of
the flow rate.127 Experimental series with variation of surface density and flow rate
could therefore be helpful for the detection of such effects and for finding a suitable
compromise between sample consumption, signal intensity and mass transport.140
The Biacore 3000 allows precise temperature variation between 4 and 40 °C. Hence,
determination of entropy and enthalpy by applying a van’t Hoff plot is possible.118
Furthermore, DMSO is tolerated up to 8% in a continuous experiment. This is
especially important when dealing with drug-like molecules where lipophilicity
(logP) is in the range of 2-5. In contrast to other buffer systems does the addition of
DMSO require a special calibration.141
In order to clean all parts of the injection system and to equilibrate the surface, a
series of pure buffer should be injected before each experiment.142 Injections of such
buffer blanks before and within binding experiment, inclusion of positive and
negative controls, washing steps, as well as a proper maintenance further increase the
accuracy and quality of the binding data.143 Sample injection should be done in a
randomized way and in replicates to eliminate the total experimental noise.
Regeneration is a critical step in a binding assay, especially when dealing with
proteins. While too soft conditions might lead to remaining ligand, too harsh
conditions can denature the protein. For strong interactions, a cocktail of different
regeneration solutions might be necessary. Approaches for the development of proper
regeneration conditions are described in literature.144
Evaluation and interpretation of obtained sensorgrams is another critical step. A huge
amount of published data is unreliable due to poor quality and processing.145 Proper
data treatment is especially important when measuring low molecular weight ligands.
Deviations from an expected binding model are often caused by poor experimental
design, low purity of ligands and/or target heterogeneity. Unfortunately, such data
can often be fitted to a more complex binding model.140 Therefore, critical parameters
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like sample purity should be verified before claiming a new binding mode or an
additional binding pocket.
Because every sample solution will cause a signal in comparison to the running
buffer, subtraction of a proper reference flow cell is needed. A reference flow cell
should mimic the target flow cell as close as possible. Equal amounts of target with
an inactivated binding site would represent an optimal reference. In general, equal
amounts of inert proteins or just a blank surface are employed. In addition, injections
of buffer blanks over the target flow cell cause small deviations from the reference
and should be included. Subtraction of blanks and a reference flow cell assure high
data quality and is termed double referencing.142
As explained, assay design should be kept easy and data should first be fitted to a
simple 1:1-binding model (Equation 5). Since some targets possess more than one
binding site, the equation has to be extended to a two independent binding site model.
If mass transport effects are suspected or reported, a mass transport coefficient (km)
might be introduced (Equation 6).
A + B ABkonkoff  [Equation 5]
A0 A + B AB
km
km
kon
koff [Equation 6]
A proper data processing is especially important for fitting kinetic data. Initially,
different algorithms using curve transformation146 or nonlinear least squares
analysis147 were used to evaluate binding kinetics. These methods only fitted single
binding curves (or even portions thereof) and were found to be insufficient to
distinguish between different binding mechanisms.140 In the global analysis approach,
the association and dissociation phases of the entire data set are fitted to a model
simultaneously, resulting in very accurate and robust data.148 Therefore, this method
is implemented in the current evaluation software tools and should always be used for
kinetic fits.
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Software for data treatment and evaluation is available from Biacore (Biaevaluation).
As a major drawback only a limited number of sensorgrams (24) can be fitted with
older versions (Version 4.1) and handling is rather user-unfriendly. This gap was
filled by Scrubber (BioLogic Software), a tool for the determination of affinity and,
in the recent version 2.0, even kinetics. Data treatment is straightforward and larger
numbers of curves e.g. from triplicate measurements can be fitted directly. Therefore,
Scrubber is highly recommended where no newer software is available. For kinetic
evaluations a software named Clamp is another possibility but rather difficult to
handle.149
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1.3.4 Immobilization of protein on biosensor surfaces
Protein immobilization is one of the most crucial steps in a Biacore experiment. Loss
of partial or entire target activity, changes in ligand affinity and many other artefacts
are directly related to unfavourable immobilization. The standard CM5 sensor chip
from Biacore contains a glass slide with a thin gold layer (50 nm) that is covered with
a carboxymethylated dextran with a dimension of 100 nm under physiological
conditions. Introduced carboxy groups on the dextran chains permit covalent
immobilization of proteins, oligosaccharides, nucleotides, or small molecules.
In general, immobilization strategies can be divided into four major groups150 (figure
26) whereof A and D are typically applied in Biacore binding assays.
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Figure. 26: Strategies for the immobilization of proteins onto solid supports. Differences are based on
orientation and linkage.150
Random, non-covalent coupling approaches (C) are typically used in microtiter plate
assays (MPA). Proteins are adsorbed randomly on coated surfaces via ionic or
hydrophobic interaction. No control of protein orientation is possible and therefore
these assays are susceptible to artefacts. In addition, such reactive surfaces need to be
protected by “inert” proteins. Bovine serum albumin (BSA) is routinely applied but,
as known by all pharmacologists, BSA is by far not inert.151
Random, covalent coupling approaches (A) usually generate stable surfaces with high
density. Functional groups e.g. amine, hydroxy or carboxy groups present on targets
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are utilised to form covalent bonds. Immobilization occurs at multiple attachment
sites e.g. lysines and therefore lead to randomized attachment which might results in
a loss of activity due to direct modification of residues in the binding site, steric
hindrance, conformational changes or surface heterogeneity. However, if a specific
functional group is available at a defined location of the target, site-specific coupling
enables generation of an oriented, homogeneous surface.
Amine coupling is routinely applied for immobilization of proteins due to the high
availability of amine groups. The amine coupling procedure makes use of the primary
amine groups on the protein surface (lysine residues and the N-terminus). A direct
reaction of amine groups with active esters generated by N-hydroxysuccinimide
(NHS)/ 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is the chemical basis
(figure 27). In order to increase efficiency of the reaction, proteins are concentrated in
the dextrane matrix. By lowering the pH of the immobilization buffer just below the
pI of the protein, surface attraction is optimized. Amine groups become positively
charged and get attracted by the negatively charged carboxyl group in the matrix.
Because the reaction will only occur with uncharged amines, the immobilization pH
should not be too low.152 A careful evaluation of pH and protein concentration is
needed to optimize the attraction.
Nearly all proteins and peptides possess multiple primary amine groups, which are
often surface-exposed due to their hydrophilicity. Furthermore, amine groups are
easily introduced artificially on molecules. In the case of proteins, lysines are often
randomly distributed over the surface and amine coupling will result in a random and
non-predictable immobilization of the protein (figure 28-A). It sometimes leads to a
massive decrease of surface activity, e.g. more than 80% loss is reported for some
antibodies, and this might also influence binding affinity and kinetics.153 Analysis of
the amino acid sequence, crystal structure and especially the binding site are
recommended to avoid interference. Another drawback is the usage of acidic
conditions for surface attraction. Acid labile proteins will result in inactive surfaces.
Yoshitani et al. demonstrated that surface attraction can be circumvented by higher
concentrations of target protein (2 mg/ml).154
Additionally, several popular buffer systems like Tris bearing primary amines are
forbidden. Sodium azide, which is frequently used as a preservative in protein
preparations, might also interfere and should consequently be removed.155 Even
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though there are several drawbacks, amine coupling still is the most frequent used
immobilization technique.
Figure 27: Coupling methods for Biacore sensor chip CM5. After activation of the matrix-based carboxyl
groups (A) by NHS and EDC (B), targets can directly be immobilized via primary amine groups (C) or the
surface can be functionalized for alternative strategies. (NHS = N-hydroxysuccinimide,, EDC = 1-ethyl-3-
(3-dimethylaminopropyl)-carbodiimide.
Thiol groups and sugar moieties present on the target are additional possible sites for
a linkage. Immobilization of thiol-bearing targets can be performed either by
formation of disulfide bridges or by covalent reactions with maleimides. Thiol groups
occur rarely compared to primary amines and therefore these approaches might lead
to a more site-directed and oriented immobilization of the target. However, since the
spontaneous formation of disulfides is thermodynamically not favoured, activation of
the thiol group either on the chip surface or in the target is needed.156 In the case of
proteins, all kind of chemical treatments are a potential source for artefacts.
Capturing (D) approaches (figure 28-B) make use of a specific biomolecular
interaction between the target and an immobilized capturing molecule. The approach
is based on non-covalent protein/protein or protein/small molecule interactions. Such
interaction systems are often utilized in biochemistry for affinity chromatography and
are therefore frequently available.
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Figure 28: Target orientation after different coupling procedures. Randomized covalent immobilization (A)
compared to a capturing approach (B). Sites of covalent attachment are marked with a star.
Capturing can be used for oriented coupling, since binding occurs at a well-defined
site of the target. Three major coupling classes can be defined: antibody-antigen
systems, interactions between proteins and naturally occurring binding sites e.g.
Protein A/IgG and capturing of artificially introduced affinity tags e.g. FLAG-tag.
Whereas naturally occurring binding sites are unproblematic, introduction of an
artificial affinity tag has the potential to alter activity of the actual protein.
A common disadvantage of all capturing approaches is their non-covalent character.
Whereas affinity purification is feasible in the µM range, creation of stable sensor
surfaces is difficult. At least low nM affinity or a multivalent capturing system is
needed for proper immobilization. Captured surfaces often show a certain degree of
bleeding (surface decay). For ligands with low signal intensities, strong bleeding can
significantly influence data quality. As an advantage, captured surface can be
regenerated by direct elution of the target. Thus, capturing is an advantage for
unstable target proteins on one side and ligands that are not regenerative on the other.
The deactivated protein is eluted but the stable capturing systems (protein A,
antibodies) can be re-used what will significantly reduce the amount of sensor chips
needed.
A B
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Covalent and site-specific immobilization (B) is the optimal procedure for a Biacore
experiment. Interesting new techniques were described based on bioengineering. One
approach avails a small enzyme based on the human DNA repair protein O6-
alkylguanine-DNA-alkyltransferase (hAGT) and is commercially available as a
mutant thereof (SNAP-tag).157,158 A second attempt utilizes a trans-splicing
mechanism of Split-Inteins.159 For both strategies, target preparation includes cloning
and expression to incorporate the actual immobilization system. Due to labour intense
preparations, these applications are rarely observed.
The SNAP-tag is a novel tool for protein research, allowing the specific, covalent
attachment of virtually any molecule to a protein of interest. The SNAP-tag is a small
enzyme based on the human DNA repair protein O6-alkylguanine-DNA-
alkyltransferase (hAGT). The hAGT is a suicide enzyme. It transfers the alkyl group
from its substrate, O6-alkylguanine-DNA, to one of its cystein residues. After the
reaction, the substrate remains covalently bound to the enzyme. For immobilization
of a target protein via SNAP-tag, the target gene is cloned into a plasmid containing
the SNAP-tag gene. For Biacore binding assays, the substrate BG-(PEG)3-NH2 is
coupled to a CM5 sensor chip by standard amine coupling (figure 29-A). After
expression, the fusion protein is immobilized enzymatically onto the derivatized
surface via the active thiol group of the SNAP-tag (figure 29-B).
It was shown that surfaces displaying these substrates result in the selective
immobilisation of hAGT fusion proteins.157 No significant reactivity against proteins
other than hAGT was observed. Immobilization was completely specific enabling
immobilization without time-consuming purification steps. By using the SNAP-tag
without the target protein, a perfect reference flow cell can be obtained.
SNAP-tag was shown to provide additional advantages for Biacore binding assays.
Cyclophilin D as a fusion protein with hAGT was successfully immobilized onto
such modified surfaces.158 The method was compared to direct amine coupling.
Immobilization of the cyclophilin D-hAGT was performed under physiological pH
and ionic strength. High immobilization rates were obtained with higher density of
immobilized substrate. At any immobilization level, the fusion protein exhibited
higher relative binding activity than cyclophilin D immobilized via amine coupling.
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A 100% relative activity was achieved at low immobilization levels of the cyclophilin
D-hAGT. Only 70% relative activity was the maximum reached when coupling
cyclophilin D directly via its amine groups. Even though the technique was shown to
be advantageous and is commercially available, only two Biacore publications are
available up to now.
Figure 29. Enzymatic immobilization: First the substrate is immobilized via standard amine coupling (A).
Afterwards the enzymatic reaction is performed (B) linking the target protein covalently to the sensor chip (C).
The SNAP-tag was successfully expressed in a variety of expression systems
including bacteria, yeast, insect and mammalian cell lines. Beside immobilization, the
SNAP-tag can be used for many other applications like FRET-assays, protein
imaging (detection, internalization, translocation) and flow cytometry.
Recently, an approach based on protein trans-splicing was shown to be useful for
immobilization on solid supports.159 The naturally occurring DnaE intein from
synechocystis sp., an intein self-processing domain that is split into two fragments
(N-intein and C-intein), was used. The two intein fragments are inactive individually
but under appropriate conditions they can bind to each other and form a functional
protein-splicing domain. This leads to trans-splicing where the intein domains are cut
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out and the ends are joined. For immobilization, the target DNA sequence is fused to
the N-intein sequence.  The C-intein fragment is coupled to the surface via a
PEGylated peptide-linker and the N-intein construct is added. After trans-splicing,
the target is directly immobilized via the linker. An advantage of the described
technology, comparing to the SNAP-tag, is the absence of a remaining protein part
needed for immobilization. Such a remaining part could be a source for non-specific
binding. Because the technology has not yet been applied on Biacore, the suitability
remains to be proven.
Concluding, every strategy possesses its specific advantages and disadvantages (table
8). For every target, the immobilization procedure should therefore be selected
carefully.
Table 8. Comparison of strategies typically applied for biosensor experiments.
A B D
Site-specific No Yes Yes
Stable Yes Yes No
Physiological conditions No/Yes Yes Yes
Surface Capacity High Medium Medium
Labour intensity Low High Medium
Controllability Low High Medium
Regenerative No No Yes
While the standard CM5 sensor chip is suitable for most applications, some
experiments require modifications of the matrix chemistry or a pre-coated capturing
structure. Biacore therefore offers a selection of sensor chip with alternative surface
coatings to extend the possible applications or to reduce experimental artefacts (table
9).
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Table 9. Available sensor chip surfaces from Biacore with their surface modification and principal
applications.156
Chip Type Application / Improvement
CM5 normal carboxymethyl dextran general purpose
CM4 lower carboxymethylation reduced non-specific binding
CM3 shorter dextran matrix large molecules
C1 flat carboxyl (no dextran matrix) dextran interference (e.g. lectins)
SA immobilized streptavidin biotinlyated molecules (e.g. RNA)
NTA immobilized nitrilotriacetic acid histidine-tagged proteins
L1 lipophilic groups on dextran liposomes, bilayers
HPA flat hydrophobic surface lipid monolayers
Au plain gold surface custom design
In general, there are no restrictions for immobilization strategies as long as they do
not interfere with the interaction mode. By using a plain gold surface a wide range of
opportunities are available to create a chip of everybody’s own imagination.
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1.4 Expression of target proteins
For biomolecular interaction analyses the target proteins have to be available in high
quantities. Today, expression of proteins has become a routine technique. This is
mainly based on two Nobel Prices: 1978 Nobel Prize in Medicine for the discovery of
restriction endonucleases (Werner Arber, Daniel Nathans and Hamilton Smith) and
1993 Nobel Prize in Chemistry for the discovery of the polymerase chain reaction
(PCR) (Kary Mullis). Combination of those techniques enabled amplification and
precise insertion of a gene of interest into a vector. Such vectors are used for
transportation into a second organism for subsequent protein expression.160 The entire
process is referred to as cloning.
Often, proteins need to be tailored (truncated or mutated) to obtain solubility or to
evaluate binding domains and active sites. Besides, recombinant proteins are
produced where the original DNA sequence is fused with another sequence to obtain
artificial proteins with special properties. To express wild type, truncated, mutated or
recombinant proteins, a wide selection of different systems is available.
Predominately used organisms are mammalian cells, baculovirus infected insect cells
and bacterial cells like E. coli or yeast.161 Very interesting developments are cell-free
expression systems, where the production machinery of cells is used in an in vitro
setup.162
Using eukaryotic cells for eukaryotic genes can be particularly important in obtaining
biologically active proteins. Nevertheless, every system exhibits specific advantages
and disadvantages that have to be assessed. An especially important process for
protein expression is the posttranslational modification (PTM). Attachment of
biochemical groups e.g. acetate, carbohydrates or enzymatic cleavage/folding
functionalize proteins by modifying amino acids or by making structural changes e.g.
disulfide bridges formation. Often, extensive PTM is required to obtain a functional
protein.161
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1.4.1 Baculovirus infected insect cells as expression system
The baculovirus infected insect cell expression system provides a eukaryotic
environment that is generally conductive to the proper folding, disulfide bond
formation, oligomerization, and post-translational modifications required for the
biological activity of some eukaryotic proteins. Post-translational modifications that
have been reported to occur in baculovirus-infected insect cells include signal
cleavage, proteolytic cleavage, N-glycosylation, O -glycosylation, acylation,
amidation, phosphorylation, prenylation and carboxylation. The sites of such
modifications are usually at identical positions on the proteins produced in insect and
mammalian cells. The precise nature of some of the post-translational modifications
observed in insect cells, however, differs from those in mammalian cells, usually in
subtle ways. Nevertheless, the insect baculovirus expression system mimics a
vertebrate cell system quite remarkably with regard to protein post-translational
modification. For genes encoding glycosylated and secreted proteins, there is a
greater likelihood of obtaining biologically active products in the baculovirus
expression vector system than in prokaryotic expression system.163
The most distinguishing feature of baculovirus expression vectors is the potential for
very strong expression of a heterologous gene. Most heterologous proteins are
produced at levels ranging from 10 mg to 100 mg per 109 cells. In the cases where
different eukaryotic expression systems have been compared, the baculovirus system
has usually outperformed the other expression systems in overall protein production.
Insect cells are generally not anchorage dependent and can therefore be propagated in
suspension culture as well as adherent. In addition, serum-free suspension culturing
allows large-scale production with easy purification. Due to the above mentioned
advantages, the use for recombinant protein production is rapidly growing.164
Different cells are used for infection and expression. The most common cell line is
sf9, a clonal isolate, derived from Spodoptera frugiperda (fall armyworm) ovarian
cells. It is used for transient or stable expression of recombinant proteins and for
baculovirus propagation and is well characterized. For secreted proteins, High Five™
(H5) cells were described to be beneficial in terms of recovered protein amounts. H5
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cells are a clonal isolate, derived from the parental Trichopulsia ni cell line and are
commonly used for the expression of recombinant proteins using the Baculovirus
Expression Vector System (BEVS).163
1.4.2 Mammalian cells as expression system
Expression in mammalian cells is considered the standard approach for human
proteins, because only mammalian cells enable the entire spectrum of post-
translational modifications.
The gene of interest is cloned into a suitable vector and transfected into appropriate
cells to obtain transient protein expression. In such an approach the DNA is not
incorporated into the genome but transcribed efficiently inside the cell. Transient
expression usually leads to high amounts of protein in only short time. Obtained
protein can then be examined in preliminary activity assays to evaluate the suitability
of the expression system.161
In case of active protein, establishment of stable clones is needed. There the gene is
incorporated into the genome and clones expressing the protein are selected via a
specific selection marker (antibiotics or vital substrates). Usage of high
concentrations of e.g. antibiotics allows selection of clones with superior
incorporation of the gene and consequently high protein expression.
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1.5 Aim of the thesis
The key goal of the MAG-project at the Institute of Molecular Pharmacy is to
identify, synthesize and pharmacodynamically and pharmacokinetically characterize
high affinity antagonists of MAG. Such antagonists would provide a tool to evaluate
the still uncertain physiological function of MAG in in vitro/in vivo models. These
antagonists could also be used as lead structures for a subsequent drug discovery
effort. Therefore, work is focused on the synthesis and the elucidation of SAR of
carbohydrate substructures and mimics binding to MAG.
For the characterization of drug/target interactions, assays are required that deliver
accurate affinity data in reasonable time. Moreover, a detailed analysis including
kinetic rate constants and entropy/enthalpy is needed to understand the process and
predict potency. Gained knowledge allows the design of new structural modifications
of ligands with advanced drug properties.
SPR-based biosensor technology provided by Biacore is a suitable tool for the
mentioned tasks. Kinetic and thermodynamic data are acquired in a reproducible way
without time-consuming and result-interfering labeling. Due to its surface-based
nature, special considerations are necessary, particularly when immobilizing proteins.
Aim of the thesis was to implement Biacore technology into the ligand optimization
process on MAG. Of great importance was the possibility to measure kinetics,
enthalpy and entropy of interactions.
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2 MATERIAL AND METHODS
2.1 GSLA-2 as a model system for carbohydrate-lectin interactions
2.1.1 Biacore instrumentation and materials
Biomolecular interaction analyses were performed on a Biacore 3000 surface
plasmon resonance based optical biosensor (Biacore AB, Sweden). Sensor chips,
immobilization kits, maintenance supply and standard buffers were purchased from
Biacore AB. Standard buffers included HBS-N (10 mM HEPES, 150 mM NaCl, pH
7.4), HBS-P (HBS-N + 0.005% (v/v) polysorbate 20) and HBS-EP (HBS-P + 3 mM
EDTA) and were ready-to-use (degassed and filtered). Proper maintenance included
documented regular desorb and sanitize cycles and an annual check by a service
technician. Sensor chips were preconditioned prior to usage by injecting a series of
conditioning solutions. A flow rate of 50 ul/min was used and 2 times 20 ul of 50
mM NaOH, 10 mM HCl, 0.1% SDS and 100 mM H3PO4 was injected. After
preconditioning the chip was used for immobilization within the next 4 hours.
Data processing and equilibrium binding constant determinations were accomplished
with Scrubber© (BioLogic Software, Version 1.1g or 2.0a). Kinetic data were
simultaneously fit using the non-linear regression program Clamp© or Scrubber 2.0a.
Double referencing was applied to correct for bulk effects and other systematic
artefacts.165
2.1.2 Biosensor experiments with GSLA-2
GSLA-2 was kindly obtained from John L. Magnani (GlycoTech Corporation, USA).
The binding epitope was analyzed in detail using Biacore and STD-NMR in co-
operation with the group of Prof. T. Peters (University of Lübeck, Germany)
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2.1.2.1 Immobilization of GSLA-2 with amine coupling
Concentration and pH scouting for amine coupling of GSLA-2
Acetate buffers (10 mM, pH 4.0, 4.5, 5.0 and 5.5) were purchased from Biacore. For
pH scouting, GSLA-2 was diluted to a 40 µg/ml concentration with different acetate
buffers (pH 4.0, 4.5, 5.0, 5.5) or HBS-N (pH 7.4). These solutions were injected
sequentially over a CM5 biosensor surface for 3 min at the flow rate of 10 µl/min.
The surface was washed between each sample by injecting 50 mM NaOH for 30 s at
a flow rate of 20 µl/min. Furthermore, 3 different concentrations (10, 20 and 40
µg/ml) were analyzed at pH 5.0 to evaluate the concentration dependency. The
procedure was performed identical to pH scouting.
Amine coupling
The amine coupling kit was purchased from Biacore. The kit included all reagents
needed for the immobilization procedure (N-hydroxysuccinimide (NHS), 3-(N,N-
dimethylamino) propyl-N-ethylcarbo-di-imide (EDC), ethanolamine HCl).
The carboxy groups on the chip were activated for 10 minutes with a 1:1 mixture of
0.1 M N-hydroxysuccinimide (NHS) and 0.1 M 3-(N,N-dimethylamino) propyl-N-
ethylcarbo-di-imide (EDC) at a flow rate of 10 µl/min. The GSLA-2 solution (3.9
mg/ml) was diluted to a 40 µg/ml concentration with acetate buffer pH 5.0. This
solution was then injected over the activated surface at the flow rate of 10 µl/min. A
high and a low capacity surface were established. Densities obtained were between
3’800 to 8’000 RU depending on the contact time. Afterwards the flow cell was
blocked with a 10 min injection of 1 M ethanolamine, pH 8.0.
2.1.2.2 Binding assays with GSLA-2
The ligands sLea and Lea were purchased from Sigma. sLea attached to a Lemieux
spacer (sLea-Lem) was a kind gift from Prof. Ole Hindsgaul (Carlsberg Laboratory,
Denmark). The sources of the compounds tested in the ranking experiments as well
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as reagents required for NMR experiments are specified in Herfurth et al..166
Additional sLea and sLex mimetics were synthesized in house by Bea Wagner.
All experiments were performed in HBS-P buffer at a flow rate of 20 µl/min. For the
binding assay, nine concentrations (0.25 µM–200 µM) of sLea-Lem and sLea were
prepared and injected in a randomized order. Five blank buffer injections were
performed before and one after each series. Association and dissociation were
monitored for either 1 or 2 min, respectively. In the second experiment where binding
of Lea and sLex mimetics was tested, concentrations up to 2 mM were injected.
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2.2 Myelin-associated glycoprotein (MAG) as drug target
The MAG project was conducted in close cooperation with the group of Prof. Sørge
Kelm (University of Bremen, Germany). The Fc-chimera of MAG was expressed in a
mutant CHO cell line synthesizing only high mannose glycans and purified as
described previously.33 The protein consisted of the Fc portion of human
immunoglobulin IgG1 and the three N-terminal domains of murine MAG. This
construct included the sialic acid binding site but the potential NgR binding site was
absent.
For assay design it was either possible to immobilize the ligands or MAG itself.
Because IC50 values were already available and kinetic data can only be derived
precisely from a 1:1-binding event, the bivalent Fc-MAG(d1-3) construct was
immobilized onto the dextran surface.
2.2.1 Immobilization of Fc-MAG(d1-3) with amine coupling
2.2.1.1 Amine coupling of Fc-MAG(d1-3)
A stock solution of Fc-MAG(d1-3) in 10 mM PBS (700 µg/ml) was a kind gift from
Prof. Sørge Kelm.
Concentration and pH scouting were performed as described (2.1.2). The carboxy
groups on the chip were activated for either 7 or 10 minutes with a 1:1 mixture of 0.1
M N-hydroxysuccinimide (NHS) and 0.1 M 3-(N,N-dimethylamino) propyl-N-
ethylcarbo-di-imide (EDC) at a flow rate of 10 µl/min. For immobilizing MAG, the
Fc-MAG(d1-3) solution was diluted with the appropriate buffer. To prevent
deactivation of MAG at low pH, different conditions were tested. To obtain sufficient
surface attraction at a higher pH, increased protein concentrations were required
(table 10). These solutions were then injected over activated surfaces at a flow rate of
10 µl/min for the appropriate contact time. Afterwards the flow cell was blocked with
either a 7 or 10 minutes injection of 1 M ethanolamine, pH 8.0.
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Table 10. Immobilization conditions for amine coupling of Fc-MAG(d1-3)
pH Concentration MAG
(µg/ml)
Immobilization time
(s)
4.0   40 120
4.5   70 360
5.0   70 360
5.5 140 600
2.2.1.2 Validation of coupled Fc-MAG(d1-3)
Compounds used were synthesized in-house by Dr. Sachin Shelke and Stefanie
Mesch. A 20 mM stock solution was prepared in HBS-EP. Interaction experiments
were performed in HBS-EP at a flow rate of 20 µl/min. The samples were injected in
a randomized order. Five blank buffer injections were performed before and one after
each experiment. Association and dissociation were monitored for 1 or 2 min,
respectively.
2.2.2 Immobilization of Fc-MAG(d1-3) on a protein A surface
2.2.2.1 Immobilization of protein A with amine coupling
Protein A (P6031) was purchased from Sigma. Concentration and pH scouting was
performed as described (p. 71). A sample and a reference surface were prepared
sequentially or in parallel. The carboxy groups on the CM5 sensor chip were
activated for 9 minutes with a 1:1 mixture of 0.1 M N-hydroxysuccinimide (NHS)
and 0.1 M 3-(N,N-dimethylamino) propyl-N-ethylcarbo-di-imide (EDC) at a flow rate
of 10 µl/min. For immobilizing protein A, a stock solution (1 mg/ml in 50 mM
phosphate buffer, pH 7.0) was diluted in 10 mM sodium acetate, pH 5.0 to obtain a
concentration of 30 µg/ml. This solution was then injected over the activated surface
for 9 min at the flow rate of 10 µl/min. Protein A densities around 4’000 RU and
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5’000 RU were achieved. Flow cells were blocked with a 9 min injection of 1 M
ethanolamine, pH 8.0. After usage the chip was stored at 4 °C in HBS-EP buffer.
2.2.2.2 Capturing of Fc-MAG(d1-3) on the protein A surface
For capturing, the Fc-MAG(d1-3) solution was diluted to a 30-40 ug/ml
concentration using HBS-EP. The protein A surface was regenerated by two
sequential injections of glycine-HCl, pH 2.5 at a flow-rate of 60 µl/min for 5 sec.
prior capturing. Afterwards the surface was equilibrated for at least 1 hour.
Subsequently, Fc-MAG(d1-3) was injected at a flow-rate of 10 ul/min for 10 min.
Stability of the surface was monitored for 30-60 min.
2.2.2.3 Validation of the capturing assay
Trial experiments
Compounds were synthesized in-house by Dr. Sachin Shelke and a 20 mM stock
solution in HBS-EP was prepared. The Triasialoganglioside GT1b was purchased from
Sigma.
The ligands used were chosen due to their difference in the rIC50 values by a factor of
70. Interaction experiments were performed in HBS-EP at a flow rate of 20 µl/min.
First, several concentrations of both ligands (SH-082 and SH-035) were injected over
the surface to screen for binding affinity. To further proof the observed binding, 9
concentrations of a twofold dilution series of ligand SH-082, starting at 200 µM,
were prepared. The samples were injected in triplicates in a randomized order. Five
blank buffer injections were performed before and one after the experiment.
Association and dissociation were monitored for 1 min. The entire experiment was
repeated twice to check for reproducibility. Determination of the equilibrium
dissociation constant KD based on the dissociation signal was accomplished with
GraphPad Prism (version 4.0a).
In a second attempt the physiological ligand GT1b was measured to validate the assay.
GT1b was dissolved in HBS-EP by sonication to obtain a 20 mM stock solution. The
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interaction experiment was performed in HBS-EP at a flow rate of 20 µl/min. For the
experiment itself, 12 concentrations of a twofold dilution series, starting at 1 mM,
were prepared. Samples were injected in a randomized order. Five blank buffer
injections were performed before and one after the experiment. Association and
dissociation were monitored for 1 min. Two pre-injections with a 200 µM solution of
ligand SH-082 were carried out.
Optimization of the surface stability
The compound was synthesized in-house by Stefanie Mesch. A 20 mM stock solution
in HBS-EP was used. For capturing MAG, the Fc-MAG(d1-3) solution was diluted to
a 40-70 µg/ml concentration with HBS-EP. Subsequently, the sample was injected at
a flow-rate of 1 µl/min for 20-30 min. If needed the injection time was prolonged to
increase the capturing level. Stability of the captured Fc-MAG(d1-3) was monitored
for 30-60 min. For increased signal stability, the surface was equilibrated over night
at 5 µl/min in HBS-EP.
Afterwards, 10 concentrations of a twofold dilution series of ligand SM-m5, starting
at 200 µM, were prepared. All interaction experiments were performed in HBS-EP at
a flow rate of 20 µl/min. The samples were injected in a randomized order. Five
blank buffer injections were performed before and one after the experiment.
Association and dissociation were monitored for 1 min. The first experiment was
performed directly after capturing and two additional experiments 24 hours later.
2.2.2.4 Evaluation of negative sensorgrams
Carboxymethyl dextran (86524) and additional reagents utilized were obtained from
Fluka.
Interaction experiments were performed in HBS-EP at a flow rate of 20 µl/min. A
CM5 and a CM4 sensor chip were prepared as described in the optimized procedure.
Buffers with the appropriate composition were filtered and degassed prior to usage.
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For each experiment, 10 concentrations of a twofold dilution series of SH-136,
starting at 400 µM, were prepared. The samples were injected in a randomized order.
Five blank buffer injections were performed before and one after the experiment.
Association and dissociation were monitored for 1 min. Afterwards, the surface on
CM4 was regenerated by two injections of glycine-HCl, pH 2.5 at a flow-rate of 60
ul/min for 5 sec and equilibrated for at least 1 hour. As a negative control, the
experiment was repeated on such a blank protein A surface using identical conditions.
2.2.2.5 DMSO tolerability
DMSO was purchased from Fluka and stored in a desiccator. Capturing was carried
out as described (2.2.2.3). A stock solution (20 mM) of SH-082 was prepared in
DMSO. The stock solution was kept in a glass vial to eliminate contaminations by
e.g. softeners. A running buffer containing the desired amount of DMSO (3 or 6%) in
HBS-EP was prepared.
To eliminate the described influence of DMSO on signals, a calibration was
necessary.141 Two solutions were prepared (A = 1 ml running buffer + 50 µl HBS-EP,
B = 1 ml running buffer + 1 µl DMSO). Solutions A and B were mixed as indicated
in table 11 and used for calibration. DMSO calibration solutions were injected after 5
blank injections and before the sample solutions.
Table 11. Solutions needed to calibrate for the influence of DMSO
A (µl) 400 300 200 100    0
B (µl)    0 100 200 300 400
Calibration 1 2 3 4 5
DMSO calibration was accomplished directly in Scrubber© (version 2.0a).
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2.2.2.6 Sialic acid derivatives
After establishment of a stable biosensor assay, a set of in house sialic acid
derivatives was measured. The KD values were compared with the rIC50 values
obtained from the hapten inhibition assay. Compounds were synthesized in-house by
Dr. Sachin Shelke and Stefanie Mesch. Stock solutions (20 mM) were prepared in
HBS-EP.
Interaction experiments were performed in HBS-EP at a flow rate of 20 µl/min.  A
CM5 sensor chip was prepared as described (p. 77). For each experiment, 10
concentrations of a twofold dilution series were done. Samples were injected in a
randomized order. Five blank buffer injections were performed before and one after
the experiment. Association and dissociation were monitored for either 1 or 2 min,
respectively.
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2.2.2.7 Detailed thermodynamic analysis
The interaction of sialic acid derivatives with MAG was further characterized by
determining the entropic and enthalpic contributions to binding affinity. Three
selected sialic acid derivatives SH-164 (KD=137 µM), SH-136 (KD=25.6 µM) and
SM-m6 (KD=0.7 µM) were measured at various temperatures (5, 10, 15, 20, 25, 30
°C) and evaluated by applying a van’t Hoff plot.118 Ligand selection was based on
structural properties and affinity. A distinct structural feature was required that
influenced affinity by a factor of at least 5 (figure 30-A, B and C). A clear picture for
the thermodynamic impact of such defined structural modifications was expected.
SH-164
SH-136
SM-m6
Figure 30: Ligands SH-164, SH-136 and SM-m6 selected for a detailed thermodynamic evaluation. Structural
modifications are highlighted in red.
Capturing and interaction analyses were carried out as described (p. 79). The order of
temperature variation for the measurements is indicated in table 12. First, each
compound was measured at 25 °C. Subsequently, the Biacore 3000 was cooled down
H
N
HO
O
COOH
O
OH
OHHN
F
O
F
F
O
Cl
H
N
HO
O
COOH
O
OH
OHHN
O
O
H
N
HO
O
COOH
O
OH
OHHN
O
O
MATERIALS AND METHODS
81
to 5 °C over night. Afterwards each compound was measured with 5 °C increments in
between. The utilized procedure eliminated a possible temperature dependent
deviation based on a stepwise temperature change.
Table 12. The order of temperature variation was inter-
rupted to eliminate a temperature dependent deviation.
Experiment Temperature (°C)
1 25
2   5
3 10
4 15
5 20
6 30
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2.2.3 Ligand optimization using second site screening
Described sialic acid derivatives were used for further optimization. A technique
named second-site screening was applied in house by Dr. Brian Cutting and Dr.
Sachin Shelke. Combination of in-situ click chemistry with second-site screening led
to direct association of sialic acid derivative with a second site fragment out of a
library.167 Obtained SSC were identified, re-synthesized and subsequently analyzed
on Biacore to proof higher affinity and to disclose the kinetic impact.
2.2.3.1 Characterization of second generation ligands
Capturing of MAG on the protein A surface and interaction measurements were
carried out as described (p. 79).
In a first screening experiment, nine concentrations of a twofold dilution series of
SSL, starting at 1 mM were prepared and injected in a randomized order. Five blank
injections were performed before and one after each experiment. Association and
dissociation were monitored for 1 min. In a second attempt, the concentration range
was adjusted. Nine concentrations of a twofold dilution series, starting at 50 µM were
prepared and injected in a randomized order. Five blank injections were performed
before and one after each experiment. Association and dissociation were monitored
for 1 min.
2.2.3.2 Competition experiments with sialic acid derivatives
Due to the observed two binding site model, a competition experiment was carried
out to proof an identical binding site for both compound classes. A standard sialic
acid derivative (SH-082) was used as competitor to verify binding of the second
generation ligand to the sialic acid binding site.
Capturing of MAG on the protein A surface and interaction measurements were
carried out as described (p. 79). Two experiments were performed were the
competitor was used at 10 or 20 µM concentration, respectively For the experiments
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itself, nine concentrations of a twofold dilution series, starting at 25 µM and
containing an indicated amount of competitor, were prepared. The samples were
injected in a randomized order. Five reference injections were performed before and
one after each experiment. Reference injections were composed by either 10 or 20
µM competitor corresponding to the proper experiment.
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2.3  Expression of MAG(d1-3)-SNAP
The mouse MAG(d1-3) gene (accesion number P20917, Swissprot database) was a
obtained from Prof. S. Kelm. The SNAP gene was kindly donated by Covalys.
2.3.1 Insect cells as expression system
The Bac-to-Bac® baculovirus expression system provided a rapid and efficient
method to generate recombinant baculoviruses for high-level expression of MAG-
SNAP and SNAP in insect cells. The entire protein and DNA sequence of the SNAP
and MAG(d1-3)-SNAP constructs are listed in appendix II.
2.3.1.1 Growth and culture of bacterial cells (E. coli)
E. coli strains
DH5α™ was used for plasmid amplification. DH5α increases insert stability and
improves the quality of plasmid DNA prepared with mini-preps. The transformation
efficacy in DH5α is high. Their background expression is minimal due to the lack of
T7-RNA polymerase.
MAX Efficiency DH10Bac™ cells were used to produce recombinant baculovirus
DNA. The bacmid propagates in DH10Bac as a large plasmid that confers resistance
to kanamycin and can complement a lacZ deletion present on the chromosome to
form colonies that are blue (Lac +) in the presence of a chromogenic substrate such as
Bluo-gal or X-gal and the inducer IPTG. DH10Bac also contain a helper plasmid,
which encodes the transposase and confers resistance to tetracycline.
Culture media for E. coli
Bacto Tryptone, Bacto Yeast extract and Bacto agar were obtained from Becton
Dickinson and ampicillin sodium salt and X-Gal from Applichem. Gentamicin,
Tetracyclin and Kanamycin from Gibco (Invitrogen).
MATERIALS AND METHODS
85
LB-medium / LB agar plates
Table 13. Concentrations for LB-medium and plates
Reagent Quantity
Bacto Tryptone 1.0%
Bacto Yeast Extract 0.5%
Sodium chloride 172 mM
Bacto Agar 1.5%
Tryptone, yeast extract and NaCl were dissolved in ddH2O (table 13). The pH was
adjusted to 7.5 and the solution was autoclaved.
For agar plates, agar was added before autoclaving the solution. After sterilization,
the medium was cooled down to 50 °C and the appropriate antibiotics were added.
The medium was poured into plates under laminar flow and after hardening, the
plates were stored at +4 °C in a sealed plastic bag.
SOC –medium
Table 14. Composition of SOC-medium
Reagent Quantity
LB medium   10 ml
2 M Magnesium chloride   50 µl
1 M D-Glucose 200 µl
LB medium   10 ml
A 2 M MgCl2 solution was prepared and autoclaved. A 1 M D-Glucose solution was
prepared and filtered (Minisart 0.2mm, Sartorius). Both solutions were added to the
LB medium under laminar flow (table 14). SOC medium was prepared freshly for
every usage.
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SOB –medium
Table 15. Composition of SOB-medium
Reagent Quantity
Bacto Tryptone 2.0%
Bacto Yeast Extract 0.5%
Sodium chloride 8.6 mM
Potassium chloride 2.5 mM
Tryptone, yeast extract, NaCl and KCl were dissolved in ddH2O (table 15). The pH
was adjusted to 7 and the solution was autoclaved. MgCl2 was added just before
usage.
Antibiotics
For clone selection after transformation ampicillin was used as antibiotic. For clone
selection after transformation of pFastBac into DH10Bac cells, gentamicin,
kanamycin and tetracycline were used.
IPTG and X-gal for Blue/White selection
β-Galactosidase is encoded by the bacterial gene lacZ. It cleaves the colorless
substrate X-gal into galactose and a blue insoluble product. A common use of lacZ is
for blue/white selection when cloning a DNA insert into a plasmid. If the insert is
ligated into the polylinker, the lacZ gene will be disrupted and the colony will remain
white.
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Table 16. Final concentrations of additives added to culture media.
Ampicillin Gentamicin Kanamycin Tetra-
cycline
X-gal IPTG
Stock
solution
(mg/ml)
100 7 50 10 20 40
Liquid
media
(mg/ml)
100 7 50 10
Agar
plates
(mg/ml)
150 7 50 10 40 40
The stocks (table 16) were prepared using ddH2O. Obtained solutions were sterilized
by filtration (Minisart 0.22 mm, Sartorius). Aliquots were stored at –20 °C.
Tetracycline and X-gal were protected from light.
Clone picking and plasmid isolation
Incubation was carried out in a shaking incubator Innova 4000 (New Brunswick
Scientific). LB-medium and agar plates were prepared as described (p. 85). Isolation
of plasmid DNA was performed using the GenElute™ plasmid mini-prep kit from
Sigma.
Using a sterile pipette-tip, a single colony was picked and inoculated in 3 ml of LB-
medium containing an appropriate antibiotic. The culture was grown on a shaking
incubator (300 rpm, 37 °C) until cells reached the stationary phase. Plasmid isolation
was performed according to the procedure of the supplier for the mini-prep kit. The
plasmid DNA out of 1 ml culture was finally eluted in 70 µl elution buffer.
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2.3.1.2 Preparation of competent cells
Cells for electroporation
Agar plates and SOB–medium were used for outgrowth and prepared as described.
For cultivation of cells an Incubator shaker Innova™  4000 (New Brunswick
Scientific) was used.
The E.coli strain was streaked out on agar plates and incubated at 37 °C overnight.
Single clones were picked and incubated overnight at 37 °C in the incubator shaker in
5 ml SOB-medium without MgCl2. Such overnight cultures were inoculated in 250
ml SOB-medium containing MgCl2. During incubation, the optical density was
measured at 600 nm (OD600) every one to two hours. After reaching an OD600
between 0.5 and 0.8 the cells were centrifuged at 5000 rpm and 4 °C for 10 min.
Cells were washed in 250 ml glycerol solution (10%, 4 °C) by re-suspension.
Afterwards they were centrifuged again at 5000 rpm and 4 °C for 10 min and re-
suspended in 50 ml glycerol solution (10%, 4 °C). After an additional centrifugation
step the cells were re-suspended in 1 ml glycerol solution (10%, 4 °C). Aliquotes
were immediately frozen in liquid nitrogen and stored at –80 °C.
Cells for heat-shock transformation
The E.coli strain was streaked out on agar plates and incubated at 37 °C overnight.
Two clones were picked and incubated overnight in 4 ml LB-medium at 37 °C in the
incubator shaker. The OD600 was measured and 1 ml overnight culture was added to
100 ml LB -medium and incubated at 37 °C on the incubator shaker. The OD600 was
measured after 1 hour and then every 20 min. until it reached a value between 0.4 and
0.5. Cultures were chilled on ice for 20 min. Subsequently the cells were aliquoted to
4 x 50 ml and centrifuged at 5000 rpm and 4 °C for 10 min.
Each pellet was re-suspended in 10 ml CaCl2 solution (50 mM, 4 °C). Then cells
were kept on ice for 40 min. Cells were centrifuged and re-suspended in 0.5 ml CaCl2
solution (50 mM, 20% glycerol, 4 °C). Aliquotes were immediately frozen in a dry
ice/ethanol bath and stored at –80 °C.
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2.3.1.3 Transformation
Electroporation
Electroporation was performed using the Micro Pulser electroporation apparatus
and Gene Pulser cuvettes 0.1 cm (Bio-Rad).
In 0.1 cm cuvettes, 50 µl cells were mixed with 5 µl mini-prep purified plasmid or 1
µl pSS26b from the clone saver punch. An electrical pulse with 1.80 kV was applied
and immediately after the pulse 1 ml SOC medium was added to the cells.
Afterwards, they were incubated at 37 °C and 550 rpm on the thermomixer for 40
min or 1.5 h. Subsequently, cell suspensions were streaked out on agar plates
containing ampicillin.
Heat-shock transformation
Mini-prep purified plasmid (2 µl) was mixed with 100 µl DH10Bac cells and chilled
on ice for 30 min. The cells were heat-shocked at 42 °C for 45 sec on the
thermomixer and afterwards put on ice for 2 min. 900 µl SOC–medium was added
and outgrowth was done for 4 hours at 300 rpm and 37 °C on the thermomixer.
Afterwards cell suspensions were streaked out on agar plates containing kanamycin,
gentamicin, tetracycline, IPTG and X-gal. After 48 hours white colonies were picked,
re-streaked on plates and incubated at 37 °C for 15-17 hours.
2.3.1.4  Analyses for plasmid DNA
Agarose gel electrophoresis
Molecular biology grade agarose was purchased from Eurogentech. Ethidium
bromide solution 1% was obtained from Applichem. Loading buffer as well as the
perfectprep gel cleanup kit was purchased from Eppendorf. DNA molecular weight
marker X was obtained from Roche Diagnostics. Visualization of the stained DNA
was performed on a GelDoc2000 transilluminator (Bio-Rad).
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A 1% Agarose solution in TBE-Buffer (44.6 mM Tris(hydroxymethyl)-aminomethan,
44.6 mM Boric acid, 1 mM Na2EDTA, pH 8), was heated in the microwave until the
agarose was dissolved. The solution was cooled down for 2-3 min to ~ 50 °C and 2 µl
ethidium bromide 1% was added. Subsequently, the mixture was poured into a gel
tray containing an appropriate comb. After formation of the gel the comb was
removed and TBE buffer was added to cover the gel.
DNA samples were diluted with ddH2O if necessary and an
appropriate amount of loading buffer was added to the
samples. 2 µl DNA marker (figure 31) were included for
size determination. The samples were loaded on the gel and
an electric field was applied (80-85 V). Afterwards, DNA
was visualised under UV light. For preparative use, the
DNA fragments were isolated and purified using the Gel
Cleanup Kit.
Figure 31. DNA marker x
Storage of positive clones
For storage of positive clones, 30 µl overnight culture was inoculated in 3 ml
LB–medium on an incubator shaker for 4-5 hours, until the cells reached the
exponential phase of growing. Afterwards 850 µl culture were mixed with 150 µl
glycerol solution and frozen directly in liquid nitrogen. Finally aliquots were stored at
–80 °C.
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2.3.1.5 Cloning of MAG(d1-3)  into pSS26b
Recovery of plasmid DNA containing the SNAP-tag Gene
The plasmid containing the SNAP-tag gene was obtained from Covalys. A total of
100 µl TE buffer (10 mM mM Tris(hydroxymethyl)-aminomethan, 0.1 mM EDTA,
pH 8.0, autoclaved) was added to the clone saver punch. After 15 min incubation at
RT the solution was gently mixed by pipetting up and down, transferred to a sterile
vial and stored at –20 °C.
For transformation into E.coli the DNA was diluted 10 fold with TE buffer. 0.5 and 1
µ l diluted solution were used for transformation of pSS26b into DH5α  by
electroporation. Clones were picked and cultured overnight. The plasmid DNA was
purified using the Genelute Plasmid Miniprep Kit and eluted in 70 µl elution buffer
Amplification of MAG(d1-3) out of pIgMAG(d1-3)
The plasmid pIgMAG(d1-3) containing the DNA sequence of the 3 N-terminal
extracellular domains of MAG was obtained from Prof. Sørge Kelm. Primers were
purchased from Microsynth if not indicated differently. Primers were dissolved in
sterile ddH20 to a 200 µM stock solution and further diluted to a 20 µM working
solution. REDTaq DNA-polymerase from Sigma and pfu DNA-polymerase from
Promega were used for PCR if no indicated differently. The pfu-polymerase exhibits
proofreading activity and therefore ensures high fidelity. PCRs were performed on
the thermal cycler icycler™ (Bio-Rad). PCR products were purified using a PCR
clean-up kit ™ from Sigma.
For ligation into the pSS26b plasmid containing the SNAP-tag gene, a N-teminal Xho
I and a C-terminal Hind III cleavage site were introduced in the primers. N-terminal
primer extensions for higher cleavage activity were incorporated as proposed by New
England Biolabs 2000/01 (presented in green).
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Fw_MAG:
5’ CCGCTCGAGGGCCACTGGGGTGCCTGGAT 3’
CTCGAG Xho I cleavage site
Tm = (G + C) * 4 + (A + T) * 2 = 68 °C
Rw_MAG:
5’ CCCAAGCTTTGCATACATGACACTCAGCTCC 3’
AAGCTT Hind III cleavage site
Tm = (G + C) * 4 + (A + T) * 2 = 66 °C
First, a PCR was carried out using REDTaq DNA-polymerase to screen for optimal
conditions (table 17).
Table 17. PCR with REDTaq DNA-polymerase to screen for optimal conditions
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 39 Hold: 94 4
10 mM PCR dNTP Mix   1 Denaturation: 94 0:30
5‘ primer   1
3‘ primer   1
Template (mini-prep)   1
Annealing:
Temperature
graduation 59.3,
62.1, 63.9, 65
1
PCR buffer, 10x   5 Elongation 1
30
Taq-polymerase   2 Final elongation: 72 5
Two different template concentrations were used (1:10 and 1:100) and a blank was
included missing the template.
To obtain a sequence suitable for cloning a second PCR was conducted with a pfu-
polymerase that exhibits higher fidelity than the taq-polymerase (table 18).168
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Table 18. PCR with Pfu DNA-polymerase for higher fidelity.
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 40 Hold: 94 3
10 mM PCR dNTP Mix   1 Denaturation: 94 1
5‘ primer   1
3‘ primer   1
Template   1
Annealing:
Temperature
graduation 59.3,
62.1, 63.9, 65
1:30
PCR buffer, 10x   5 Elongation 2
30
Pfu-polymerase   1 Final elongation: 72 10
Double-Digest of MAG(d1-3) insert
All enzymes utilized for digestion were obtained from New England Biolabs except
Hind III that was purchased from Roche Applied Science. Digestion of DNA was
performed in an incubator overnight or in a thermomixer (eppendorf) for shorter
incubation times.
Table 19. Mixture for a double-digest of MAG(d1-3)
Reagent Quantity (µl)
PCR product table 18 100.0
Buffer 2 10x   14.0
BSA 10x   14.0
Xho I     4.0
Hind III     4.0
ddH2O     4.0
The mixture (table 19) was incubated overnight at 37 °C.
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Double-Digest of pSS26b vector
Table 20. Mixture for a double-digest of pSS26b
Reagent Quantity (µl)
pSS26b mini prep 50.0
Buffer 2 10x   7.0
BSA 10x   7.0
Xho I   2.0
Hind III   2.0
ddH2O   2.0
The mixture (table 20) was incubated overnight at 37 °C.
Dephosphorylation of digested pSS26b
Removing the 5’ phosphate from both ends of a double-stranded DNA molecule (e.g.
cloning vector) renders such molecules resistant to DNA ligase. However,
phosphorylated experimental DNA can be ligated to dephosphorylated vector DNA.
Thus, dephosphorylation provides a mechanism for reducing the potential
background of re-circularized vectors in cloning experiments.169 A suitable Shrimp
alkaline phosphatase was purchased from Promega.
Table 21. Dephosphorylation of digested pSS26b
Reagent Quantity (µl)
pSS26b (table 20) 70.0
Shrimp alkaline phosphatase (SAP)   1.5
SAP buffer   8.0
ddH2O   0.5
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The mixture (table 21) was incubated for 1 hour at 37 °C, then the enzyme was heat-
inactivated at 65 °C for 15 min.
Ligation of MAG(d1-3) into pSS26b
The T4 DNA Ligase catalyzes the formation of a phosphodiester bond between
juxtaposed 5’ phosphate and 3’ hydroxyl termini in duplex DNA/RNA. This enzyme
will join blunt end and cohesive end termini as well as repair single stranded nicks in
duplex DNA, RNA or DNA/RNA hybrids.169 The T4 DNA ligase was obtained from
NEB.
Table 22. Ligation of MAG(d1-3) into pSS26b
Ligation (table 22) was done overnight in a water bath which cooled slowly down
from room temperature to 4 °C passing the optimal ligation temperature. To desalt
the ligation product before electroporation, a dialysis was performed for 30 min using
a 0.025 mm membrane. Afterwards, the plasmid was transformed into DH5α cells by
electroporation (p. 88).
Reagent Quantity (µl)
MAG(d1-3) digested (table 19) 2.0
pSS26b digested and dephos (table 21) 1.0
Buffer T4 DNA Ligase 1.0
10mM ATP 1.0
T4 DNA Ligase 1.0
ddH2O 4.0
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Digest analysis of pSS26b-MAG(d1-3)
Table 23. Ligation of MAG(d1-3) into pSS26b
The mixture (table 23) was incubated overnight at 37 °C. A blank was included
missing the digestion enzymes.
2.3.1.6 Cloning of MAG(d1-3)-SNAP / SNAP into pFastBac-S
Amplification of MAG(d1-3)-SNAP and SNAP
For ligation into the pFastBacSS plasmid, a N-teminal Xba I and a C-terminal XhoI
cleavage site were introduced in the primers. N-terminal primer extensions for higher
cleavage activity were included as proposed in the product catalogue of New England
Biolabs 2000/01 (presented in green).
Primer sequences: 
Fw_MAG_XbaI:
5’GCTCTAGAGGCCACTGGGGTGCCTGGAT3’
TCTAGA (XbaI cleavage site)
Tm = (G + C)*4 + (A + T)*2 = 68 °C
Reagent Quantity (µl)
pSS26b_MAG(d1-3) mini prep 10.0
Buffer 2 10x   2.0
BSA 10x   2.0
Xho I   1.0
Hind III   1.0
ddH2O   4.0
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FW_SNAP_XbaI:
5’ GCTCTAGAATGGACAAAGATTGCGAAATGA 3’
TCTAGA (Xba I cleavage site)
Tm = (G + C)*4 + (A + T)*2 = 66 °C
Rw_SNAP_FLAG_XhoI:
5’CCGCTCGAGCTATTACTTATCGTCATCGTCCTTGTAGTCTCCCAGACCCG
GTTTACCCAG3’
CTCGAG (Xho I cleavage site)
CTATTA (stop codon)
CTTATCGTCATCGTCCTTGTAGTC (FLAG-tag)
Tm = (G + C)*4 + (A + T)*2 = 68 °C
Table 24. PCR setup for MAG(d1-3)-SNAP amplification
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 40 Hold: 94 3
10 mM PCR dNTP Mix   1 Denaturation: 95 1
5‘ primer: FW-MAG   1
3‘ primer: RW-SNAP   1
Template: clone 14   1
Annealing
Temperature: 55 1:30
PCR buffer, 10x   5 Elongation: 72 2
35
pfu-polymerase   1 Final elongation: 72 10
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Table 25. PCR setup for SNAP amplification
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 40 Hold: 94 3
10 mM PCR dNTP Mix 1 Denaturation: 95 1
5‘ primer: FW-SNAP 1
3‘ primer: RW-SNAP 1
Template: clone 14 1
Annealing
Temperature: 55 1:30
PCR buffer, 10x 5 Elongation: 72 2
35
pfu-polymerase 1 Final elongation: 72 10
Both PCRs (table 24 and 25) were carried out using a hot start.
Double digest of pFastBac-S, MAG(d1-3)-SNAP and SNAP inserts
Table 26. Digest of MAG-SNAP and SNAP Table 27. Digest of pFastBac
The mixtures (table 26 and 27) were incubated overnight at 37 °C.
Reagent Quantity (µl) Reagent Quantity (µl)
MAG(d1-3)-SNAP or
SNAP mini-prep
80.0 pFastBac_S
mini-prep
40.0
Buffer 2 10x 10.0 Buffer 2 10x   6.0
BSA 100x   1.0 BSA 10x   6.0
Xho I   2.0 Xho I   2.0
Xba I   2.0 Xba I   2.0
Sterile ddH2O   5.0 ddH2O   4.0
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Dephosphorylation of digested pFastBac-S
Table 28. Deposphorylation of pFastBac-S
Reagents Quantity (µl)
pFastBac_S digested (table 27) 70.0
Shrimp alkaline phosphatase (SAP)   1.5
SAP buffer   8.0
ddH2O   0.5
The mixture (table 28) was incubated for 1 hour at 37 °C, then the phosphatase was
heat-inactivated at 65 °C for 15 min.
Ligation of MAG(d1-3)-SNAP and SNAP into pFastBac-S
Table 29. Mixtures for ligation of MAG(d1-3)-SNAP and SNAP into pFast-Bac-S
Reagents Quantity (µl)
MAG(d1-3)_SNAP or SNAP 2.0
PFastBac-S (table 28) 0.5
Buffer T4 DNA Ligase 1.0
10mM ATP 1.0
T4 DNA Ligase 1.0
ddH2O 4.5
Ligation (table 29) was done overnight in a water bath which cooled slowly down
from room temperature to 4 °C passing the optimal ligation temperature. To desalt
the ligation product, a dialysis was done for 1 h with a 0.025 mm membrane.
Afterwards, the plasmid was transformed into DH5α cells by electroporation (p. 88).
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Digest analysis of pFastBac-S-MAG(d1-3)-SNAP and -SNAP
Table 30. Successful ligation was checked by digest analysis.
Reagents Quantity (µl)
MAG(d1-3)-SNAP or SNAP 10.0
Buffer 2 10x   2.0
BSA 100x   0.2
Xho I   1.0
Xba I   1.0
ddH2O   6.0
The mixtures (table 30) were incubated overnight at 37 °C. 5 µl of digest product
were mixed with 5 µl ddH2O and 1 µl loading buffer. DNA analysis was carried out
on an agarose gel.
2.3.1.7 Growth and culture of insect cells
Sf-900 II SFM with L-glutamine, Express Five SFM and all additives for culturing
insect cells were purchased from Gibco (Invitrogen). Sf-900 II SFM is a protein-free
medium which supports increased cell growth of a variety of insect cell lines as well
as significantly increased production of recombinant protein using the baculovirus
expression vector system (BEVS). Express Five is a protein-free medium, which
supports increased cell growth of High Five insect cells as well as significantly
increased production of recombinant protein using the BEVS. Cell cultures were
propagated either as an adherent or a suspension culture in an Innova 4230 Incubater
(New Brunswick Scientific). Cell culture grade DMSO was purchased from Sigma.
Shaker cultures of High Five™ and Sf9 cells were grown in sterile 250 ml
Erlenmeyer flasks, covered with cotton and tin foil, in 30 ml medium on an incubator
shaker maintained at 122 rpm and 27 °C. A viability test was done with trypan blue
stain 0.4% and cells were sub-cultured to 4•105 cells/ml twice a week.
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2.3.1.8 Isolation and analysis of bacmid DNA
Isolation and analysis of bacmid DNA out of DH10Bac
All chemicals used were purchased from Sigma except SDS that was obtained from
Bio-Rad.
Bacmid DNA was isolated using a standard procedure given by the manufacturer.170
1.5 ml of bacterial culture were transferred to an eppendorf tube and centrifuged at
14’000 g for 1 minute to pellet the cells. The supernatant was removed and the pellets
were re-suspended in 0.3 ml of Solution I (15 mM Tris, 10 mM EDTA, 100 µg/ml
RNase A, pH 8.0, filter-sterilized) by gently pipetting up and down.
Afterwards, 0.3 ml of Solution II (0.2 M NaOH, 1% SDS, filter-sterilized) were
added by mixing gently. The mixture was incubated at room temperature for 5
minutes. Subsequently, 0.3 ml of sterile 3 M potassium acetate pH 5.5 were added
and gently mixed. A thick white precipitate of protein and E. coli genomic DNA was
formed. The sample was placed on ice for 7 minutes and then centrifuged for 10
minutes at 14’000 g. The resulting supernatant (without any white precipitate) was
transferred to an eppendorf tube containing 0.8 ml of isopropanol. The tube was
inverted a few times to mix and placed on ice for 7 minutes. After centrifugation for
15 minutes at 14,000 g at room temperature the supernatant was removed. 0.5 ml of
70% ethanol was added and the tube was inverted several times and centrifuged for 5
minutes at 14,000 g at room temperature. The supernatant was removed and the pellet
air-dried for 7 minutes at room temperature. The pellet was dissolved in 40 µl TE
buffer by gentle tapping against the bottom. Finally the bacmid was stored at +4 °C
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PCR analysis of bacmid DNA MAG(d1-3)-SNAP and SNAP
Table 31. PCR analysis of bacmid DNA
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 39 Hold: 93 3
10 mM PCR dNTP Mix   1 Denaturation: 94 0:45
5‘ primer:   1
3‘ primer:   1
Template: bacmid   1
Annealing
Temperature: 55 0:45
PCR buffer, 10x   5 Elongation: 72 5
30
taq-polymerase 2 Final elongation: 72 7
The PCR (table 31) was performed with a Hot-Start.
2.3.1.9 Transfection of bacmid DNA into insect cells
Transfection was carried out with common sf9 cells. The transfection reagent
Cellfectin, a 1:1.5 (M/M) liposome formulation of the cationic lipid N, NI, NII, NIII-
Tetramethyl-N , N I, NII, NIII-tetrapalmitylspermine (TM-TPS) and dioleoyl
phosphatidylethanolamine (DOPE), was purchased from Invitrogen. 6-well tissue
culture plates were used for transfection.
First 1•106 cells in 2 ml growth medium were seeded in a well and incubated for 2
hours at 27 °C to let the cells attach to the well. 30 µl bacmid DNA was mixed with
100 µl sf900 II SFM without antibiotics (solution A). Then 6 µl cellfectin reagent
was mixed with 100 µl sf900 II SFM without antibiotics (solution B). Solution B was
added to solution A and incubated for 30 min at RT (solution C). Afterwards 0.8 ml
of sf900 II SFM (no antibiotics) was added to C (solution D). The medium was
removed from the cells and solution D was added. After 5 hours of incubation at 27
°C, transfection mix was removed from the cells and replaced by 2 ml fresh sf900 II
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SFM. Cells were checked for signs of infection till 5 days post-transfection. After 5
days the media was collected, centrifuged (500 g, 5 min., 4 °C) and stored at 4 °C.
The obtained solution was referred to as the P1 viral stock. For protein expression the
viral stock was amplified.
2.3.1.10 Amplification of P1 viral stock
For amplification of the P1 viral stock, 75 cm2 culture flasks were used. A total of
3•106 sf9 cells were seeded in a 75 cm2 culture flask with a final volume of 13 ml.
After 1 h the cells had attached and 1 ml of P1 viral stock was added to the cells.
After 5 days the medium was collected, centrifuged (500 g, 5 min., 4 °C) and stored
at 4 °C.
2.3.1.11 Evaluation of insect cell lines for espression
Viral stocks from both MAG-SNAP and SNAP were used to infect sf9 and H5 cells.
Expression was carried out in sf900 II SFM.
For expression of SNAP and MAG-SNAP, a 30 ml suspension culture at a density of
1 • 106 cells/ml was infected with 2 ml of P2 viral stock. Samples were taken after 24,
48 and 120 h for SNAP and 24, 48, 72 and 120 h for MAG-SNAP respectively.
Analyses of obtained samples by SNAP-vista and western blot were conducted.
2.3.1.12 Purification of FLAG-tag Proteins
For affinity chromatography, ANTI-FLAG M2 Affinity gel from Sigma (Fluka) was
filled into a 2 ml Bioscale MT-2 column (Bio-Rad). The entire purification of the
FLAG-tag constructs was carried out on a BioLogic Chromatography system (Bio-
Rad).
Purification steps were carried out at 4 °C. The supernatant obtained from expression
in insect cells was cleared from cell debris by centrifugation at 22’000 rpm for 20
min. In addition, the centrifuged supernatant was filtered using a 0.20 µm Minisart
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(Sartorius) prior to purification. The pH of the final filtrate was adjusted to 7.4 using
1 M Tris pH 8.0 to obtain optimal binding to the column. All purification steps were
carried out at a flow-rate of 1 ml/min. The column was first equilibrated with PBS
(50 mM phosphate, 150 mM NaCl, pH 7.4) for 20 minutes. The supernatant was
loaded onto the column followed by a 60 min. wash step. Elution was performed with
a 100 mM glycine buffer pH 3.5 during 15 minutes. Aliquots of 1 ml were collected
and the pH was immediately corrected to neutral using 1 M Tris pH 8.0. Afterwards
the column was immediately re-equilibrated to neutral pH using PBS. Fractions were
checked for protein and purity on SDS-PAGE using enhanced coomassie staining.171
If the column was re-used within 24 h, equilibration in storage buffer (PBS, 0.02 %
sodium azide) for 20 min. was conducted to avoid microbial growth and stored at
4°C. For long-term storage, 10 % glycerol was added to the storage buffer to protect
the resin from degradation.
2.3.1.13 Buffer exchange and sample concentration
Due to known stability of MAG in 10 mM PBS, the buffer of both SNAP-tag and
MAG-SNAP-tag was exchanged to PBS after purification. Additionally, the
concentration was increased to allow testing different concentrations for
immobilization.
PBS (10 mM sodium phosphate, pH 7.4, 150 mM NaCl) was prepared, filtered and
stored at 4 °C. Buffer exchange and sample concentration was carried out with
centrifugal filter devices Amicon Ultra-4 (Millipore). All centrifugation steps were
performed at 4 °C using 4’000 g. First, the filter device was washed once with 4 ml of
PBS. Then a maximum of 4 ml of sample was applied. The final concentrated sample
was washed twice using 4 ml of PBS.
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2.3.1.14 Western blot of FLAG-tagged proteins
The blotting was performed using the trans-blot SD semi-dry transfer cell (Bio-Rad).
The nitrocellulose (NC) membrane as well as the whatman paper was purchased from
Bio-Rad. The primary antibody ANTI-FLAG M2 and the secondary antibody Anti-
Mouse IgG (Fc specific)-alkaline phosphatase were obtained from Sigma. The
alkaline phosphatase substrate mixture 5-bromo-4-chloro-3-indolyl phosphate
dipotassium (BCIP), nitrotetrazolium blue chloride (NBT) was purchased from Fluka.
For blotting, eight pieces of whatman paper and one NC membrane were incubated in
transfer buffer (25 mM Tris, 150 mM glycine, 20% (v/v) methanol). Four whatman
papers were placed on the anode followed by the NC-membrane, the SDS-PAGE gel,
additional 4 papers and the cathode. Transfer was carried out for 1 h applying 15 V.
After the transfer the membrane was stained with ponceau S solution to visualize the
marker and verify transfer. Afterwards the membrane was washed with TBS (10 mM
Tris, 150 mM NaCl, pH 7.5) for 10 min. Then the membrane was blocked for 15 min.
with blocking buffer (2% BSA). Afterwards, 3 washing steps were done (2•TTBS
(TBS with 0.05% Tween 20), 1•TBS) for 10 min. each. Subsequently, the membrane
was incubated with the primary antibody (1:2’000 in TBS, 1% BSA, 0.1% sodium
azide) for either 1 h at RT or over night at 4°C. Additional 3 washing steps were
carried out before incubation with the secondary alkaline phosphatase coupled
antibody (1:5’000 in TBS, 1% BSA, 0.1% sodium azide) for 1 h at RT. After
additional 3 washing steps the complex was visualized with BCIP/NBT.
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2.4 Mammalian cells as expression system
The entire DNA sequence of the MAG(d1-3)-SNAP construct is listed in appendix II.
Cloning of SNAP into pcDNAIII-Strep
The pcDNAIII-Strep plasmid containing a Strep-tag was kindly obtained from Dr.
Frank Dietz. All cloning and expression were carried out in the Centre for
Biomolecular Interactions Bremen. For cloning SNAP into the pDNAIII-Strep
plasmid, an N-teminal Bam HI cleavage site including a 3C protease cleavage site
and a C-terminal Eco RI cleavage site were introduced. Primer extensions for higher
cleavage activity were included as proposed by New England Biolabs 2000/01.
OSK 1043:
5’CGGGATCCCTGGAGGTGCTGTTCCAGGGCCCCATGGACAAAGATTGCG
AAATGA 3’
GGATCC Bam HI cleavage site
OSK 1044:
5’ CGGAATTCTCCCAGACCCGGTTTACCCAG 3’
AAGCTT Eco RI cleavage site
Table 32. PCR performed with pfu DNA-polymerase.
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 41.0 Hold: 95 4
10 mM PCR dNTP Mix   1.0 Denaturation: 95 0:30
5‘ primer (OSK 1043)   0.5
3‘ primer  (OSK 1044)   0.5
pSS26b   1.0
Annealing: 62 1
PCR buffer, 10x   5.0 Elongation: 72 1:20
30
pfu-polymerase   1.0 Final elongation: 72 5
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The primer concentration was adjusted to 100 pmol/µl. A master mix was prepared
for three samples and divided prior to PCR (table 32). pSS26b was used as template
with a concentration of 2 µg/ml. A total of 50 µ l plasmid solution with a
concentration of 140 ng/µl was obtained.
Double-Digest of SNAP insert
Table 33. Digest of the amplified SNAP gene
Reagent Quantity (µl)
PCR product (table 32) 45.0
Tango buffer 10x 14.0
Bam HI   2.0
Eco RI   1.5
ddH2O   7.5
The mixture (table 33) was incubated overnight at 37°C.
Ligation of SNAP into pcDNAIII
Table 34. Ligation of the SNAP gene into pcDNAIII
Reagent Quantity (µl)
pcDNAIII-Strep 10 ng/µl 2.0
SNAP insert 10 ng/µl (table 33) 1.5
Ligation buffer 5x 3.0
T4 ligase 1.0
ddH2O 7.5
The ligation mixture (table 34) was incubated for 2 h at RT.
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Colony PCR
Table 35. Colony PCR for positive clone selection
Reagent Quantity
(µl)
Temperature (°C) Time
(min)
N° of
cycles
Sterile ddH2O 19.9 Hold: 95 3
10 mM PCR dNTP Mix 0.5 Denaturation: 95 0:30
5‘ primer T7 100 pM 0.25
3‘ primer Sp6 100 pM 0.25
Single clones picked
Annealing: 56 1
PCR buffer, 10x 2.5 Elongation: 72 1:30
30
MgCl2 1.5 Final elongation: 72 3
taq-polymerase 0.1
DNA loading buffer (10 µl) was added to each finished PCR reaction (table 35).
Marker (10 µl) and 20 µl of each sample were mixed and loaded onto an agarose gel.
Transfection of pcDNAIII-SNAP into Cos-7 cells
The transfection reagent Exgen 500 was purchased from fermentas.
A total of 1 µg of isolated plasmid from positive clones was added to 95 µl 150 mM
NaCl and 2.2 µl Exgen 500. The mixture was incubated for 10 min at RT. A 24 well
plate with 80% confluent Cos-7 cells in DMEM media containing 2% FCS was used
and 1 well was transfected with each clone.
Harvest and analysis of transfected Cos-7 cells
The cells were harvested after 24 h and analyzed for protein production. The medium
was removed and cells were washed twice with PBS. The cells were boiled in 50 µl
sample buffer containing DTT at 95 °C for 10 min. The samples (20 µl) were run on
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a SDS-PAGE and finally analyzed with western blot using a primary anti-Strep
antibody with a secondary horseradish peroxidase labelled antibody (pierce).
2.4.1 Cloning of MAG(d1-3) into pcDNAIII-SNAP
Amplification of MAG(d1-3)
For cloning MAG(d1-3) into the pcDNAIII-SNAP plasmid, an N-teminal Hind III and
a C-terminal Bam HI cleavage site were introduced. Primer design included the
natural MAG signal sequence for secretion. At the N-terminus, an additional Xba I
cleavage site was included to allow direct ligation into a pDEF vector for stable
expressing clones.
OSK 1051:
5’CGAAGCTTATATCTAGAATGATATTCCTCGCCACCCT 3’
AAGCTT Hind III cleavage site
TCTAGA Xba I cleavage site
OSK 1052:
5’ CGGGATCCTCCTGCATACATGACACTCAGCT 3’
GGATCC Bam HI cleavage site
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Table 36. PCR setup for MAG(d1-3) amplifikation
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 41 Hold: 95 4
10 mM PCR dNTP Mix 1 Denaturation: 95 0:30
5‘ primer OSK 1051 100 pM 0.5
3‘ primer  OSK 1052 100 pM 0.5
pigBos-MAG(d1-3) 100 ng/µl 1
Annealing: 58 1
PCR buffer, 10x 5 Elongation: 72 1:20
30
pfu-polymerase 1 Final elongation:
72
5
PCR (table 36) was carried out using a hot-start.
Double-Digest of MAG insert and pcDNAIII-SNAP
Table 37: Digest of MAG(d1-3) insert Table 38. Digest of pcDNAIII-SNAP
Reagent Quantity
(µl)
Reagent Quantity
(µl)
PCR product (table 36) 45.0 pcDNAIII-SNAP 60.0
Bam HI buffer   6.0 Bam HI buffer   8.0
Bam HI   1.5 Bam HI   2.5
Hind III   2.5 Hind III   3.5
ddH2O   5.0 ddH2O   6.0
The mixtures (table 37 and 38) were incubated overnight at 37°C.
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Ligation of MAG(d1-3) into pcDNAIII-SNAP
Table 39. Ligation of MAG(d1-3) into pcDNAIII-SNAP
Reagent Quantity (µl)
pcDNAIII-SNAP 10 ng/µl 2.0
MAG(d1-3) insert 10 ng/µl 2.0
Ligation buffer 5x 3.0
T4 ligase 1.0
ddH2O 7.0
The ligation mixture (table 39) was incubated for 2 h at RT.
Colony PCR
Table 39. Colony PCR setup
Reagent Quantity
(µl)
Temperature
(°C)
Time
(min)
N° of
cycles
Sterile ddH2O 19.9 Hold: 95 3
10 mM PCR dNTP Mix   0.5 Denaturation: 95 0:30
5‘ primer T7 100 pM     0.25
3‘ primer Sp6 100 pM     0.25
Clone x
Annealing: 56 1
PCR buffer, 10x   2.5 Elongation: 72 1:30
30
MgCl2   1.5 Final elongation: 72 3
taq-polymerase   0.1
A total of 10 µl DNA loading buffer was added to each finished PCR reaction (table
39). Then, 10 µl marker and 20 µl of each sample were loaded onto an agarose gel.
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Digest analysis of MAG(d1-3) plasmids
Table 40. Digest analysis of MAG(d1-3) plasmids
Reagent Quantity (µl)
plasmid 5.0
Tango buffer 1.0
Xba I 0.5
ddH2O 3.5
The mixture (table 40) was incubated overnight at 37 °C.
Transfection of pcDNAIII-MAG(d1-3)-SNAP into Cos-7 cells
Plates were prepared with 80 % confluent Cos-7 cells and 2 % FCS in DMEM media.
A total of 10 µg of midi-prep plasmid DNA was added to 970 µl 150 mM NaCl and
20 µl Exgen 500. The mixture was incubated for 10 min at RT. A total of 5 plates
with a diagonal of 10 cm were transfected with each clone.
Harvest and analysis of COS-7 supernatant
Strep-Tactin beads and Strep-tag antibody were purchased from IBA. The collected
supernatant was incubated with such Strep-Tactin beads over night at 4 °C under
constant rotation. The beads were centrifuged at 2’000 rpm and the supernatant was
discarded. The beads were washed 4 times with cold PBS. Finally, the beads were
heated for 10 min at 95 °C in non-reducing sample buffer to elute MAG-SNAP. The
beads were centrifuged at 5’000 rpm and the supernatant was collected. The samples
were analyzed under reducing and non-reducing conditions on a western-blot using
an anti-Strep-tag antibody.
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2.5 Enzymatic immobilization
2.5.1 Evaluation of immobilization conditions
2.5.1.1 Testing of different SNAP substrates
SNAP-tag protein expressed and purified as described with a concentration of 140
µg/ml and 340 µg/ml was used for screening a set of BG substrates. All substrates
were obtained from Covalys and immobilized on standard CM5 sensor chips using
amine coupling and HBS-N buffer. DMSO was purchased from Fluka.
A 33 mM stock solution in DMSO was prepared of all substrates. Additionally, a 5
mM carboxy-BG stock solution was prepared in a 30% DMSO 1 M NaHCO3 mixture
to evaluate described solubility problems. Experiments were carried out in HBS-N as
running buffer. A CM5 sensor chip was preconditioned as described. The carboxy
groups on the chip were activated for 10 minutes with a 1:1 mixture of 0.1 M N-
hydroxysuccinimide (NHS) and 0.1 M 3-(N,N-dimethylamino) propyl-N-ethylcarbo-
di-imide (EDC) at a flow rate of 10 µl/min. Stock solutions were diluted with HBS-N
buffer to 1 or 2 mM concentration. These solutions were then injected over the
activated surface for 10 or 20 min at the flow rate of 1 or 10 µl/min. Afterwards the
flow cells were blocked with a 10 min injection of 1 M ethanolamine, pH 8.0.
After immobilization of the substrates the system was primed once before usage.
SNAP-tag was injected over the modified surface at a flow rate of 1 µl/min. The
velocity and the final level of immobilized protein were evaluated.
2.5.1.2 Testing of different SNAP concentrations
SNAP-tag protein with a concentration of 125 µg/ml was expressed and purified as
described. The sample was used for screening different concentrations.
The influence of the concentration of SNAP-tag on immobilization velocity was
tested. A 33 mM stock solution of BG-PEG12 in DMSO was used. Immobilization of
the substrate was performed in parallel on all flow cells. Experiments were carried
out in HBS-P as running buffer. A CM5 sensor chip was preconditioned as described.
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The carboxy groups on the chip were activated for 10 minutes with a 1:1 mixture of
0.1 M N-hydroxysuccinimide (NHS) and 0.1 M 3-(N,N-dimethylamino) propyl-N-
ethylcarbo-di-imide (EDC) at a flow rate of 10 µl/min. The DMSO stock solution
was diluted with HBS-N buffer to a 1 mM concentration. This solution was then
injected over the activated surface for 5 min at the flow rate of 10 µl/min. Afterwards
the flow cells were blocked with a 10 min injection of 1 M ethanolamine, pH 8.0.
After immobilization of the substrate the system was primed once. The SNAP-tag
sample was diluted twice 1:2 with 10 mM PBS to obtain two lower concentrations.
The samples were injected sequentially for 150 min at a flow rate of 1 µl/min on the
corresponding flow cell (Fc2: 62.5 µg/ml, Fc3: 31.25 µg/ml, Fc4: 125 µg/ml). The
velocity and the final level of immobilized protein were evaluated.
2.5.1.3 Testing of different substrate immobilization times
SNAP-tag protein expressed and purified as described with a concentration of 40
µg/ml was used for screening different substrates immobilization times.
A 33 mM stock solution of BG-PEG12 in DMSO was used. Immobilization of the
substrate was performed sequentially on flow cell 2 and 3. All experiments were
carried out in HBS-P as running buffer. A CM5 sensor chip was preconditioned as
described. The carboxy groups on the chip were activated for 10 minutes with a 1:1
mixture of 0.1 M N-hydroxysuccinimide (NHS) and 0.1 M 3-(N,N-dimethylamino)
propyl-N-ethylcarbo-di-imide (EDC) at a flow rate of 10 µl/min. The DMSO stock
solution was diluted with HBS-N buffer to a 1 mM concentration. This solution was
then injected over the activated surface for 5 min (Fc2) or 20 min (Fc3) at the flow
rate of 10 µl/min. Afterwards the flow cells were blocked with a 10 min injection of 1
M ethanolamine, pH 8.0.
After immobilization of the substrate the system was primed once before injection of
the SNAP-tag. Two sequential injections for 150 min at the flow rate of 1 µl/min
were performed. The velocity and the final level of immobilized protein were
evaluated. In addition, the second injection was utilized to monitor a potential loss of
enzyme activity during the 150 min injection time at 25 °C.
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2.5.1.4 Preparation of a BG-PEG12 sensor chip
Immobilization was carried out in HBS-P or HBS-N as running buffer. A CM5
sensor chip was preconditioned as described. If desired all flow cells were prepared
in a single step. The carboxy groups on the chip were activated for 10 minutes with a
1:1 mixture of 0.1 M N -hydroxysuccinimide (NHS) and 0.1 M 3-(N ,N -
dimethylamino) propyl-N-ethylcarbo-di-imide (EDC) at a flow rate of 10 µl/min. The
DMSO stock solution of BG-PEG12 was diluted with HBS-N buffer to a 2 mM
concentration. This solution was then injected over the activated surface for 20 min at
the flow rate of 1 µl/min. Afterwards the flow cells were blocked with a 10 min
injection of 1 M ethanolamine, pH 8.0. After immobilization of the substrates the
system was primed once before injection of the SNAP-tag.
2.5.1.5 Comparison of SNAP and MAG(d1-3)-SNAP
SNAP (170 µg/ml) and MAG(d1-3)-SNAP (290 µg/ml) expressed in insect cells and
purified as described were used for immobilization. In addition, insect cell culture
supernatant with an estimated SNAP concentration of 4 µg/ml was used for direct
immobilization. The anti-FLAG M2 monoclonal antibody was purchased from
Sigma.
A BG-PEG1 2  surface was prepared as described (2.5.1.4). Purified MAG(d1-3)-
SNAP was injected for 150 min at a flow rate of 1 µl/min. To created equal molar
surfaces SNAP was injected for 10 min. Insect cell culture supernatant containing
SNAP was injected for 100 min at a flow rate of 1 µl/min.
To finally compare immobilization levels quantitatively, a monoclonal anti-FLAG
antibody was utilized. A concentration of 290 nM was injected for 1 min and levels
obtained were compared.
Additionally, the antibody was characterized to ensure saturation level at 290 nM.
Interaction experiments were performed in HBS-EP at a flow rate of 20 µl/min.
Starting at 290 nM, 8 concentrations of a twofold dilution series were prepared. To
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remove the remaining antibody after binding a 15 sec. injection of glycine pH 1.5
was necessary. Association and dissociation were monitored for 1 min.
2.5.1.6 MAG(d1-3)-SNAP expressed in mammalian cells
The monoclonal anti-MAG antibody was a kind gift from Dr. Frank Dietz.
Expression of MAG(d1-3)-SNAP was done in CHO cells on 10 cm plates. The
supernatant was concentrated by a factor of 16. A BG-PEG12 surface was prepared as
described (p. 115) and a direct immobilization was performed. A monoclonal anti-
MAG antibody (0.6 mg/ml) was diluted 100 fold in running buffer and injected for 60
s at 20 µl/min.
Interaction experiments with SH-136 were performed in HBS-EP at a flow rate of 20
µl/min. A total of 10 concentrations of a twofold dilution series, starting at 400 µM,
were prepared. The samples were injected in triplicates in a randomized order. Five
blank buffer injections were performed before and one after the experiment.
Association and dissociation were monitored for 1 min.
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3 RESULTS AND DISCUSSION
3.1 GSLA-2 as a model system for carbohydrate/lectin interactions
Antibodies were among the first proteins to be analyzed on SPR-based biosensors.172
They have drawn increased interest in pharmaceutical companies where the market of
therapeutic antibodies increased by 30% annually since 2000.173 Therapeutic
antibodies like Herceptin, Humera, Avastin and Xolair are among the most well
known ones. Antibodies are extensively screened on SPR-based biosensors for their
kinetic characterization and in 2005 a total of 151 papers were published.145
For SPR-based biosensors a clear advantage of antibodies as ligands are their high
molecular weight that results in larger signals and the high affinity in the µM and nM
range. Furthermore, immobilization of antibodies on biosensor chips was achieved
with standard amine coupling. In general, antibodies are a straightforward system and
can be used for training and validation.
GSLA-2 is a monoclonal antibody used for tumor diagnostics.174 It recognizes the
sialyl Lewisa (sLea) epitope that has an increased occurrence on mucin type
glycoproteins of patients with e.g. colon cancer.
3.1.1 Biosensor experiments with GSLA-2
3.1.1.1 Immobilization of GSLA-2 with amine coupling
pH and concentration scouting for amine coupling of GSLA-2
The first step for the coupling of proteins via their amine groups is the evaluation of
immobilization conditions. By finding an optimal pH, a higher attraction to the
carboxymethyl dextran matrix and, as a consequence, higher immobilization
efficiency can be achieved (p. 59). In addition, an assessment of the optimal protein
concentration allows the fine-tuning of the process. By adjusting concentration and
pH the immobilization velocity can be optimized to permit a better controllability of
the resulting immobilization level. Although the use of pH  attraction is not a
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necessity, it is usually applied to enable immobilization at lower protein
concentrations, thus limiting sample consumption. Immobilization of a pH labile
protein under physiological conditions (p H  7.4) was achieved with high
concentrations (2 mg/ml).154
In general, proteins possess different conformations at different pH due to changes in
intramolecular hydrogen bonding. The asialoglycoprotein for example elicits its
physiological function via a pH-induced conformational change.175,176 Although a
protein can change back to its native state under physiological conditions, attachment
to the carboxymethyl dextran matrix at several sites could diminish such
rearrangements. Therefore one has to bear in mind that amine coupling could affect
the proteins conformation.
Table 41. Surface attraction levels obtained for Fc-MAG(d1-3) at different pH values and concentrations.
pH Response*
(RU)
Concentration
(µg/ml)
Response**
(RU)
7.4        67 10 15’000
5.5 19’853 20 25’000
5.0 30’136 40 28’000
4.5 20’886
4.0 12’559
* at a concentration of 40 µg/ml
** at pH 5.0
The surface attraction was maximal at pH 5.0 (table 41). Higher concentrations led to
an increased attraction, as expected. For lower concentrations, surface attraction
decreased, but the velocity was slower what enables a better controllability of the
final immobilization level. Nevertheless, a concentration of 40 µg/ml seemed to be
optimal for sufficient attraction at pH 5.0 and was used for immobilization.
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3.1.1.2 Binding assays with GSLA-2
For both sLea and sLea-Lem (Lem = (CH2)8COOMe) block signals were obtained
displaying fast association and dissociation behaviour (figure 32-A and C). This is a
typical kinetic for carbohydrate/protein interactions that are based on a fast
recognition, but a weak interaction.177,178 Injection of triplicates proved a high
reproducibility and evaluation of the steady state demonstrated a perfect fit to a
simple 1:1-binding site model (saturation binding plot in figure 32-B and D).
Figure 32. Sensorgrams and saturation binding plots for both sLea-Lem (A,B) and sLea (C,D).
A clear difference of the Rmax values for the high (30 RU) and low (18 RU) capacity
surface was observed that was consistent for both ligands (table 42). The surface
capacity is referred to as the amount of protein immobilized. The calculated protein
activity based on the Rmax value displayed significant differences (table 42). The
protein activity is calculated as the fraction of protein that is actually binding the
ligand based on equation 4 (p. 54). In both cases the activity was 10% higher for the
low capacity (sLea-Lem: 36.4%, sLea 44.5%) than the high capacity surface (sLea-
Lem: 25.6%, sLea 34.5%). The effect of higher activity on surfaces with lower
amounts of protein was already described earlier.179
A B
C D
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Even more interesting was the fact that signal intensity was in general 10% higher for
sLea compared to sLea-Lem. Therefore, not only surface capacity but also the type of
ligand had an influence on signal intensity. The observed phenomenon nicely
highlighted that for small ligands the signal to molecular mass correlation is not
exact. In the case of GSLA-2 a total deviation of approximately 20% was observed.
Table 42. Calculated activity for the high and low capacity surfaces.
Compound Surface capacity
(RU)
Rmax
(RU)
Activity
(%)
sLea-Lem 8000 27.1 25.6
sLea-Lem 3800 18.1 36.2
sLea-Lem 3800 18.2 36.4
sLea 8000 30.4 34.5
sLea 3800 18.7 44.5
sLea 3800 18.4 43.8
Comparing KD’s derived from steady state and kinetic date evaluation proved
consistency (table 43). Even for such fast interactions, determination of KD values via
kinetic data was feasible.
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Table 43. Comparison of thermodynamic and kinetic data for sLea-Lem and sLea. Steady state saturation
binding resulted in identical KD values as calculated via the kinetic data.
Compound KD
(µM)
Rmax
(RU)
kon
(M-1•s-1)
koff
(s-1)
kon•koff-1
(µM)
sLea-Lem 11.8 27.1 3.9•104 0.46 12.4
sLea-Lem 10.4 18.1 5.6•104 0.59 10.5
sLea-Lem   9.5 18.2 8.3•104 0.79 10.4
sLea 24.2 30.4 1.8•104 0.42 23.9
sLea 20.6 18.7 2.8•104 0.55 19.9
sLea 24.5 18.4 2.2•104 0.57 25.4
Table 44. Calculated average values for thermodynamic and kinetic data of both sLea-Lem and sLea.
Compound KD (µM) kon (M-1•s-1) koff (s-1) t1/2 (s)
sLea-Lem 10.6 +/- 1.2 5.9•104 0.61 1.1
sLea 23.1 +/- 2.2 2.3•104 0.51 1.4
Comparison of the affinity for sLea (23.1 µM) and sLea-Lem (10.6 µM) underlined
the impact of artificially added labels or linkers. The KD values deviated by a factor
of 2. Interestingly, sLea-Lem showed a higher affinity though a flexible chain was
added. Either the hydrophobic chain established an additional hydrophobic contact or
the higher lipophilicity forced the ligand out of the hydrophilic environment. The
influence of such labels on affinity, specifically enzyme kinetics, was described
before.180 In the case of sLea-Lem, the label was added to enable easy purification of
such hydrophilic molecules on RP-18 columns. In many other cases, the assay itself
requires labeling for its detection system.
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Figure 33. The antigen sLea (R = (CH2)8COOMe) (R =  H) and the desialiylated Lea measured.
The kinetic evaluation was more problematical because the data was close to the
detection limit for the Biacore 3000 (kon 102-107, koff 10-1-10-5). Nevertheless,
triplicate experiments allowed a consistent determination and values obtained were in
good agreement with published data of carbohydrate/protein interactions.178 Faster
complex association was the driving force for higher affinity of sLea-Lem whereas
complex dissociation behaviour remained roughly unaffected.
Figure 34. sLex mimics tested for binding to GSLA-2
To proof the high selectivity of GSLA-2 towards the sLea epitope, Lea and two sLex
derivatives were tested. In both sLex derivatives the GlcNAc moiety was replaced by
a cyclohexyl ring what removed the isomerism between sLea and sLex (figure 34).
Desialydation of sLea completely prevented binding to GSLA-2 up to a 2 mM
concentration. The importance of the sialic acid moiety for recognition was therefore
nicely shown. Furthermore, none of the sLex mimetics bound to GSLA-2 up to a 2
mM concentration. Concluding, a specific interaction of the GlcNAc moiety with
GSLA-2 is needed.
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Additionally, a set of sLea derivatives were analyzed by our collaborators in Lübeck
using STD-NMR, transferred NOE analysis and surface plasmon resonance. The C6-
methyl group of fucose and the N-acetyl group of the GlcNAc residue were found to
contribute significantly to binding.
Combination of NMR and surface plasmon resonance technologies permitted to
describe the binding epitope of GSLA-2 in detail. The N-acetyl group of the GlcNAc
moiety as well as the sialic acid moiety were shown to be essential for binding. In
addition, the C6-methyl group of the fucose residue contributed significantly to
binding affinity (figure 35).
Figure 35. Binding epitope of GSLA-2 for the antigen sLea as determined by NMR and Biacore experiments.
The characterization of the GSLA-2/sLea interaction by the SPR-based biosensor and
NMR was published in the J. Med. Chem.166
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3.2 Myelin-associated glycoprotein (MAG) as drug target
The MAG project was conducted in close cooperation with the group of Prof. Sørge
Kelm (University of Bremen, Germany). The protein consisted of the Fc portion of
human immunoglobulin IgG1 and the three N-terminal domains of murine MAG
(figure 36-B). The construct included the described sialic acid binding site in the v-
domain but the potential NgR binding site in was absent.33
Figure 36. MAG including the five extracellular domains, the transmembrane and cytoplasmatic domain. The
Fc-MAG(d1-3) construct composed by the three extracellular domains including the N-terminal v-type domain
and the Fc portion of human immunoglobulin IgG1.
For the design of the Biacore assay there were to alternative approaches, either to
immobilize the ligands or MAG itself. Because IC50 values were already available
and kinetic data can only be derived precisely from a 1:1-binding event, the bivalent
Fc-MAG(d1-3) construct was immobilized onto the dextran surface. Deviations of
kinetic data for bivalent ligands were described before.155 Coupling of MAG to the
biosensor chip further provided the opportunity to measure several ligands on one
surface leading to a reduced number of sensor chips needed. Additionally, also lower
amounts of MAG were required. The major concerns were the activity of MAG after
Siglec-4 (MAG) Fc-MAG(d1-3)
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immobilization with standard covalent immobilization strategies and the signal
intensity for ligands with a molecular weights in the range of 500 Da.
All compounds synthesized at the Institute of Molecular Pharmacy were measured by
our collaborators in a hapten inhibition assay using the same Fc-MAG(d1-3)
construct (p. 38). Because no KD reference values for MAG-ligands were available,
relative IC50 values from the hapten inhibition assay were used for assay validation.
Due to the oligovalent interaction and the weak competitor used in the hapten
inhibition assay, only a qualitative validation was possible.
3.2.1 Amine coupling of Fc-MAG(d1-3)
A careful evaluation on a homology model was carried out to identify attachment
sites. The homology model of the sialic acid binding v-domain is based on
sialoadhesin (Siglec 1).181 Lysines in the sialic acid binding site would prohibit amine
coupling as immobilization strategy.
Figure 37. (A) Homology model of the N-terminal v-domain displaying all three lysines (Lys67, 85 and 114)
as attachment sites for amine coupling. (B)
The potential sialic acid binding site (figure 37-B) was found to be in proximity of
Lys114 (figure 37-A, yellow). The distance between Lys114 and the carboxyl group
on the ligand is rather long (18 Å). Nevertheless, a disturbance of the binding site was
BA
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possible due to the flexibility of the lysine side chain and the orientation of the 9’-
modification of the ligand towards that lysine.
3.2.1.1 Immobilization of Fc-MAG(d1-3)
Table 45. Immobilization conditions (pH and concentration tested.
pH Response*
(RU)
Concentration
(µg/ml)
Response**
(RU)
Response***
(RU)
7.4         -8 20   8’000   1’500
5.5       200 40 22’500   5’000
5.0       400 80 26’000 15’000
4.5   6’981
4.0 19’095
*at a concentration of 40 µg/ml
** at pH 4.0
*** at pH 4.5
A maximal attraction was obtained at pH 4.0 when injecting a 40 µg/ml concentration
(table 45). Furthermore, three different concentrations (20, 40 and 80 µg/ml) for pH
4.0 and 4.5 were evaluated (table 45). A clear correlation between concentration and
surface attraction was observed. The low attraction at pH 5.0 ad 5.5 was overcome by
higher concentrations and enabled coupling at somewhat milder conditions. In the
case of MAG, it was known that a low pH (around 3.0) is only tolerated for a short
period as employed for affinity purification. In this case, exposure is limited to
approximately 10 minutes. For pH 4.0 high surface densities were achieved easily
with a protein concentration of 40 µg/ml. Unfortunately, fast surface attraction did
complicate controllability of the final immobilization level. After stopping the
immobilization, a drop was observed (figure 38-A).
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Figure 38. Amine coupling profile performed at pH 4.0 (A) and 5.5 (B): After activation of the surface with a
mixture of EDC-NHS (1) the protein sample was injected (2). The procedure was finished by a deactivation
step where all remaining activated carboxyl groups were capped by EA (3).
By increasing the concentration to 140 µg/ml, it was possible to immobilize sufficient
Fc-MAG(d1-3) (6802 RU) at pH 5.5 within 10 minutes (figure 38-B). Levels
achieved for other pH conditions are displayed in table 46.
Table 46. Immobilization levels at different pH values
pH Immobilization level
(RU)
Concentration
(µg/ml)
Immobilization time
(s)
4.0   7693 40 120
4.5 17184 70 360
5.0   3995 70 360
5.5   6802 140 600
A
1 2 3
B
2 31
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3.2.1.2 Validation of coupled Fc-MAG(d1-3)
For all ligands measured, the chemical structure can be looked up in the appendix I
via its specific label.
The validation process was performed with a set of sialic acid derivatives (SH-082,
SH-136, SM-I3 and SM-I4) for which the relative affinity (rIC50) was known from
the hapten inhibition assay. As described (p. 38), this assay is based on a multivalent
interaction of MAG and a weak competitor and IC50 values were therefore likely to
deviate from the KD value. Additionally, the absolute values deviated significantly
between different plates and were therefore normalized with a standard compound
(SH-019). Nevertheless, the KD for SH-082, SH-136, SM-I3 and SM-I4 was
expected in the µM range.
Figure 39. Sensorgrams (A) and saturation binding plot (B) for SH-082 measured on a surface that was created
at pH 4.0.
For the Fc-MAG(d1-3) surface prepared at pH 4.0, no saturation of the binding was
obtained for SH-082 (figure 39). The surface appeared inactive due to the fact that
concentrations up to 2 mM were used.
Immobilization at pH  5.5 resulted in an active surface and the equilibrium
dissociation constants of all four ligands were in the expected range. A simple 1:1-
binding model fitted best with the experimental data (figure 40). The fit and the
sensorgrams were of inferior quality compared to the GSLA-2 results. This was most
likely due to the overall lower signal intensity leading to a lower signal-to-noise ratio.
A B
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Figure 40. Sensorgrams and fitting curves for SH-082 (A,B), SM-I3 (C,D) and SM-I4 (E,F).
Table 47. Equilibrium binding constants obtained on an amine-coupled surface at pH 5.5.
Analyte KD      (µM) rIC50 Rmax        
(RU)
MW
(g/mol)
Activity
(%)
SH-082 4.5   0.87 12.9 570# 15
SH-136 3.4   1.00   8.1 501* 13
SM-I3 1.9   0.29 13.4 626* 17
SM-I4 1.2   0.16   8.0 594* 11
SH-164 n.d. 10.00   4.0 425#   6
*measured on a surface with 7300 RU of Fc-MAG(d1-3)
#measured on a surface with 8400 RU of Fc-MAG(d1-3)
Maximal signal intensity observed was 17% what was rather low. The protein seemed
to loose activity during immobilization. For SH-164 no evaluation was possible due
to an insufficient signal intensity (Rmax = 4.0). Interestingly, SH-019 that differed by
only one benzyl group compared to SH-164 displayed a doubled Rmax. The increased
signal intensity found was in good agreement with published data where a higher
refractive index increment for aromatic groups was described.182 Furthermore, a high
influence of chlorides on the signal intensity was visible (table 47). Even though the
molecular weight for a difluoro (SM-I3) and a dichloro (SM-I4) compound (figure
A
FD
EC
B
RESULTS AND DISCUSSION
130
39) deviated only by 5 %, the Rmax value for the dichloro compound was 35% larger.
The highest activity was found for SM-I4 containing the highest number of chlorides
(3).
The deviations between the molecular weight and the SPR signal were similar to
effects observed in the GSLA-2 project. Especially for low molecular weight ligands
the nature of the ligand influences the signal intensity significantly. An extended
study to correlate refractive indices of ligands with their signal intensity would
provide a clearer picture. Nevertheless, such rules of thumb can provide an
explanation for deviations.
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3.2.2 Immobilization of Fc-MAG(d1-3) on a protein A surface
To evaluate a possible influence of amine coupling on MAG activity, a capturing
approach was applied where no structures of MAG were involved in surface
attachment. Due to the availability of a Fc fragment in the Fc-MAG(d1-3) construct,
protein A was an obvious option. Usage of protein A to capture antibodies on sensor
chips was described earlier.183-185 Protein A was immobilized using standard amine
coupling and Fc-MAG(d1-3) was captured on the prepared protein A surface.
3.2.2.1 Immobilization of protein A with amine coupling
High surface attraction was observed in the range of pH 4.0-5.0. This was in good
agreement with a pI of 5.1 for protein A.
Table 48. Surface attraction obtained for the tested pH conditions.
pH Response
(RU)
7.4     n.d.
5.5   2’063
5.0 12’042
4.5 14’225
4.0 11’077
For immobilization, pH 5.0 (30 µg/ml) was chosen even though protein A should
remain active at conditions below (table 48). Immobilization levels of 8’000-9’000
RU were obtained routinely on CM5 sensor chips. Parallel immobilization was
carried out where two flow cells were prepared simultaneously. The protein A surface
was stabilized over night at 5 µl/min in HBS-EP.
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3.2.2.2 Capturing of Fc-MAG(d1-3) on the protein A surface
An injection at 10 µl/min for 10 minutes at a concentration of 40 µg/ml enabled
capturing of sufficient Fc-MAG(d1-3) (4’500 RU) onto the protein A surface (figure
41). Two 5 s pulses of glycine pH 2.5 at a flow rate of 60 µl/min allowed complete
removal of Fc-MAG(d1-3) (regeneration). Protein A maintained its activity after
regeneration proven by a subsequent capturing of an equal amount of Fc-MAG(d1-3).
As expected, a minor drift of baseline was observed that got stabilized after 30 to 60
minutes (figure 41).
Figure 41. Capturing of Fc-MAG(d1-3) on protein A: After stopping the injection a drift of baseline was
observed. This is due to the noncovalent bonding between the Fc part of Fc-MAG(d1-3) and protein A.
3.2.2.3 Validation of captured MAG)
For all ligands measured, the chemical structure can be looked up in the appendix I
via its specific label.
Trial experiments on captured MAG
Ligand SH-035 and SH-082 were chosen for a first validation due to their difference
in affinity (factor 100) found in the hapten inhibition assay. Injections of both
compounds showed negative signals and a decaying baseline (figure 42-A,B and
figure 43). The unstable baseline was expected but the negative sensorgrams were
contradictory. In the simplified picture of a Biacore experiment were a positive signal
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corresponds to a mass increase, such negative sensorgrams represented a mass
reduction during the injection of the sample.
Figure 42. Trial experiments on the freshly captured surface: (A) Injections of SH-035 (100 µM) and (B)
Injections of SH-035 (200 µM and 400 µM)
Beside the negative signals, a significant difference between the two ligands in
respect to the dissociation signal was found (table 49). For SH-035, the major
observation was that higher concentrations led to larger dissociation signals whereas
for SH-082 dissociation signals remained constant. This was a sign for saturation in
the case of SH-082 when accounting that the dissociation signal was independent of
any baseline drift.
SH-035 SH-082
rIC50 0.01 1.15
100 µM -13 RU -66 RU
200 µM -25 RU
400 µM -40 RU -69 RU
The first injection of SH-082 resulted in a larger drop during association compared to
the following injections (figure 43). It appeared that the surface got further stabilized
after a first injection.
The second trail experiment, where triplicate injections of nine concentrations of SH-
082 were carried out, further indicated the necessity of a pre-injection. The decay of
Figure 43. Injection of SH-082 (100 µM = 1
and 400 µM  = 4)
Table 49. Evaluation of dissociation signals
A B 200
400
1 11 4
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the surface (100 RU) for the first injection of a high concentration was clearly visible
(figure 44). Afterwards, the drift of baseline was comparable to blank injections and
subtraction of blank injections eliminated the drift in the experimental data.
Figure 44. Evaluation of the drift of baseline in an experiment performed with triplicate injections. Each point
marks the baseline (amount of MAG on the chip) before injection of a sample. The first injection of a
saturation concentration led to a higher surface decay (injection 8). Before and after the mentioned injection no
such drop is observed even for equal concentrations.
The data obtained was analyzed based on a saturation binding plot using two different
approaches. The steady state signals were evaluated with scrubber (figure 45) and
compared with the dissociation signals analyzed with GraphPad Prism (figure 47).
Figure 45. Original (A) and inverted sensorgrams (B) for SH-082. Sensorgrams were simply multiplied by –1,
what can be done directly in the scrubber software.
B
A
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Figure 46. Saturation binding plot of data for SH-082 displaying a perfect fit to a simple 1:1-binding model.
For standard evaluation in scrubber, the sensorgrams needed to be inverted (figure
45-A,B). High reproducibility was proven by almost overlaying curves for the
triplicates. The surface decay was clearly visible during and after injection.
Nevertheless, a perfect fit to a simple 1:1-binding model was obtained (figure 46).
Figure 47. Fitting curve for the dissociation signals of SH-082 based on a simple 1:1 binding model.
During the entire first experiment the surface capacity was reduced by 200 RU (from
4650 to 4450 RU). This corresponded to approximately 5% of the captured Fc-
MAG(d1-3). For the observed Rmax value of 29 RU for this experiment the maximal
calculated shift was only 1.45 RU. Such a small deviation can be neglected. As
expected, the Rmax value was lower in the second experiment (27.9 RU) in correlation
to the reduced surface capacity. After regeneration and capturing of fresh MAG
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(experiment 3), the Rmax value was higher again (33.1 RU). Both approaches for data
evaluation led to identical KD values and a highly precise result was obtained when
comparing all three experiments (table 50).
Table 50. Evaluation and comparison of triplicate experiments performed with SH-082. Highly reproducible
equilibrium binding constants were obtained for both evaluation methods.
Experiment KD (µM)
steady state
KD (µM)
dissociation signal
Rmax (RU)
steady state
1 13.4 13.4 29.2
2 14.4   14.75 27.9
3 13.4 14.8 33.1
For the physiological ligand GT1b, a different picture was obtained. GT1b most likely
forms aggregates in aqueous solution. The higher molecular weight of GT1b and the
formed micelles were supposed to result in larger signals and therefore positive
signals were expected.
Indeed, the sensorgrams of GT1b were positive and showed slow association but faster
dissociation (figure 48-A). Even though the steady state was not finally reached for
all concentrations, steady state signals were evaluated.
Figure 48. Positive sensorgrams obtained for GT1b (A) and the fit of the steady state signals to a simple 1:1-
binding model (B).
A decent fit was obtained as indicated in figure 48-B. The calculated KD was 79.3 µM
but had to be considered as an apparent KD due to expected multivalency of micelles
A B
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and consequential concentration deviations. Nevertheless, positive sensorgrams and
saturation binding somewhat supported the capturing assay.
An interesting direct immobilization of gangliosides on CM5 chips without usage of
any immobilization chemistry was described in literature.186 Several attempts were
conducted to apply the setup for the MAG/GT1b interaction but all failed. After
referencing no reasonable signals were detectable. A possible reason is that GT1b did
not penetrate the matrix sufficiently due to its negative charges resulting in an ionic
repulsion. On the other hand, immobilization without any real attachment was
somehow not logical and, when accounting the fast dissociation of GT1b in the
experiment above, not very likely.
Optimization of the surface stability
In an optimized capturing procedure, the flow rate was adjusted to 1 µl/min what led
to a reduced consumption of protein and increased stability of the surface. The ligand
SM-m5 was used to compare the stability of the surface directly after capturing and
after over night equilibration.
Figure 49. Results obtained for SM-m5 (red = experiment performed directly after capturing, blue and black =
experiment performed the next day after over night equilibration). Fitting curves based on a simple 1:1-binding
model for the three different measurements (A) and normalized to 100 % capacity (B).
As expected, the loss of MAG (3%) and the deviation of the steady state signals
compared to the fit were highest for the first experiment that was performed directly
after capturing (red curve, figure 49). After 24 hours, the surface was stabilized and
A B
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the loss of MAG was significantly lower. Accordingly, the Rmax values were lower in
correspondence to the reduced amount of MAG on the surface (table 51).
Table 51. Results calculated for the three different experiments performed with SM-m5. A clear influence of
over night equilibration after capturing is visible.
Experiment KD
(µM)
Rmax
(RU)
MAG
(RU)
Ratio
(Rmax/MAG)
Loss of MAG
(%)
1 2.2 61.8 4628 0.13 3.0
2 2.2 47.5 3618 0.13 1.0
3 2.3 46.3 3548 0.13 0.6
3.2.2.4 Evaluation of negative sensorgrams
Evaluation of buffer conditions on negative signals and KD values
Shifts of pH were already shown to influence the signal by far more than the small
signals obtained for low molecular weight ligands.179 Consequently, deviations of the
pH between running buffer and sample should be avoided. Especially ligands
containing acid or base functional groups bear potential to alter pH in a 10 mM buffer
system. For that reason an experiment with an increased buffer capacity (50 mM
instead of 10 mM HEPES) was carried out to prove the absence of such an effect.
Beside, a non-specific interaction of either target or ligand with the matrix has the
potential to influence the binding signal leading to negative sensorgrams.179 An
additional experiment where 1 mg/ml carboxymethyl dextran was added to the buffer
system (HBS-EP) was conducted to eliminate such an effect. To further exclude an
ionic repulsion effect on the sensorgrams, an attempt with an increased salt
concentration (150 to 500 mM NaCl) was conducted. A higher ionic strength should
prevent ionic interference to a certain degree. To explore carboxyl groups on the
sensor chip as a source for negative sensorgrams, an additional assay on a surface
with a reduced amount of carboxylic groups (CM4 sensor chip) was carried out.
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All experiments were performed with SH-019 as standard ligand. The chemical
structure of SH-019 can be looked up in the appendix I.
Table 52. Overview of all parameters tested including the obtained equilibrium binding constant for SH-019.
No significantly different KD was found and all sensorgrams remained negative.
Assay KD (µM)
HBS-EP* 21.8 +/- 0.2
HEPES 50 mM 17.6 +/- 0.1
NaCl 500 mM 14.9 +/- 0.1
CMD 1 mg/ml 17.8 +/- 0.1
CM4 chip 20.0 +/- 0.1
HBS-EP** 25.6 +/- 0.1
*10 mM HEPES pH 7.4, 150 mM NaCl, 3mM EDTA, 0.005% polysorbate 20
**exp. with a different stock solution
None of the parameters (buffer capacity, ionic strength or CMD) tested led to any
significant shift of the KD or influenced the negative signals considerably (table 52).
The negative signals were accounted to be independent of ionic attraction or
repulsion, pH-dependent shifts or non-specific binding to the carboxymethyl dextran
matrix. Comparing the KD of identical experiments performed with different stock
solutions (21.8 and 25.6 µM) accentuated a high reproducibility for the assay.
Furthermore, binding experiments on the CM4 sensor chip led to negative
sensorgrams identical to those obtained on CM5 sensor chips. Evaluation of the data
showed a perfect fit to a simple 1:1-binding model (figure 50-A) and a similar KD
(20.0 µM). Recapitulating, no differences were perceived compared to the standard
CM5 sensor chip. Hence, the amount of carboxylic groups on the surface was
excluded as source for negative signals.
RESULTS AND DISCUSSION
140
Figure 50. SH-019 measured on a CM4 sensor chip: A perfect fit to a simple 1:1-binding model was obtained
(A). After removal of all Fc-MAG(d1-3) from the surface, the identical concentrations were injected but no
binding was observed.
After successful measurements with SH-019, the surface was regenerated by
injections of glycine buffer pH 2.5 as mentioned before. Subsequent experiments on
the protein A surface within the identical concentration range showed no binding of
SH-019 (figure 50-B). This excluded an unspecific binding to the protein A surface
as a source for negative signals. In addition, it was clarified that the obtained negative
signals were not derived from matrix effects but from specific interaction with the
captured Fc-MAG(d1-3).
The very careful validation of the capturing assay was necessary to proof absence of
any artefacts causing the negative signals. One possible explanation was a
conformational change upon ligand binding that compensates the small positive
signal of the ligand. Extensive experiments with CD or FTIR would be required to
proof such a change of radius upon ligand binding. An interesting finding was that
negative sensorgrams for a carbohydrate/lectin interaction were already published but
not evaluated in detail.187 In this publication the binding of different monosaccharides
to the asialoglycoprotein receptor (ASGP-R) was investigated. The investigators
interpreted that no significant positive signal was obtained and therefore attached the
monosaccharides to BSA what consequently led to positive signals. A closer look on
the monosaccharide/ASGP-R interaction displayed that the negative signals were
concentration-dependent and that affinity data was comparable to literature data.179
Usage of SPR for the detection of conformational changes was already described
before.124,125 It was found to be comparably sensitive to CD and FTIR.122 In a
A B
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carbohydrate-lectin system, the influence of the hydrodynamic radius of proteins on
SPR signals was described. The decrease of the protein radius correlated with a
negative signal.125 The hydrodynamic radius is the effective size of the
molecule/protein as detected by its diffusion. Supporting experiments displayed that
changes towards compact helical structures resulted in positive signals whereas β-
sheets, turns or unordered structures led to negative signals.123
Unfortunately, an exact separation of a conformational change derived signal from a
binding signal is likely to be difficult or even impossible in cases where kinetics for
both processes are similar.
3.2.2.5 DMSO tolerability
To enable an analysis of water-insoluble compounds, the protein A based capture
assay was validated for DMSO tolerability. The ligand SH-082 was measured in
HBS-EP containing 3% and 6% DMSO. This represented the usual DMSO range
applied on Biacore 3000 though concentrations up to 8% are tolerated in a continuous
flow. The chemical structure of SH-082 can be looked up in the appendix I.
Table 53. Comparison of KD values obtained for SH-082 in a buffer system including DMSO.
HBS-EP 3% DMSO 6% DMSO
KD (µM) 19.2 19.6 19.2
For both 3 and 6% DMSO no deviation of the KD was observed. Signals remained
negative and the Rmax values were slightly higher but still in the same region as
observed for the standard assay. Furthermore, dissociation of the Fc-MAG(d1-3)
protein A complex did not increase by addition of DMSO what was important for
data quality and feasibility in general. Additionally, almost identical KD values
proved that no significant ligand agglomeration occurred in the water-based and the
DMSO-based buffer system.
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3.2.2.6 Sialic acid derivatives
Establishment of an accurate and precise assay setup with sufficient sensitivity
enabled screening of ligands in respect to affinity, kinetics and thermodynamics. For
all ligands measured, the chemical structure can be looked up in the appendix I.
The sialic acid core was chosen as scaffold for ligand development. Multiple options
for modifications were possible in the side chains. The core included the selective
ionic interaction of the carboxy group with Arg118.71 In terms of molecular weight
(309.27 g/mol) the scaffold fulfilled the Lipinski’s rule of five (<500 g/mol).9,94 On
the other hand, too many H-bond acceptors (11) and H-bond donors (6) were present
(Lipinski’s: acceptors <10 and donors <5). Nevertheless, the core exhibited lead-
likeness when accounting for the higher polarity what permitted extensive
hydrophobic modifications.95 Molecular flexibility is rather low for the core but the
side chains are pretty flexible.
Figure 51. The core structure representing the minimal binding epitope with its modification sites R1, R2 and
R3. The carboxyl group forming an ionic interaction with MAG was included to maintain high specificity.
Three different positions on the core structure R1, R2 and R3 (figure 51) were
modified to increase affinity, improve kinetics and optimize drug-likeness.
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In a first attempt, the focus was laid on the benzamido-group (R1, R2 and R3) and the
anomeric substituent R4 (figure 52). The starting point was a patented structure (SH-
164, R1-R3=H and R4=Me) known to bind to MAG with a higher affinity than sialic
acid. Synthetic work was done in-house by Dr. Sachin Shelke.
Figure 52. The starting point for the modifications was a patented structure (SH-164, R1-R3=H and R4=Me)
known to bind to MAG with a higher affinity than sialic acid. Modification sites R1, R2, R3 and R4 were used
for the first optimization round.
Substitution of the OMe-group of SH-164 at the anomeric centre with an OBn (SH-
019) led to an increased affinity by a factor 5 (table 54). An even bigger effect was
obtained for the incorporation of a triazole instead of the OMe (SH-2-6) where
affinity increased by a factor of 2. A further enhancement was achieved by the
introduction of a para-chloro at the 9’-position (SH-081). Halogens like chlorine or
fluorine are regularly used in drug discovery.188 Fluorines are often introduced for
metabolic and pharmacokinetic reasons.
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Table 54. First optimization round for the sialic acid scaffold with the KD values determined.
Compound R1 R2 R3 R4 KD (µM)
SH-141 Cl H Cl OBn >300
SH-164* H H H OMe 137.0
SH-140 N2O H H OBn 59.6
SH-264 H H H OCH2CCH 76.4
SH-246 H H H O(CH2)4CCH 39.6
SH-143 H Cl H OBn 33.9
SH-019 H H H OBn 25.6
SH-082 Cl Cl H OBn 19.2
SH-081 Cl H H OBn 17.1
SH-2-6 H H H OTr 11.7
Bn = benzyl, Me = methyl, Tr = triazole
*the patented structure WO03/000709 A2 was resynthesized in-house.
Due to the lack of a crystal structure of MAG, a homology model was build up by
Heiko Gaethje (University of Bremen, Germany) and Dr. Michele Porro based on
sialoadhesin, a protein with high homology to MAG.181 The homology model was
employed to rationalize the Biacore data and propose future ligand modifications.
Ligand SH-081 was docked onto the MAG-model (figure 53). The proposed docking
mode displayed that the carboxylic group of the ligand generates a salt bridge with
Arg118. Additionally, the hydrophobic modifications at the 2- and 9-position of the
sialic acid scaffold found ideal partners for hydrophobic interactions in the side
chains of Phe129 and Glu131. Especially the π-π interactions between Phe129 and
the ligand are interesting. It provides an explanation for the increased affinity of the
para-chloro modification in SH-081 due to an enhanced interaction.189 Moreover, a
further hydrophobic contact between the acetate-group at position 5 and Trp22 as
well as a hydrogen bond between the NH-group of the N-acetate and the backbone
carbonyl group of Gln126 were observed. The important hydrogen bond between the
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NH (donor) at the 9-position of the ligand and its protein partner, found to be the
carbonyl backbone of Phe129, was identified. Indeed, the presented docking mode
seemed to be very plausible, because of the similarity to the observed binding mode
for methyl 9-benzamido-9-deoxy-Neu5Ac (SH-164) in the crystal structure of
Sialoadhesin.
Figure 53. Docking of SH-081 onto the homology model of MAG.
In the case of SH-141, SH-143 and SH-082, a steric hindrance was possible to cause
the reduced affinity. It seemed that only the para-position was modifiable.
Furthermore did the extension at the anomeric centre by a hydrophobic chain (SH-
264 and SH-246) increase affinity in correlation to the length. Higher affinity due to
an attached hydrophobic chain was already found in the GSLA-2 project.
Only SH-081 was kinetically characterized in detail because all ligands exhibited a
similar fast kinetic profile (table 55). The calculated on- and off-rate was in the same
range as data from GSLA-2 ligands. The calculated complex half-life time was 1.4 s.
Phe129
Glu131
Trp22
Arg118
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Table 55. Kinetic evaluation of the sensorgrams obtained for SH-081.
Compound KD (µM) kon (M-1•s-1) koff (s-1) t1/2 (s)
SH-081 17.1 2.8•104 0.48 1.4
In a next optimization round, the focus was shifted towards modifications at the
anomeric centre and the N-acetyl side chain (figure 54). Ligand SH-081 was chosen
as new lead. Mostly electron withdrawing groups were incorporated to enhance the
interaction of the OBn-group with Phe129 identical to effects observed for the
benzamido group at the 9’-position. Additionally, known improvements on the N-
acetate side chain were included to further enhance affinity.68
Figure 54. Modification sites R1, R2, R3 and R4 used for the optimization of the N-acetate side chain to enhance
the π-π interaction between Phe129 and the OBn at the anomeric centre.
Table 56. Overview on all modifications done and the corresponding KD values determined.
Compound R1 R2 R3 R4 KD (µM)
SH-081 H H H H 17.1
SM-I4 F F H H 4.4
SM-I3 Cl Cl H H 4.3
SM-I6 H H F H 12.4
SM-I5 H H Cl H 15.0
SM-m6 F F H F 0.7
SM-m4 F F H Cl 2.0
SM-m5 F F H OMe 2.2
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As expected from the homology model, introduction of chlorines (SM-I3) and
fluorines (SM-I4) in the ortho- and meta-position of the OBn further enhanced the π-
π-interaction with the Phe129. Interestingly, no specific difference between chlorides
and fluorides were observed. Compared to SH-019, affinity increased for both SM-I3
and SM-I4 by a factor of 4.
Figure 55. Chemical structure of the kinetically interesting compound SM-m6. Introduction of a fluorine (red)
in the N-acetate side chain doubled complex half-life.
Introduction of a fluorine in the N-acetate side chain (SM-m6) further increased
affinity by a factor of 6 (figure 55). This modification was already reported by Kelm
et al. to enhance the interaction by a factor of 17.68 Furthermore, complex half-life
was doubled what was highly interesting but not explainable (table 57). Structure-
kinetics relationship still remains a major challenge for kinetics-based ligand design.
In addition, kinetic behaviour of ligands might be based on specific properties of the
target protein e.g. the occurrence of a ideal binding pocket and therefore not
universally applicable.
Table 57. Comparison of the kinetic data for the N-acetyl side chain modified with a fluoride.
Compound kon (M-1•s-1) koff (s-1) t1/2 (s) KD (µM)
SH-081 7.00 • 104 0.3000 2.3 4.4
SM-m6 2.24 • 105 0.1638 4.2 0.7
Nevertheless, a selection of lead structures based on kinetics was proposed earlier.114
Considering all data, it appeared that the sialic acid core resulted in a fast interaction
profile. No significant progress towards slower complex dissociation was achieved
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even though a large number of modifications were tested. A complete change of the
core appeared promising to influence dissociation behaviour as long as the flat
binding pocket does not favour fast dissociation in general. Modifications based on
gained SAR would permit fast progress with a new core structure.
The large set of equilibrium dissociation constants determined by Biacore was
correlated with the hapten inhibition assay data (table 58).
Table 58. All ligands, for which a rIC50 values from the hapten inhibition assay was available were compared
to its KD values determined by Biacore. A linear correlation analysis was carried out to prove qualitative
agreement of the data. The reference ligand SH-019 is highlighted in yellow.
Compound KD (µM) rIC50
SH-164* 137.0 +/- 0.5 10.00
SH-264   76.4 +/- 0.3   4.95
SH-140   59.6 +/- 0.4   1.67
SH-246   39.6 +/- 0.2   0.60
SH-143   33.9 +/- 0.1   1.43
SH-019   25.6 +/- 0.1   1.00
SH-082   19.2 +/- 0.1   0.87
SH-081   17.1 +/- 0.1   0.54
SH-2-6   11.7 +/- 0.1   0.43
SM-I4     4.4 +/- 0.1   0.16
SM-I3     4.3 +/- 0.1   0.29
SH-272                 1.7   0.05
*Patent: S. Kelm, R. Brossmer, WO 03/000709 A2, 19.06.2001
A high linear correlation (R2 = 0.91) between the equilibrium dissociation constants
and the hapten inhibition assay based rIC50 values was obtained on a double-
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logarithmic scale (figure 56). This supported the accuracy of the negative
sensorgrams.
Figure 56. Linear correlation between KD and rIC50 values on a double-logarithmic scale. High qualitative
comparability between the Biacore and the hapten inhibition assay was proven by a R2 factor of 0.91.
In terms of signal intensity, an interesting relation to the amine coupling assay was
found. The Rmax for SM-I3  and SM-I4 deviated considerably even though the
molecular weight was almost identical (table 59). The negative signal of SM-I3 was
partially compensated by its higher signal intensity. The same effect of higher signal
intensity for SM-I3 was already found in the amine coupling assay (p. 128). The
identical observation was made for SH-019 and SH-082.
Already for the GSLA-2 characterization, such deviations enclosed a considerable
influence on low molecular weight ligands (500 Da). These results further underlined
that a direct correlation of signal intensity to mass is delusive. The impact of aromatic
groups on signal intensity was already published in 2000 but needs to be extended by
halogens.182 Whenever dealing with low molecular weight ligands, deviations are
likely to occur, what is especially important when comparing data from injections of
only one concentration. In these cases, it might be that different signal intensities,
normalized by the molecular weight, do still related to the same affinity.
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Table 59. Comparison of results from amine-coupled and captured Fc-MAG(d1-3)
Analyte Rmax  capt. (RU) Rmax  amine (RU)
SH-082 -21.2 12.9
SH-136 -32.3   8.1
SM-I3 -24.5 13.4
SM-I4 -31.5   8.0
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3.2.2.7 Detailed thermodynamic analysis
The interaction of sialic acid derivatives with MAG was further characterized by
determining the entropic and enthalpic contributions to binding. A detailed
entropy/enthalpy characterization of inhibitors binding to the HIV protease was done
before with a Biacore 3000 and delivered interesting data about the interaction
events.118,190
The selection focused on structural properties because only one class of ligands was
available. A distinct structural feature was needed that influenced affinity by a factor
of at least 5 (figure 57). The patented structure SH-164 was used as starting point.
Addition of a benzyl ring (SH-019) increased affinity by a factor of 5 that was
proposed to be derived from an additional π-π interaction with Phe129. Incorporation
of halogens (SM-m6) further enhanced the interaction by a factor of 25.
ln(KD) = ΔH/R•1/T - ΔS/R Equation 7
The three derivatives were measured at various temperatures (5, 10, 15, 20, 25, 30
°C) and evaluated by applying a van’t Hoff plot. After linear regression, equation 7
allowed to determine entropy and enthalpy via the slope (ΔH/R) and the y-intercept
(ΔS/R).
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SH-164 KD = 137 µM
SH-019 KD = 25.6 µM
SM-m6 KD = 0.7 µM
Figure 57. Selected compounds (SH-164, SH-019 and SM-m6) that were used for a closer thermodynamic
description of the interaction between sialic acid derivatives and MAG. All chemical features introduced were
meant to enhance the interaction and therefore augment the enthalpic contribution.
SH-164
Affinity of SH-164 is based on a specific ionic interaction and hydrogen bridges as
well as a π-π interaction. The core is rather rigid what should limit the entropic cost
upon binding.191 The side chain at the 9-position on the other hand is flexible. This
forecast was in agreement with the obtained results. A 2-fold increase in affinity
(132.3 to 64.5 µM) was observed over the range of 25 °C (table 60) what is
characteristic for an enthalpy driven interaction.
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Table 60. KD values obtained for SH-164 at different temperatures.
T
(°C)
KD
(µM)
30 132.3
25 105.6
20   92.5
15   83.8
10   67.6
  5   64.5
Affinity data were transferred into a van’t Hoff plot and further analyzed (figure 58).
Figure 58: Van’t Hoff plot for SH-164 displaying a high correlation (0.97) for the linear regression.
Linear regression on the van’t Hoff plot displayed a high correlation with a R2 value
of 0.97 (table 61). This confirmed a constant heat capacity within the temperature
range applied what is a prerequisite for a proper van’t Hoff analysis.118 A clearly
enthalpy driven interaction was found with a ∆H of -20.09 kJ•mol-1 and a T∆S of
–2.52 (table 62).
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Table 61. Linear regression of SH-164 Table 62. Entropy and enthalpy calculated for 25 °C
Slope Intercept R2 ∆H
(kJ•mol-1)
∆S
(kJ•mol-1•K-1)
-T∆S
(kJ•mol-1)
-2416.4 -1.0147 0.9698 -20.09 0.0084 -2.52
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SH-019
Incorporation of an O-benzyl group at the anomeric centre was anticipated to create a
π-π interaction with Phe129. An increased enthalpic contribution was expected due to
the additionally introduced interaction.192
The KD changed by a factor of 2 (9.8 to 21.8 µM) over the range of 20 °C. A higher
affinity for lower temperatures was found (table 63) identical to SH-164, hence the
interaction was enthalpy driven.
Table 63. KD values obtained for SH-019 at different temperatures.
T
(°C)
KD
(µM)
25 21.8
20 17.7
15 15.5
10 12.8
5   9.7
Affinity data was transferred into a van’t Hoff plot and further analyzed (figure 59).
Figure 59: Van’t Hoff plot for SH-019 displaying a high correlation (0.99) for the linear regression.
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Linear regression on the van’t Hoff plot displayed a high correlation with a R2 value
of 0.99 (table 64). The heat capacity within the temperature range applied was
constant and the plot was further analyzed to derive the entropy and enthalpy
changes. A clearly enthalpy driven interaction was found with a ∆H of -26.85 kJ•mol-
1 and a T∆S of 0.25 (table 65).
Table 64. Linear regression of SH-019 Table 65. Entropy and enthalpy calculated for 25 °C
Slope Intercept R2 ∆H
(kJ•mol-1)
∆S
(kJ•mol-1•K-1)
-T∆S
(kJ•mol-1)
-3229 0.1005 0.9887 -26.85 -0.00084 0.25
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SM-m6
An enforcement of the π-π interactions was achieved by introducing electron
withdrawing groups.192 This was supposed to further increase the enthalpic
contribution.
For SM-m6 the KD tripled from 0.277 to 0.807 µM over the entire temperature range
(table 66) following the same enthalpic behaviour as observed for SH-164 and SH-
019.
Table 66. KD values obtained for SM-m6 at different temperatures.
T
(°C)
KD
(µM)
30 0.999
25 0.807
20 0.557
15 0.440
10 0.333
  5 0.277
Affinity data was transferred into a van’t Hoff plot and further analyzed (figure 60).
Figure 60: Van’t Hoff plot for SM-m6 displaying a high correlation (0.99) for the linear regression.
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Linear regression on the van’t Hoff plot displayed a high correlation with a R2 value
of 0.99 (table 67). The heat capacity within the temperature range applied was
constant and the plot was further analyzed to derive the entropy and enthalpy
changes. A clearly enthalpy driven interaction was seen with a ∆H of -37.33 kJ•mol-1
and a T∆S of 2.42 (table 68).
Table 67. Linear regression for SM-m6 Table 68. Entropy and enthalpy calculated for 25 °C
Slope Intercept R2 ∆H
(kJ•mol-1)
∆S
(kJ•mol-1•K-1)
-T∆S
(kJ•mol-1)
-4489.7 0.975 0.9887 -37.33 -0.00811 2.42
Recapitulating the results (table 69), introduction of an additional π-π interaction via
an O-benzyl group led to an enthalpic gain by -6 kJ•mol-1. This was in good
agreement with published computational data.189 In general, substitution of the O-
methyl group by an O-benzyl improved ∆G at 25 °C by -3.99 kJ•mol-1. Introduction
of halogens to both aromatic rings and the N-acetate side chain was stated to further
increase the enthalpic contribution by e.g. enhancing the π-π interaction potential.192
Indeed, the evaluated results displayed such an increase (-10.48 kJ•mol-1) compared
to the unsubstituted ligand. The entropic penalty increased by 2.17 kJ•mol-1 at 25 °C.
This could be the result of a disymmertization of the reducing end. Overall, ∆G
improved at 25 °C by -8.31 kJ•mol-1.
Table 69. Overview of thermodynamic data obtained for the selected sialic acid derivatives.
∆H
(kJ•mol-1)
∆S
(kJ•mol-1•K-1)
-T•∆S*
(kJ•mol-1)
∆G*
(kJ•mol-1)
KD*
(µM)
SH-164 -20.09 + 0.00840 -2.52 -22.61 105.6
SH-019 -26.85 - 0.00084   0.25 -26.60   21.8
SM-m6 -37.33 - 0.00811   2.42 -34.91     0.8
*values calculated for 25 °C
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Using the selected three ligands with distinct structural modifications and affinities
spanning a range of two orders of magnitude enabled correlation of structural
modifications to thermodynamic data. For planning such experiments, careful
selection of ligands and access to interesting ligands is most important.
Additional information on kinetics was obtained for the measurements at the different
temperatures. For the first time, a sialic acid derivative (SM-m6) displayed
dissociation behaviour that was visible in the sensorgrams. At 5 °C, the impact was
most distinct (figure 61). To determine the exact dissociation rate, a kinetic
evaluation was performed for data measured at all temperatures. A decent kinetic fit
to a simple 1:1 binding model was obtained.
Figure 61. Kinetic fit to a simple 1:1-binding model on SM-m6 sensorgrams acquired at 5 °C.
Over the measured temperature range, a trend of slower complex dissociation at
lower temperatures was observed (table 70). At 25 °C the half-life time of the SM-
m6/MAG complex was tripled (4.2 s) compared to SH-081 (1.4 s). This was a clear
kinetic advantage of S M - m 6  compared to all other ligands synthesized.
Unfortunately, a coherent explanation for the kinetic improvement by incorporation
of halogens is missing.
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Table 70. Kinetic evaluation of data obtained for SM-m6 at different temperatures.
T (°C) kon (M-1•s-1) koff (s-1) t1/2 (s) KD (nM)
  5 2.75 • 105 0.0669 10.4 243
10 3.05 • 105 0.0977   7.1 320
15 2.30 • 105 0.0960   7.2 417
20 2.73 • 105 0.1380   5.0 505
25 2.24 • 105 0.1638   4.2 732
30 1.98 • 105 0.1888   3.7 954
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3.2.3 Ligand optimization using second site screening
In a pioneering technique termed “SAR by NMR”, NMR screening was used to
identify a ligand binding to the target through the use of an isotopically enriched
protein and structural information.193-195 At saturating concentrations of this first
ligand, a second round of NMR screening was used to identify a second ligand that
bound to the target simultaneously and in the vicinity to the first ligand (“second-site
screening”). Later, an optimized procedure of second site screening through the use
of a spin-labeled first site ligand was described.196
Second-site screening based on such a spin-labeled first site ligand was applied to
MAG in-house by Dr. Brian Cutting and Dr. Sachin Shelke. By combination of in-
situ click chemistry with second-site screening direct association of a first ligand with
a second site fragment was achieved.167 A nitro-indole was identified to bind in
vicinity to the first site. By using spacers of different length, the first site ligand was
coupled in situ to the nitro-indole in presence of MAG (figure 62). Such obtained
second-site ligands were subsequently analyzed on Biacore to proof higher affinity.
Figure 62. A molecular fragment (green) that binds close to the first site ligand (blue) is detected via a spin-
label (yellow) attached to the ligand (A). After appropriate linkage of the found fragment to the first site ligand
affinity should increase (B).
A B
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3.2.3.1 Characterization of second generation ligands
Second-site ligands were composed by a nitro-indole, the first-site sialic acid
derivative and a triazole derived from linkage, differing only by spacer lengths
(figure 63). First-site fragments as well as the nitro-indole were included in the
measurements for comparison.
Figure 63: Chemical structure of the second generation ligand SH-272 that was used for binding site
evaluation. The second site fragment is highlighted in green.
Second generation ligands in general showed a different behaviour in the capturing
assay compared to sialic acid derivatives. The main deviation was that all
sensorgrams were positive. In a first evaluation on a low capacity surface using SH-
272 an increase was observed for concentrations above 125 µM and sensorgrams
displayed fast interaction kinetics (figure 64).
Figure 64. Sensorgrams obtained for SH-272 starting at a 1 mM concentration. A liner increase was visible but
signals went not properly back to baseline.
Interestingly, the steady state signal never went totally back to baseline for lower
concentrations leading to a plateau on the level of 6-8 RU. Binding signals obtained
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were perfectly fit to a two binding site model (figure 65-B) whereas the simple 1:1-
binding site model failed (figure 65-A). The higher KD was estimated in the range of
unspecific binding events (6.2 mM) and for the first site a KD of 1.3 µM was
calculated. Therefore the concentration range was adjusted to the first binding site for
additional experiments performed on a higher MAG density. A simple 1:1-binding
site fit and an enhanced positive signal was expected.
Figure 65. Fitting curves for SH-272: simple 1:1-binding site (A) and two-binding site model (B). A decent fit
was obtained for the two binding site model.
To obtain larger signals, the surface was used directly after capturing of MAG. This
led to a higher surface decay and broader signal distribution (figure 66-A) .
Nevertheless, signal intensity increased as expected. A clear drop of signal intensity
during all injection was observed for triplicate measurements (figure 66-B). In an
experiment performed 24 h later on a lower surface, the Rmax value was back to 8 RU
as seen in previous measurements (figure 66-C). Hence, second-site ligands had to be
measured on a higher surface density to obtain sufficient signal intensity. A simple
1:1-binding event was observed with the indicated variation for the triplicates.
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Figure 66. Sensorgrams and fitting curves for SH-272 on a high (A, B) and low capacity surface (C).
All KD values determined for SH-272  on different surfaces and at different
concentrations were in good agreement (table 71).
Table 71. Comparison of KD’s obtained for SH-272 on different surfaces and concentrations.
Two binding-site modelCompound
site 1 site 2
High capacity
surface
Low capacity
surface
SH-272 1.30 µM 6.3 mM 1.74 µM 1.69 µM
Furthermore, SH-272 was measured on an amine coupling surface to compare the
data. A high correlation was found for both affinity as well as activity (table 72). This
supported our hypothesis that negative sensorgrams were derived from a
conformational change and that amine coupling did not alter protein activity, but
limited its conformational freedom. Second-site ligands somehow acted differently
and did not elicit a conformational change.
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C
RESULTS AND DISCUSSION
165
Table 72. Comparison of results for SH-272 on capturing and amine coupling surfaces.
Assay KD capt.
(µM)
Rmax
(RU)
Activity
(%)
Capturing 1.74 17.7 23
Amine coupling 1.75 17.5 26
For the isolated nitro-indole (245.24 g/mol) no binding was observed up to a 600 µM
concentration. This was most likely due to a combination of very low affinity and low
molecular weight. The triazole derivative (SH-2-6) of the first-site ligand showed an
affinity of 11.7 µM and negative signals. In general, negative signals were found for
all first-site ligands. Furthermore, affinity increased with extension of the
hydrophobic chain at the anomeric centre (table 73). An identical behaviour was
already discussed for the GSLA-2 system and therefore appeared to be a general
effect as long as no steric hindrance occurs. Either an additional hydrophobic
interaction was established or the increased hydrophobicity pushed the ligand out of
the hydrophilic buffer environment.
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Table 73: First site fragments were analyzed to compare the exact gain of the second site fragment.
Compound Chemical structure KD (µM)
SH-2-6
OAcHN
HO
CO2H
H
N
OH
OH
OO
N N
NH
11.7
SH-264
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OH CO2Na
O
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3.2.3.2 Competition experiments with sialic acid derivatives
To evaluate the proposed competitive binding mode, a sialic acid derivative (SH-082)
and a second-site ligand (SH-272) were used in a competition experiment. By
including blanks that contained the specific competition molecule SH-082, it was
possible to both clarify the crossing from negative to positive sensorgrams but also to
perform a KD determination by simply subtracting the blanks.
As expected, the binding of the SH-272 compensated the negative signal of SH-082.
Several observations proved the identical binding site. First, the Rmax value displayed
about the same positive value (figure 67). In case of a non-competitive binding, the
negative signal would just have been compensated by the Rmax value from SH-272 (8-
10 RU). Hence, crossing zero and the similar positive Rmax value was a strong proof
for a competition event.
Figure 67. Compensation of the negative signal by binding of the second-site ligand to MAG (A). After
subtraction of the blanks containing SH-082, it was possible to fit the data to a simple 1:1-binding model (B).
The experiments further revealed that a higher concentration of competitor led to a
higher apparent KD (figure 68, table 74). This represents the expected behaviour and
further supported the identity of the binding site.
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Table 74. Obtained KD values for the
competition experiment
Competitor
(µM)
Apparent KD
(µM)
0 1.7
10 7.8
20 11.8
Figure 68. Normalized fitting curves obtained for
All three competition experiments.
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3.3  Expression of MAG(d1-3)-SNAP
Due to the discussed drawbacks, an additional immobilization strategy beside
capturing and amine coupling was evaluated, with the focus on a gentle, oriented and
covalent immobilization. A rather new technique (SNAP-tag) based on an enzymatic
immobilization fulfilled all these requirements. The SNAP-tag is a mutant of the
human DNA repair protein O6-alkylguanine-DNA-alkyltransferase (hAGT)
exhibiting advanced properties for immobilization. After attachment of its substrate
to the sensor chip, the suizide enzyme links itself to the surface covalently (figure
69). Hence, a target protein that is genetically linked to the enzyme is immobilized
onto the chip at physiological conditions (pH 7.4, 150 mM NaCl).
Figure 69. Enzymatic immobilization: First the substrate is immobilized via standard amine coupling (A).
Afterwards, the enzymatic reaction of SNAP (blue) is performed (B) linking the target protein (red) covalently
to the sensor chip (C).
In the case of MAG, it is known that glycosylation and post-translational
modifications are important to obtain an active protein (unpublished results).
Expression of active MAG was described in COS-7 and CHO cells. Therefore, E.coli
and yeast were considered unsuitable. In contrast, mammalian or insect cells were
applicable. Finally, due to its in-house availability, the baculovirus infected insect
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cell expression system was applied for preliminary experiments. In a subsequent
attempt, MAG(d1-3)-SNAP was expressed in COS-7 and CHO cells at the University
of Bremen. The three different construct are described in figure 70.
Even though a direct enzymatic immobilization out of E. coli lysate was described
earlier, insect cell media or the dilute sample for secreted protein could demand
purification for proper immobilization. Therefore, an appropriate tag system was
included. The His-tag was not applicable due to interference with the insect cell
media. On the other hand, Invitrogen recommended the FLAG-tag. For the MAG(d1-
3)-SNAP construct for the mammalian cell expression system a Strep-tag was
applied.
Figure 70. Overview of the constructs: In the first construct the SNAP-tag (blue) was fused to a FLAG-tag
(orange) and expressed in insect cells (A). In the target construct the MAG(d1-3) sequence was fused to SNAP-
FLAG and expressed in insect cells. For the expression in mammalian cells, the Strep-tag (green) was used for
purification (C).
Several uncertainties complicated the usage of the SNAP-tag in insect cells. First,
secretion of SNAP-tag from insect cells in its active form was not described yet. In
addition, no information about stability of the SNAP-tag under low pH conditions
(pH 3.5) was available. Stability at low pH  was a prerequisite for FLAG-tag
purification.
A B C
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3.3.1 Insect cells as expression system
In a first attempt, PCR-integration was applied for cloning MAG(d1-3)-SNAP and
SNAP into a pFastBac vector containing the acidic glycoprotein gp67 secretion
signal.197 PCR-integration results in a direct linkage of the secretion signal to the N-
terminal MAG sequence. Unfortunately, no successful integration was obtained and a
standard restriction-ligation approach was conducted instead. The major drawback
was the incorporation of 2 N-terminal amino acids due to the restriction site. The N-
terminal sequence was already known to be critical for the sialic acid binding site
(unpublished results). The binding mode proposed based on the in the homology
model displayed a potential problematic involvement of Trp22 that lies close to the
N-terminus. Nevertheless, an evaluation of SNAP activity in such a construct was
possible.
3.3.1.1 Cloning of MAG(d1-3) into pSS26b
Amplification of MAG(d1-3) out of pIgMAG(d1-3)
Fig.ure 71. Screening for optimal temperature conditions. The correct size of the product was obtained for all
PCRs (936 bp).
A single band was observed for all temperatures screened (figure 71). Because a
temperature gradient led to no differences, future PCR reactions were done without
Lane 1: DNA marker X, 2 µl
Lane 2-5: vector conc. 1:10, 5 µl
Lane 2: 59.3°C , 5 µl
Lane 3: 62.1°C, 5 µl
Lane 4: 63.9, 5 µl
Lane 5: 65°C, 5 µl
Lane 6-9: vector conc. 1:100, temperature
graduation as Lanes 2-5, 5 µl
Lane 10: Blank
1     2     3    4     5    6    7    8    9  10
936 bp
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prior temperature evaluation but just based on primer melting temperature Tm. For
higher template concentrations, a higher amount of PCR product was obtained.
Double-digest of pSS26b and MAG(d1-3) insert
Figure 72. Quantification of insert and vector after digest.
The pSS26b vector and the MAG(d1-3) PCR product were digested using XhoI and
HindIII. The vector was clearly linearized (3506 bp) and the MAG(d1-3) insert still
displayed the correct size (939 bp).
Digest analysis of pSS26b-MAG(d1-3)
Figure 73. Digest analysis of clones 2,3,5 and 6 displayed the correct fragment size of 936 bp.
Lane 1: DNA marker X, 2 µl
Lane 2: digested pSS26b, 1 µl
Lane 3: digested MAG(d1-3) insert, 1 µl
Lane 1: DNA marker X, 2 µl
Lane 2: Clone 1 MAG, 5 µl
Lane 3: Clone 2 MAG, 5 µl
Lane 4: Clone 3 MAG, 5 µl
Lane 5: Clone 4 MAG, 5 µl
Lane 6: Clone 5 MAG, 5 µl
Lane 7: Clone 6 MAG, 5 µl
1        2       3       4       5       6        7
939 bp
3506 bp
1        2        3
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Obtained mini-prep DNA was digested using XhoI and HindIII. Clones 2, 3, 5 and 6
were found to be positive (figure 73).
3.3.1.2 Cloning of MAG(d1-3)-SNAP / SNAP into pFastBac-S
Double digest of pFastBac-S, MAG(d1-3)-SNAP and SNAP inserts
Figure 74. Quantification of inserts and vector after digestion with XhoI and XbaI.
After digestion with XhoI and XbaI, an equal amount of all inserts and vector was
obtained (figure 74). For ligation, a ratio of 1: 4 (vector:inserts) was defined.
Digest analysis of pFastBac-MAG(d1-3)-SNAP and pFastBac-SNAP
Figure 75. Digest analysis of clones for MAG-SNAP using XhoI and XbaI.
Lane 1: DNA marker X, 2 µl
Lane 2: pFastBac-S, 1 µl
Lane 3: SNAP-FLAG, 1 µl
Lane 4: (not relevant)
Lane 5: MAG-SNAP-FLAG, 1 µl
Lane 1: DNA marker X, 2 µl
Lane 2: Clone 1 MAG-SNAP, 5 µl
Lane 3: Clone 2 MAG-SNAP, 5 µl
Lane 4: Clone 3 MAG-SNAP, 5 µl
Lane 5: Clone 4 MAG-SNAP, 5 µl
Lane 6: Clone 5 MAG-SNAP, 5 µl
1       2       3       4        5       6
1       2      3      4       5
690 bp 1629 bp
RESULTS AND DISCUSSION
174
After digestion of obtained mini-prep DNA with XhoI and XbaI clones 1-4 were
found to be positive (figure 75).
Figure 76. Digest analysis of clones for MAG-SNAP using XhoI and XbaI.
After digestion of obtained mini-prep DNA with XhoI and XbaI clone 2, 3 and 5
were found to be positive (figure 76).
3.3.1.3 Isolation and analysis of bacmid DNA
Figure 77: PCR analysis of isolated bacmid DNA. Incorporation of the genes of interest was checked before
proceeding to transfection of sf9 cells.
Only one negative bacmid (300 bp) was found on lane 4 (figure 77). All other
bacmids had successfully incorporated the gene.
Lane 1: DNA marker X, 2 µl
Lane 2: Clone 1 SNAP, 5 µl
Lane 3: Clone 2 SNAP, 5 µl
Lane 4: Clone 3 SNAP, 5 µl
Lane 5: Clone 4 SNAP, 5 µl
Lane 6: Clone 5 SNAP, 5 µl
1    2    3    4    5    6    7   8    9   10  11
1       2       3      4      5       6
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3.3.1.4 Evaluation of insect cell lines for Expression
Figure 78. (A) Western blot of expressed SNAP-tag in either sf9 or H5 cells. Samples were taken after 24 (1),
48 (2) and 120 h (3). (B) Western blot of expressed MAG-SNAP-tag in either sf9 or H5 cells. Samples were
taken after 24 (1), 48 (2), 72 (3) and 120 h (4).
Figure 79. (A) Fluorescently labelled SNAP expressed in either sf9 or H5 cells. Samples were taken after 24
(1), 48 (2) and 120 h (3). (B) Fluorescently labeled MAG(d1-3)-SNAP expressed in either sf9 or H5 cells.
Samples were taken after 24 (1), 48 (2), 72 (3) and 120 h (4).
The expression of SNAP (figure 78-A) and MAG-SNAP (figure 78-B) in insect cells
was verified by western blot analysis using a anti-FLAG antibody. The band seen for
SNAP (20.5 kDa) was in the range of 20 – 24 kDa and the one for MAG-SNAP (55
kDa) between 45 – 66 kDa. No additional bands were visible. For both constructs, an
expression for 48 h was shown to be optimal. After 48 h, the protein bands
disappeared probably due to cleavage by proteases present in the medium. For the
MAG-SNAP construct, a benefit of H5 as expression system was observed.
M   1    2    3    1    2    3
sf9 H5
A sf9 H5
M   1    2    3    4    1    2    3    4
B
1    2    3    1    2    3
sf9 H5A
1    2    3    4    1    2    3    4
sf9 H5
B
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The successful labeling of both constructs proved the enzymatic activity of the
SNAP-tag after expression in insect cells (figure 79-A and B). Furthermore, the N-
and C-terminal attachment of additional sequences did not disable enzyme activity.
Unfortunately, the seen activity for the MAG-SNAP construct was lower even though
the western blot showed as high expression as seen for SNAP. As a final
consequence, all further expressions were carried out in H5 cells for 48 h.
3.3.1.5 Purification of FLAG-tag Proteins
Figure 80. (A) SDS-PAGE of fractions 2 – 8 including a low molecular marker. Staining was performed with
enhanced Coomassie. An even distribution of samples containing SNAP was observed as supposed.
Visualization of active SNAP by using SNAP-vista blue after purification was possible (B).
The purification via the FLAG-tag was performed successfully resulting in pure
protein (figure 80-A). The visualization of SNAP with a fluorescently labeled
substrate proofed the resistance of SNAP against a pH of 3.5 during elution (figure
80-B). In addition, the observed intensity correlated to the amount of protein found in
the coomassie-stained SDS-PAGE. Because MAG(d1-3) was known to withstand pH
3.5 in such a purification procedure, the FLAG-tag was proven to be suitable for the
purification of MAG(d1-3)-SNAP.
f2   f3   f4   f5  f6   f7   f8MA f2   f3   f4   f5   f6   f7   f8
B
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3.3.2 Mammalian cells as expression system
Cloning and expression was performed at the Centre for Biomolecular Interactions,
University of Bremen in the laboratory of Prof. Soerge Kelm, All enzymes used were
purchased from Fermentas GmbH. The purification system was changed to Strep-
tag/Streptactin that is routinely utilized in the group. In a first attempt, a transient
expression was performed in COS-7 cells to check for expression of the construct.
Afterwards a stable CHO cell line was established. Due to the use of the natural
MAG secretion signal, no additional N-terminal amino acids were incorporated. The
construct was build the way active MAG(d1-3) was produced earlier.
3.3.2.1 Cloning of SNAP into pcDNAIII-Strep
Colony PCR
Colony PCR is used as a fast and easy technique to screen for positive clones after
ligation. Clones were picked from an agar plate and directly added to a prepared PCR
mixture. Clones containing the correct gene resulted in a PCR product of the correct
size.
Figure 81. Colony PCR samples on agarose gel
All clones except clone 5 were positive (figure 81).
Lane 1: DNA marker, 10 µl
Lane 2-10: Colony PCR of clones 1-9, 10 µl
1    2     3    4    5   6   7    8    9   10
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Harvest and analysis of transfected Cos-7 cells
Figure 82. Western blot with an anti-Strep antibody.
Harvested and lysed cells were checked for intracellular SNAP expression on a
western blot using an anti-Strep antibody (figure 82). All eight positive clones
showed expression of SNAP at the correct molecular weight (20.5 kDa).
3.3.2.2 Cloning of MAG(d1-3) into pcDNAIII-SNAP
Colony PCR
Figure 83. Colony PCR of five clones for MAG(d1-3).
Only three positive clones (clone 1, 3 and 5) were found in colony PCR (figure 83).
Lane 1-8: Lysate, 10 µl
Lane 9: MWM in kDa, 10 µl1     2      3      4      5      6      7      8      9
1   2   3   4   5   6
Lane 1: DNA marker, 10 µl
Lane 2-6: Colony PCR of clones 1-5, 10 µl
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Digest analysis of MAG(d1-3) plasmids
Figure 84. Digest analysis of clones 1 and 5.
Clone 1 and 5 showed the correct size (975 bp) for the insert (figure 84).
Harvest and analysis of COS-7 supernatant
Fig.ure 85. Western blot of purified supernatant after transient expression with clone 1 and 5.
By both clone 1 and 5 MAG(d1-3)-SNAP was successfully expressed and secreted as
observed by western blot (figure 85). The molecular weight was slightly higher for
the reduced sample compared to the non-reduced sample. In addition, a low amount
of dimer was observed under non-reducing conditions.
Furthermore, it was possible to recognize the MAG(d1-3)-SNAP construct with an
anti-MAG antibody (in-house, Bremen) that required a native structure for binding
(data not shown). The results were very promising and a stable CHO clone was to be
produced.
Lane 1: DNA marker, 10 µl
Lane 2: clone 1, 10 µl
Lane 3: clone 5, 10 µl
1     2    3
1     2     3                    4     5 Lane 1: DNA marker, 10 µl
Lane 2: clone 1 red., 10 µl
Lane 3: clone 5 red., 10 µl
Lane 4: clone 1 non-red., 10 µl
Lane 5: clone 5 non-red., 10 µl
RESULTS AND DISCUSSION
180
3.4 Enzymatic immobilization
Enzymatic immobilization was already applied in surface plasmon resonance
experiments successfully.158 For the procedure itself, the substrate immobilization,
time was known to have an influence on enzymatic immobilization.157,158
Investigations done included a set of modified substrates and the concentration
dependency of the enzymatic immobilization. Screening of different substrates was
interesting for the SNAP immobilization, but also for a general aspect where small
molecules should be immobilized. Gained knowledge was used to develop a
procedure for the immobilization of secreted proteins out of cell culture supernatants
at low concentrations (1-10 µg/ml).
Figure 86. Final setup for a gentle production and immobilization of proteins. The gene of interest is cloned
and transferred into a suitable expression system (A). After successful secretion, the protein is concentrated if
necessary (B). Direct enzymatic immobilization of the target protein is performed on a modified biosensor chip
(C). Interactions are measured on the highly active surface (D).
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Refinement of the enzymatic immobilization procedure would enable a gentle
generation of active biosensor surfaces (figure 86).
3.4.1 Evaluation of immobilization conditions
3.4.1.1 Testing of different SNAP substrates
To optimize SNAP immobilization, a set of different substrates was synthesized at
Covalys (table 75). The original substrate (BG-PEG3) was modified towards higher
water solubility and better enzyme accessibility. Lower hydrophobicity was supposed
to limit deposition in tubings and IFC, thus enable efficient in situ immobilization.
Two strategies were followed: Extension of the hydrophilic chain between the amine
group and the guanine (BG-PEG12) as well as introduction of different hydrophilic
groups at the C8 position of the guanine (carboxy-BG, gluco-BG and sulfo-BG).
RESULTS AND DISCUSSION
182
Table 75. Set of substrates synthesized for generation of substrate surfaces with increased immobilization
capacities and velocities. A red circle marks the amine coupling attachment site.
Substrate Chemical structure
BG-PEG3
BG-PEG12
Carboxy-BG
Sulfo-BG
Gluco-BG
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Figure 88. Immobilization of SNAP (140 µg/ml) using different substrates (green = BG-PEG12, blue =
carboxy-BG , pink = gluco-BG , red = reference) (A). After normalized to the start of injection the
immobilization is clearly visible (B).
Since no immobilization of SNAP on the reference surface occurred (figure 88-B, red
sensorgram), an unspecific binding to the surface could be excluded. Direct usage of
concentrated fractions from purification led to a bulk signal due to differences in the
buffer composition (100 mM glycine buffer and Tris) (figure 88-A). Buffer exchange
to 10 mM PBS eliminated the bulk signal (figure 90). After normalization to the start
of injection, immobilization could clearly be observed on all modified surfaces (table
76).
Table 76. Immobilization levels obtained for different substrates
Substrate Immobilization of substrates Immobilization level
BG-PEG12 5 ul/min, 10 min, 1 mM 894 RU
Carboxy-BG 5 ul/min, 10 min, 1 mM 607 RU
Gluco-BG 5 ul/min, 10 min, 1 mM 178 RU
A clear advantage in respect to the immobilization level was observed for BG-PEG12.
Because BG-PEG12 was immobilized on flow cell 2, a lower SNAP concentration on
the two sequential flow cells might have led to a lower result. Therefore, in a second
experiment, BG-PEG12 was immobilized on flow cell 4 to exclude such an effect.
Nevertheless, BG-PEG12 proved to be advantageous for SNAP immobilization.
Carboxy-BG and sulfo-BG performed equally and the gluco-BG was inferior to the
others (figure 89).
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Figure 89. Immobilization of SNAP (140 µg/ml) using different substrates pink = BG-PEG12, blue = carboxy-
BG, red = sulfo-BG, green = gluco-BG
When carboxy-BG was dissolved in 30 % DMSO and 1 M NaHCO3 pH 8.4, equal
immobilization levels of carboxy-BG and BG-PEG12 were obtained (figure 90).
Equal immobilization using a more hydrophilic substrate was possible but due to a
more complex dissolution procedure BG-PEG12 was used for further experiments. In
comparison to the original BG-PEG3, immobilization was improved by a factor of 5
(table 77).
Figure 90. Immobilization of SNAP (340 µg/ml ) on BG-PEG3 (red), carboxy-BG (blue, 10 µl/min),
carboxy-BG (pink, 1 µl/min), BG-PEG12 (green). Binding of an anti-FLAG antibody proved the differences
for the immobilization capacities (B). The antibody is described more in detail on p. xxx.
To reduce substrate consumption, immobilization of carboxy-BG was performed at 1
µl/min flow rate for 20 min. No significant deviation of the immobilization capacity
or velocity was observed (pink curve in figure 90).
A B
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Table 77. Immobilization of SNAP on BG-PEG3, BG-PEG12 and carboxy-BG.
Substrate Immobillization level anti-FLAG AB
BG-PEG3   400 RU 1350 RU
BG-PEG12 2000 RU 5700 RU
carboxy-BG 1950 RU 5450 RU
Faster immobilization and consequently higher immobilization levels obtained with
BG-PEG12 was supposed to be derived from the longer spacer. A longer distance
between the reactive amine group and the substrate might allow the substrate to be
positioned further away from the dextrane matrix. Most likely this leads to an
increased accession to the substrate. In contrast, carboxy-BG resulted in equal
immobilization levels even though no such spacer was included. A beneficial effect
of the introduced negative charge on substrate accessibility is a possible explanation.
3.4.1.2 Testing of different SNAP concentrations
The sensorgrams obtained showed a dependency of the SNAP concentration on the
immobilization velocity (figure 91). Injection of 125 µg/ml SNAP resulted in a fast
increase with signs of saturation towards the end. In contrast to 125 µg/ml, the
injection of 31.3 µg/ml SNAP exhibited a rather linear increase.
Figure 91. Sensorgrams of injections of three different SNAP concentrations over equal surfaces (magenta:
125 µg/ml, green: 62.5 µg/ml, blue: 31.3 µg/ml)
RESULTS AND DISCUSSION
186
It seems that by longer injections of lower concentrations equal immobilization level
can be achieved. An injection of 60 µg/ml allowed fast immobilization of high levels
with the use of only 10 µg SNAP (table 78).
Table 78. Immobilization behaviour and total sample consumption for SNAP immobilization.
Level (% max.)
50 min
Level (% max.)
150 min
Total sample
consumption
125.0 µg/ml 1058 RU (80 %)   1324 RU (100 %) 18.8 µg
62.5 µg/ml 699 RU (53 %) 1149 RU  (87 %) 9.4 µg
31.3 µg/ml 393 RU (30 %) 861 RU  (65 %) 4.7 µg
On the created surfaces with low, mid and high SNAP capacity, SH-019 and
diazepam were tested for binding. Diazepam was evaluated because its binding to an
earlier mutant of hAGT was described.158 Interestingly, no binding of diazepam was
observed (figure 92-A). Hence, efforts by Covalys to further optimize the hAGT to
reduce unspecific binding appeared successful. In addition, SH-019 did not bind to
SNAP (figure 92-B) what was a prerequisite to use the technology for MAG.
Figure 92. Steady state evaluation of binding experiments with Diazepam (A) and SH-019 (B).
3.4.1.3 Testing of different substrate immobilization times
The difference between a substrate immobilization time of 5 and 20 minutes was
analyzed using identical concentrations (1 mM) of BG-PEG12. A SNAP sample (40
µg/ml) was injected over the surface and after 150 min, 53 % more SNAP (1967 RU)
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was immobilized on the surface with 20 min substrate contact time then on the one
with only 5 min (931 RU). After a second injection of a new SNAP sample, even
more SNAP was immobilized but the ratio of the immobilization levels between the
two surfaces did not change. This proved the reaction to be highly dependent on the
substrate concentration on the sensor chip. The second injection of fresh SNAP led to
the same slope what excluded a decreased velocity due to a denaturation of SNAP
during the 150 min injection time (figure 93). Therefore, the saturation seemed to
directly monitor the substrate level on the chip.
Figure 93. Sensorgrams of two sequential injections of SNAP over three different surfaces (magenta:
reference, green: 5 min substrate contact time, blue: 20 min substrate contact time)
Comparing these results with earlier data using a SNAP concentration of 62.5 µg/ml
(table 79) demonstrated that immobilization levels were highly controllable and
reproducible by the substrate contact time and the actual SNAP concentration.
Table 79. Immobilization of SNAP obtained for surfaces with different substrate contact times.
5 min contact time
(40 µg/ml)
20 min contact time
(40 µg/ml)
5 min contact time
(62.5 µg/ml)*
150 min   931 RU 1967 RU 1149 RU
300 min 1120 RU 2397 RU
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3.4.1.4 Comparison of SNAP and MAG(d1-3)-SNAP
The conditions discovered for an optimal enzymatic immobilization were used to
immobilize purified MAG(d1-3)-SNAP (290 µg/ml) onto the sensor chip.
Furthermore, a direct immobilization of insect cell culture supernatant containing
SNAP (4 µg/ml) was examined.
Injection of supernatant led to a big bulk signal in contrast to purified SNAP and
MAG-SNAP present in 10 mM PBS (figure 94).
Figure 94. Immobilization of SNAP (red) and MAG-SNAP (green). In addition, a direct immobilization of
SNAP (4 µg/ml) out of insect cell culture supernatant was carried out (blue).
Controllability for such an enzymatic immobilization was proven to be high when
comparing levels that were normalized by the molecular weight (SNAP 36 RU,
MAG(d1-3)-SNAP 30 RU).
Table 80. Immobilization of MAG(d1-3)-SNAP, SNAP and SNAP (supernatant)
Sample Immobilization
(RU)
Immobilization*
(RU)
MAG(d1-3)-SNAP 1600 29
SNAP   730 36
SNAP
(supernatant) 1050 52
*normalized by the MW
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To compare protein levels quantitatively, a monoclonal anti-FLAG antibody was
utilized. The antibody was characterized and then single injections at an adequate
concentration (290 nM) were used to determine the protein level on the chip (figure
94 and table 81).
Figure 94:.Immobilization of SNAP (red) and MAG(d1-3)-SNAP (green). In addition, a direct immobilization
of SNAP out of the supernatant was carried out (blue). An empty flow cell was used as reference.
Table 81. Responses obtained for the anti-FLAG antibody binding to immobilized SNAP/MAG(d1-3)-SNAP
Sample anti-FLAG*
(RU)
Rmax
(RU)
Response/Rmax**
(%)
MAG(d1-3)-SNAP 1770 4364 81.2
SNAP 2150 5341 80.6
SNAP
(supernatant)
2250
*injection of a 290 nM concentration
**Normalized to a bivalent ligand
A kinetic evaluation proved bivalent ligand behaviour as expected for an antibody
(figure 95). The bivalent behaviour was in good agreement with the 40% binding
observed. Therefore the antibody seemed to bind to more than 80% of the
immobilized protein. A concentration of 290 nM seemed optimal to compare
immobilization levels when considering the observed steady state signals for the two
highest concentrations (290 and 145 nM).
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Figure 95. Injection series for determination of the apparent KD of the anti-FLAG monoclonal antibody to
SNAP-FLAG.
The anti-FLAG antibody provided a trivial tool to determine the actual amount of
protein immobilized. In the case of direct immobilization of supernatant from insect
cell cultures, the immobilization response was higher than the final corresponding
antibody binding response. This pointed towards the fact that during immobilization,
media reagents or other contaminants bound weakly to the surface leading to a
slightly higher immobilization signal. The antibody allowed detecting such a
deviation accurately.
The immobilization velocity was compared between SNAP and MAG(d1-3)-SNAP
based on the molar protein concentration. A clear difference between immobilization
of MAG(d1-3)-SNAP and SNAP was observed (table 82). For the MAG construct a
slower immobilization velocity was found what could be derived from a reduced vmax
of the enzyme or by the size of the protein. The amount of immobilized MAG(d1-3)-
SNAP was 2311 RU and corresponded to a Rmax value of 23 RU for a 500 Da ligand.
Even though the amount of immobilized MAG was sufficient to measure low
molecular weight ligands, higher protein concentrations should allow generating
higher capacity surfaces. This was obvious when comparing results from SNAP
where an increase of protein concentration by a factor of 8 resulted in a decrease of
sample consumption by a factor of 5. On the other hand, injections of lower
concentrations over night should result in saturation levels and increase capacity as
well.
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Table 82. Comparison of enzymatic immobilization of SNAP and MAG(d1-3)-SNAP.
Construct Level*
(RU)
Concentration
(µg/ml) / (µM)
Injection
(µl)
Chip#
(substrate)
SNAP 96   40 / 2.0 150 20min, 1mM
SNAP 65 125 / 6.1 150   5min, 1mM
SNAP 56   63 / 3.1 150   5min, 1mM
SNAP 42   32 / 1.6 150   5min, 1mM
SNAP 98 340 / 16.6 30 20min, 2mM
MAG-SNAP 42 290 / 5.3 350 20min, 1mM
*The response was normalized with the molecular weight to be in relation to the immobilized molar amount of
protein.
# Immobilization of substrate on the sensor chip
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3.4.1.5 MAG(d1-3)-SNAP expressed in mammalian cells
The entire enzymatic immobilization procedure for secreted proteins out of
supernatant was applied to MAG(d1-3)-SNAP expressed in CHO cells.
A total of 1780 RU of MAG(d1-3)-SNAP was immobilized. An anti-MAG antibody
(0.6 mg/ml) was diluted 100 fold in running buffer and injected for 60 s at 20 µl/min.
A specific binding to MAG(d1-3) was observed whereas no binding to the reference
surface occurred (figure 96-A). Removal of the anti-MAG antibody was only
achieved using pH 1.5. Unfortunately, the MAG(d1-3) activity was diminished by
more than 50% after regeneration. Such an acid instability was already known for
MAG. Therefore, no repetitive experiments were possible to further characterize the
interaction between the anti-MAG antibody and MAG.
Figure 96. Binding of a specific anti-MAG antibody to immobilized MAG(d1-3)-SNAP (blue). No binding to
the reference surface was seen (pink).
The reference ligand SH-019 was used to compare MAG(d1-3)-SNAP with Fc-
MAG(d1-3). A high reproducibility was observed for triplicate injections and
sensorgrams displayed an identical kinetic profile compared to the capturing assay
(figure 97-A). No baseline drift occurred what was expected due to the covalent
immobilization. Sensorgrams remained negative what was congruent with the
conformational change hypothesis. Beside the C-terminal SNAP-tag, no other
attachment to MAG(d1-3) was needed what assured an entire conformational
freedom.
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Figure 97. Sensorgrams (A) and fitting curve to a simple 1:1-binding model (B) obtained for SH-136.
The calculated KD was 9.6 µM what was 2-fold lower than for the capturing assay.
The fitting was of extraordinary good quality what further supported the usability of
enzymatic immobilization (figure 97-B).
A B
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4 CONCLUSIONS AND OUTLOOK
GSLA-2
Preliminary experiments conducted with a diagnostic carbohydrate-binding antibody
(GSLA-2) disclosed major advantages of the Biacore technology. Besides, a set of
drawbacks and pitfalls were identified, specifically important for drug-like molecules
of low molecular weight (<500 Da).
The antibody was coupled to the biosensor surface using a standard amine coupling
procedure. A stable surface was generated on which the binding properties of its
specific antigen sLea were characterized. Interaction of sLea with GSLA-2 displayed a
fast kinetic profile with a complex half-life time in the range of 1.4 s and an
equilibrium dissociation constant of 23.1 µM. Fast kinetics and µM affinity is a
common attribute of monovalent carbohydrate/lectin interactions.
An interesting finding was that incorporation of a hydrophobic and flexible chain
(Lem = (CH2)8COOMe) used for purification of sLea increased affinity by a factor of
2. The gain is based on a higher association rate constant. This can be explained by a
higher drive to leave the buffer due to higher lipophilicity of the ligand. Lipophilic
fluorescent or radioactive tags are often required for the investigation of
ligand/receptor interactions. A label-free technique like Biacore possesses a vital
advantage that is especially important for small compounds were any attachment is
critical due to possible steric interference.
Real-time interaction measurements on Biacore result in a very detailed picture of the
entire binding process. However, the highly sensitive detection system requires
special carefulness for sample quality and signal interpretation. Not only the binding
of the specific ligand but also conformational changes, matrix effects or unspecific
binding are reflected in a sensorgram. This was specifically observed in the case of
sLea, where an impure ligand led to a two-phase binding event. Upon a specific fast
association a slow accumulation of potential impurities was observed. In this case,
commercial availability of sLea enabled discrimination between specific signal and
impurity.
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Results obtained for the two ligands sLea and sLea-Lem further disclosed interesting
phenomena in terms of signal interpretation. Comparison of the protein activity
displayed differences between those ligands in the range of 20%. The protein activity
is defined as the active part of the immobilized protein. A surface with a higher
amount of immobilized GSLA-2 (8’000 RU) was 10% less active than a surface with
only 3’800 RU. This was consistent for sLea and sLea-Lem. A possible explanation
was the distribution of GSLA-2 inside the carboxymethyl matrix. Because sensitivity
decreases linearly within the matrix (100nm), a change in distribution does influence
the signal significantly. An additional 10% deviation was caused by the ligand itself.
On both high and low capacity surfaces sLea displayed a 10% higher signal than sLea-
Lem. This led to a final spectrum of the GSLA-2 activity between 26 and 44% for the
different assays and ligands. At least for such small ligands a specific activity
calculation seemed rather difficult.
In a co-operation with the University of Lübeck, Biacore data was combined with
STD-NMR and a detailed description of the actual sLea binding site was attained.
High specificity of GSLA-2 against the sLea epitope was confirmed by several
experiments. Desialidation or exchange of the GlcNAc moiety by a cyclohexyl ring
prohibited binding completely. Hence, cross-reactivity for other carbohydrates was
rather obnoxious. Kinetic and affinity data from Biacore were optimal complemented
by the STD-NMR interaction profile. Such combination appeared highly promising
for future projects.
Myelin-associated glycoprotein as drug target
The myelin-associated glycoprotein as target protein for spinal cord injury and
myelination disorder treatment is well characterized. Gangliosides with their sialic
acid moieties were depicted to be physiological ligands for MAG. In-vitro assays on
isolated neurons supported a ganglioside mediated outgrowth inhibition beside a
cascade activated by protein/protein interaction. Interestingly, downstream signalling
was described to be identical for both activations. Several branches of the inhibition
cascade still need to be elucidated but a first FDA approval for a drug influencing a
downstream modulator (rho GTPase) in 2005 is highly promising.
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While numerous publications are dealing with the biological pathway of MAG,
important data required for a pharmaceutical approach are missing. Although efforts
were conducted, no crystal structure is available complicating the rational design of
ligands. A homology model was built in collaboration with Prof. Kelm based on
Siglec 1 co-crystallized with methyl 9-benzamido-9-deoxy-Neu5Ac (SH-164).
Biacore assay development
For amine coupling, the analysis of the potential carbohydrate-binding domain based
on the homology model was conducted. It exhibited three lysines in a distance of 10
Å to Arg118. In addition, the N-terminus is located in proximity of Trp22, which was
found to be involved in carbohydrate binding. Though the distances between the
binding site and the surface attachment sites were rather large, interference was
possible.
Immobilization was performed successfully at pH 5.5 whereas pH 4.0 led to an
inactive surface. The lower surface attraction at pH 5.5 was overcome by a 4-fold
higher protein concentration. Instability of MAG at lower pH is known and might
lead to immobilization of an inactive conformation or inactivated protein.
Signals obtained for the sialic acid derivatives were rather small (Rmax < 15 RU), what
diminished signal quality. For SH-164 (425 g/mol) no data evaluation was possible
due to the low signal intensity. Introduction of an aromatic group increased signal
intensity by far more then the molecular weight, what enabled analysis of e.g. SH-
019 (501 g/mol). Besides, the introduction of two chlorides almost doubled the signal
(SH-082). Such an impact was not described in literature but could occur for other
low molecular weight ligands as well. Surface activity is often not published and
therefore only little data is available.
To evaluate a possible deactivation of MAG after immobilization via its amine
groups, a capturing approach was examined. The Fc fragment in the Fc-MAG(d1-3)
construct offered a non-covalent immobilization via protein A. Immobilization of
protein A via standard amine coupling was achieved easily and capturing of Fc-
MAG(d1-3) led to optimal surface capacities. A steady baseline drift presented the
major drawback. Nevertheless, a reduced flow rate for capturing and over night
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stabilization facilitated triplicate measurements with an overall loss of only 0.6% of
MAG per experiment.
Most astonishing was the fact that sensorgrams obtained were negative in a
reproducible way. Such negative signals were only obtained for sialic acid
derivatives. Larger molecules like GT1b resulted in standard positive signals. The
binding was saturable and after signal inversion a state of the art evaluation was
possible. Signal intensity itself was higher compared to amine coupling and the
evaluation of the SPR-experiment was possible for all ligands measured.
Furthermore, a clear correlation between the MAG capacity and the Rmax value was
found and binding to protein A was ruled out. To specifically exclude a matrix effect
as source for negative signals, a set of experiments was conducted with different
buffer conditions. Higher ionic strength, increased buffer capacity, addition of DMSO
or carboxymethyl dextrane and a sensor chip with a reduced amount of carboxyl
groups were tested. None of the parameters influenced the negative signal or the KD
significantly. The remaining hypothesis was a ligand-induced conformational change
that influenced the hydrodynamic radius of MAG. In this case, the negative signal
derived from a conformational change was larger than the small positive signal of the
ligand binding resulting in a net negative signal upon binding.
As described on the amine coupling surface, the same correlation of chlorides and
higher signal intensity was found. These results further underlined that a direct
correlation of signal intensity to mass was delusive for low molecular weight ligands.
Biacore data compared with relative IC50 values from the hapten inhibition assay
revealed a high correlation what further supported our interpretation of the negative
signals.
Based on the established assay, a thermodynamic characterization of the interaction
between MAG and the sialic acid derived ligands was performed. Selection of three
compounds with distinct modifications enabled description of the exact impact of
specific structural features. A general finding was that the interaction was enthalpy
driven. Creation of a specific π-π interaction with Phe129 increased enthalpy by -6
kJ•mol-1 (1.4 kcal•mol-1). In contrast, the increased flexibility led to a small loss of
entropy. Enforcement of the π-π  interaction by halogens further fortified the
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enthalpy. A detailed picture for the interaction was obtained which is in strong
agreement with the docking mode of the ligands to the homology model.
Interestingly, all ligands measured displayed fast on- and off-rates. Only for SM-m6
(KD = 0.8 µM) a deceleration at lower temperatures (5 °C) was clearly visible in the
sensorgrams. The sialic acid core structure and/or the flat binding site do most likely
lead to such a fast interaction profile.
In a different ligand discovery approach, improved affinity was obtained by a so-
called second-site approach. 5-Nitro-indole was found to bind in close proximity to
the sialic acid binding site. Optimal linkage of the nitro-indole to the sialic acid core
(= second generation ligand) increased binding affinity by a factor of 50. However,
the kinetic behaviour remained fast what supported the core theory. Ligands obtained
were of higher molecular weight (MW > 700 Da) and resulted in higher positive
signals on the amine coupling surface. Interestingly, the capturing assay equally led
to a positive signal. The identical binding site of sialic acid derivatives and the second
generation ligands was verified by a competitive Biacore experiment.
Important is the fact that the sensorgrams turn positive after the attachment of the
nitro-indole. Considering the conformational change hypothesis it seemed that second
generation ligands did not elicit such changes. The nitro-indole might lock the
conformation. Comparison of affinities of second generation ligand fragments
disclosed a well-known circumstance. Affinity increased even though a longer
hydrophobic chain with higher flexibility was introduced. This finding was consistent
with results from the GSLA-2 project.
Enzymatic immobilization
For MAG, the importance of the protein immobilization strategy was clearly
demonstrated. Either the surface was not stable or the attachment resulted in different
binding properties. An enzymatic approach was considered to be a promising
technique to circumvent difficult and/or doubtful immobilizations of proteins. The
technique is based on the human suicide enzyme O 6-alkylguanine-DNA-
alkyltransferase (hAGT) and referred to as SNAP-tag. After immobilization of its
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substrate on a biosensor chip, the enzyme links itself to the surface via a specific
enzymatic reaction. Hence, a genetically linked target protein can be immobilized
covalently under physiological conditions. In the case of pH labile proteins, amine
groups present in the binding site or conformational issues, the enzymatic
immobilization approach would assure an active protein. Especially for non-
characterized proteins or ligands, as it is often the case in drug discovery, a high
fidelity is a prerequisite. Alteration of the target activity due to the linked enzyme
represents the only drawback of the system.
For preliminary experiments, SNAP was expressed in insect cells in a secreted form.
Expression levels were about 4 mg/L what represented an average value. Purification
under low pH conditions (pH 3.5) did not diminish enzyme activity.
To enhance immobilization velocity, a set of modified substrates was tested for which
substrate accessibility was optimized. A longer chain between the substrate and the
amine group (attachment site) and the introduction of a carboxyl group on the
substrate led to substantial improvements. A 4-fold increase was achieved allowing
lower protein concentrations for the immobilization. This was especially needed for a
direct immobilization of secreted protein out of cell culture supernatant at
concentrations around 4 µg/ml.
For the enzymatic reaction, a clear protein concentration dependency and high
stability at 25 °C was found. Immobilization levels obtained were optimal for the
measurement of low molecular weight ligands and a high controllability of the
immobilization level was achieved.
No unspecific binding of sialic acid derivatives to SNAP was detected what was a
prerequisite for its usability. In comparison to SNAP (20.5 kDa), a slower
immobilization velocity was observed for the MAG(d1-3)-SNAP construct (55 kDa).
A decreased enzyme activity or the larger protein might have caused the deceleration.
Usability of the optimized procedure was evaluated with MAG(d1-3)-SNAP
expressed in CHO cells. MAG was directly immobilized out of supernatant what was
proved by a conformation-dependent anti-MAG antibody. To compare capturing with
enzymatic immobilization, a sialic acid derivative was measured. A similar affinity
and negative sensorgrams were observed. The negative sensorgrams were expected
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due to the same conformational freedom as for captured MAG. Results further
supported that the negative binding signals were directly related to MAG(d1-3). By
combination of enzymatic immobilization and expression of the target in a secreted
form, all harsh conditions for the protein were avoided.
Biosensors based on surface plasmon resonance proved its applicability for the
characterization of drug-like ligands. Kinetic as well as thermodynamic data provided
a detailed picture of the interactions and revealed possible directions for lead
optimization. Especially the screening of compound libraries for a specific kinetic
behaviour on a target protein adds a new dimension to drug development. Importance
of this dimension is discussed extensively among pharmaceutical researchers
nowadays and seems to be considered to a greater extent. Nevertheless, future
success in predicting efficacy and safety by kinetic data will determine the spreading
of technologies like Biacore within pharmaceutical companies.
Outlook
For the future of the MAG project, an in vivo assay or at least an in vitro neurite
outgrowth assay is needed to test the available MAG ligands for their activity.
Especially between sialic acid derivatives and second generation ligands a different
impact is highly possible due to potential differences in ligand-induced
conformational changes. Furthermore, supporting experiments on the potential
ligand-induced conformational change with e.g. circular dichroism are required to
support the hypothesis. Another aspect is the usability of the enzymatic
immobilization. More proteins should be expressed and enzymatically immobilized
on Biacore to prove its versatility.
LITERATURE
201
5 LITERATURE
(1) Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. Opinion - How many drug
targets are there? Nature Reviews Drug Discovery 2006, 5, 993-996.
(2) Greener, M. Drug safety on trial - Last year's withdrawal of the anti-arthritis
drug Vioxx triggered a debate about how to better monitor drug safety even
after approval. Embo Reports 2005, 6, 202-204.
(3) Reuters www.reuters.com, 2007.
(4) Russ, A. P.; Lampel, S. The druggable genome: an update. Drug Discovery
Today 2005, 10, 1607-1610.
(5) Hopkins, A. L.; Groom, C. R. The druggable genome. Nature Reviews Drug
Discovery 2002, 1, 727-730.
(6) Hertzberg, R. P.; Pope, A. J. High-throughput screening: new technology for
the 21st century. Current Opinion in Chemical Biology 2000, 4, 445-451.
(7) Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection criteria for drug-like
chemical matter. Journal of Medicinal Chemistry 2001, 44, 1841-1846.
(8) Walters, W. P.; Murcko, A.; Murcko, M. A. Recognizing molecules with drug-
like properties. Current Opinion in Chemical Biology 1999, 3, 384-387.
(9) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Advanced Drug Delivery Reviews 1997,
23, 3-25.
(10) Kandel, E. R. Nerve cells and behavior; McGraw-Hill, 2000; 19-35.
(11) Vyas, A. A.; Schnaar, R. L. Brain gangliosides: functional ligands for myelin
stability and the control of nerve regeneration. Biochimie 2001, 83, 677-682.
(12) Salzer, J. L. Clustering sodium channels at the node of Ranvier: Close
encounters of the axon-glia kind. Neuron 1997, 18, 843-846.
(13) Dobkin, B. H.; Havton, L. A. Basic advances and new avenues in therapy of
spinal cord injury. Annual Review of Medicine 2004, 55, 255-282.
(14) Berkowitz, M.; O’Leary, P.; Kruse, D.; Harvey, C. Spinal cord injury: An
analysis of medical and social costs. New York: Demos Medical Publishing
Inc. 1998.
(15) Schnell, L.; Schwab, M. E. Axonal Regeneration in the Rat Spinal-Cord
Produced by an Antibody against Myelin-Associated Neurite Growth-
Inhibitors. Nature 1990, 343, 269-272.
(16) Filbin, M. T. Myelin-associated inhibitors of axonal regeneration in the adult
mammalian CNS. Nat Rev Neurosci 2003, 4, 703-713.
(17) David, S.; Aguayo, A. J. Axonal Elongation into Peripheral Nervous-System
Bridges after Central Nervous-System Injury in Adult-Rats. Science 1981,
214, 931-933.
(18) Richardson, P. M.; McGuinness, U. M.; Aguayo, A. J. Axons from Cns
Neurons Regenerate into Pns Grafts. Nature 1980, 284, 264-265.
(19) Bixby, J. L.; Harris, W. A. Molecular Mechanisms of Axon Growth and
Guidance. Annual Review of Cell Biology 1991, 7, 117-159.
LITERATURE
202
(20) Bovolenta, P.; Fernaud-Espinosa, I. Nervous system proteoglycans as
modulators of neurite outgrowth. Progress in Neurobiology 2000, 61, 113-
132.
(21) McKeon, R. J.; Hoke, A.; Silver, J. Injury-Induced Proteoglycans Inhibit the
Potential for Laminin-Mediated Axon Growth on Astrocytic Scars.
Experimental Neurology 1995, 136, 32-43.
(22) Davies, S. J. A.; Fitch, M. T.; Memberg, S. P.; Hall, A. K.; Raisman, G. et al.
Regeneration of adult axons in white matter tracts of the central nervous
system. Nature 1997, 390, 680-683.
(23) Davies, S. J. A.; Goucher, D. R.; Doller, C.; Silver, J. Robust regeneration of
adult sensory axons in degenerating white matter of the adult rat spinal cord.
Journal of Neuroscience 1999, 19, 5810-5822.
(24) Tang, X. F.; Davies, J. E.; Davies, S. J. A. Changes in distribution, cell
associations, and protein expression levels of NG2, neurocan, phosphacan,
brevican, versican V2, and tenascin-C during acute to chronic maturation of
spinal cord scar tissue. Journal of Neuroscience Research 2003, 71, 427-444.
(25) Caroni, P.; Schwab, M. E. Antibody against Myelin-Associated Inhibitor of
Neurite Growth Neutralizes Nonpermissive Substrate Properties of Cns White
Matter. Neuron 1988, 1, 85-96.
(26) Chen, M. S.; Huber, A. B.; van der Haar, M. E.; Frank, M.; Schnell, L. et al.
Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for
monoclonal antibody IN-1. Nature 2000, 403, 434-439.
(27) GrandPre, T.; Nakamura, F.; Vartanian, T.; Strittmatter, S. M. Identification of
the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000,
403, 439-444.
(28) Prinjha, R.; Moore, S. E.; Vinson, M.; Blake, S.; Morrow, R. et al.
Neurobiology - Inhibitor of neurite outgrowth in humans. Nature 2000, 403,
383-384.
(29) Huang, J. K.; Phillips, G. R.; Roth, A. D.; Pedraza, L.; Shan, W. S. et al. Glial
membranes at the node of Ranvier prevent neurite outgrowth. Science 2005,
310, 1813-1817.
(30) Mikol, D. D.; Gulcher, J. R.; Stefansson, K. The Oligodendrocyte Myelin
Glycoprotein Belongs to a Distinct Family of Proteins and Contains the Hnk-1
Carbohydrate. Journal of Cell Biology 1990, 110, 471-479.
(31) Williams, A. F.; Davis, S. J.; He, Q.; Barclay, A. N. Structural Diversity in
Domains of the Immunoglobulin Superfamily. Cold Spring Harbor Symposia
on Quantitative Biology 1989, 54, 637-647.
(32) Williams, A. F.; Barclay, A. N. The Immunoglobulin Superfamily - Domains
for Cell-Surface Recognition. Annual Review of Immunology 1988, 6, 381-
405.
(33) Kelm, S.; Pelz, A.; Schauer, R.; Filbin, M. T.; Tang, S. et al. Sialoadhesin,
myelin-associated glycoprotein and CD22 define a new family of sialic acid-
dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol
1994, 4, 965-972.
(34) Crocker, P. R. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-
cell interactions and signalling. Curr Opin Struct Biol 2002, 12, 609-615.
LITERATURE
203
(35) Quarles, R. H.; Everly, J. L.; Brady, R. O. Demonstration of a Glycoprotein
Which Is Associated with a Purified Myelin Fraction from Rat-Brain.
Biochemical and Biophysical Research Communications 1972, 47, 491-&.
(36) Quarles, R. H.; Everly, J. L.; Brady, R. O. Evidence for Close Association of a
Glycoprotein with Myelin in Rat-Brain. Journal of Neurochemistry 1973, 21,
1177-&.
(37) Frail, D. E.; Braun, P. E. 2 Developmentally Regulated Messenger-Rnas
Differing in Their Coding Region May Exist for the Myelin-Associated
Glycoprotein. Journal of Biological Chemistry 1984, 259, 4857-4862.
(38) Salzer, J. L.; Pedraza, L.; Brown, M.; Struyk, A.; Afar, D. et al. Structure and
Function of the Myelin-Associated Glycoproteins. Annals of the New York
Academy of Sciences 1990, 605, 302-312.
(39) Trapp, B. D. Myelin-Associated Glycoprotein - Location and Potential
Functions. Annals of the New York Academy of Sciences 1990, 605, 29-43.
(40) Lai, C.; Brow, M. A.; Nave, K. A.; Noronha, A. B.; Quarles, R. H. et al. 2
Forms of 1b236 Myelin-Associated Glycoprotein, a Cell-Adhesion Molecule
for Postnatal Neural Development, Are Produced by Alternative Splicing.
Proceedings of the National Academy of Sciences of the United States of
America 1987, 84, 4337-4341.
(41) Kursula, P.; Lehto, V. P.; Heape, A. M. The small myelin-associated
glycoprotein binds to tubulin and microtubules. Molecular Brain Research
2001, 87, 22-30.
(42) Kursula, P.; Merilainen, G.; Lehto, V. P.; Heape, A. M. The small myelin-
associated glycoprotein is a zinc-binding protein. Journal of Neurochemistry
1999, 73, 2110-2118.
(43) Kursula, P.; Tikkanen, G.; Lehto, V. P.; Nishikimi, M.; Heape, A. M.
Calcium-dependent interaction between the large myelin-associated
glycoprotein and S100 beta. Journal of Neurochemistry 1999, 73, 1724-1732.
(44) Schachner, M.; Bartsch, U. Multiple functions of the myelin-associated
glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia
2000, 29, 154-165.
(45) Turnley, A. M.; Bartlett, P. F. MAG and MOG enhance neurite outgrowth of
embryonic mouse spinal cord neurons. Neuroreport 1998, 9, 1987-1990.
(46) DeBellard, M. E.; Tang, S.; Mukhopadhyay, G.; Shen, Y. J.; Filbin, M. T.
Myelin-associated glycoprotein inhibits axonal regeneration from a variety of
neurons via interaction with a sialoglycoprotein. Molecular and Cellular
Neuroscience 1996, 7, 89-101.
(47) Domeniconi, M.; Filbin, M. T. Overcoming inhibitors in myelin to promote
axonal regeneration. Journal of the Neurological Sciences 2005, 233, 43-47.
(48) Bandtlow, C. E. Regeneration in the central nervous system. Experimental
Gerontology 2003, 38, 79-86.
(49) Cai, D. M.; Shen, Y. J.; De Bellard, M.; Tang, S.; Filbin, M. T. Prior exposure
to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin
via a cAMP-dependent mechanism. Neuron 1999, 22, 89-101.
LITERATURE
204
(50) Yamashita, T.; Higuchi, H.; Tohyama, M. The p75 receptor transduces the
signal from myelin-associated glycoprotein to Rho. Journal of Cell Biology
2002, 157, 565-570.
(51) Wong, S. T.; Henley, J. R.; Kanning, K. C.; Huang, K. H.; Bothwell, M. et al.
A p75(NTR) and Nogo receptor complex mediates repulsive signaling by
myelin-associated glycoprotein. Nature Neuroscience 2002, 5, 1302-1308.
(52) Wang, K. C.; Kim, J. A.; Sivasankaran, R.; Segal, R.; He, Z. p75 interacts with
the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 2002,
420, 74-78.
(53) Lehmann, M.; Fournier, A.; Selles-Navarro, I.; Dergham, P.; Sebok, A. et al.
Inactivation of Rho signaling pathway promotes CNS axon regeneration.
Journal of Neuroscience 1999, 19, 7537-7547.
(54) Burridge, K.; Wennerberg, K. Rho and Rac take center stage. Cell 2004, 116,
167-179.
(55) Bishop, A. L.; Hall, A. Rho GTPases and their effector proteins. Biochemical
Journal 2000, 348, 241-255.
(56) Ishizaki, T.; Maekawa, M.; Fujisawa, K.; Okawa, K.; Iwamatsu, A. et al. The
small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr
protein kinase homologous to myotonic dystrophy kinase. Embo Journal 1996,
15, 1885-1893.
(57) Leung, T.; Manser, E.; Tan, L.; Lim, L. A Novel Serine/Threonine Kinase
Binding the Ras-Related Rhoa Gtpase Which Translocates the Kinase to
Peripheral Membranes. Journal of Biological Chemistry 1995, 270, 29051-
29054.
(58) Madura, T.; Yamashita, T.; Kubo, T.; Fujitani, M.; Hosokawa, K. et al.
Activation of Rho in the injured axons following spinal cord injury. Embo
Reports 2004, 5, 412-417.
(59) Aimone, J. B.; Leasure, J. L.; Perreau, V. M.; Thallmair, M. Spatial and
temporal gene expression profiling of the contused rat spinal cord.
Experimental Neurology 2004, 189, 204-221.
(60) Brabeck, C.; Beschorner, R.; Conrad, S.; Mittelbronn, M.; Bekure, K. et al.
Lesional expression of RhoA and RhoB following traumatic brain injury in
humans. Journal of Neurotrauma 2004, 21, 697-706.
(61) Dubreuil, C. I.; Winton, M. J.; McKerracher, L. Rho activation patterns after
spinal cord injury and the role of activated Rho in apoptosis in the central
nervous system. Journal of Cell Biology 2003, 162, 233-243.
(62) Tanaka, H.; Yamashita, T.; Yachi, K.; Fujiwara, T.; Yoshikawa, H. et al.
Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional
recovery after spinal cord injury in rats. Neuroscience 2004, 127, 155-164.
(63) Sung, J. K.; Miao, L.; Calvert, J. W.; Huang, L. X.; Harkey, H. L. et al. A
possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat.
Brain Research 2003, 959, 29-38.
(64) Dergham, P.; Ellezam, B.; Essagian, C.; Avedissian, H.; Lubell, W. D. et al.
Rho signaling pathway targeted to promote spinal cord repair. Journal of
Neuroscience 2002, 22, 6570-6577.
LITERATURE
205
(65) Hara, M.; Takasu, M.; Watanabe, K.; Noda, A.; Takagi, T. et al. Protein kinase
inhibition by fasudil hydrochloride promotes neurological recovery after
spinal cord injury in rats. Journal of Neurosurgery 2000, 93, 94-101.
(66) Fournier, A. E.; Takizawa, B. T.; Strittmatter, S. M. Rho kinase inhibition
enhances axonal regeneration in the injured CNS. Journal of Neuroscience
2003, 23, 1416-1423.
(67) Vyas, A. A.; Patel, H. V.; Fromholt, S. E.; Heffer-Lauc, M.; Vyas, K. A. et al.
Gangliosides are functional nerve cell ligands for myelin-associated
glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci U
S A 2002, 99, 8412-8417.
(68) Kelm, S.; Brossmer, R.; Isecke, R.; Gross, H. J.; Strenge, K. et al. Functional
groups of sialic acids involved in binding to siglecs (sialoadhesins) deduced
from interactions with synthetic analogues. Eur J Biochem 1998, 255, 663-
672.
(69) Collins, B. E.; Yang, L. J.; Mukhopadhyay, G.; Filbin, M. T.; Kiso, M. et al.
Sialic acid specificity of myelin-associated glycoprotein binding. J Biol Chem
1997, 272, 1248-1255.
(70) Yang, L. J.; Zeller, C. B.; Shaper, N. L.; Kiso, M.; Hasegawa, A. et al.
Gangliosides are neuronal ligands for myelin-associated glycoprotein. Proc
Natl Acad Sci U S A 1996, 93, 814-818.
(71) Tang, S.; Shen, Y. J.; DeBellard, M. E.; Mukhopadhyay, G.; Salzer, J. L. et al.
Myelin-associated glycoprotein interacts with neurons via a sialic acid binding
site at ARG118 and a distinct neurite inhibition site. J Cell Biol 1997, 138,
1355-1366.
(72) Niederost, B.; Oertle, T.; Fritsche, J.; McKinney, R. A.; Bandtlow, C. E.
Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition
by antagonistic regulation of RhoA and Rac1. Journal of Neuroscience 2002,
22, 10368-10376.
(73) Vinson, M.; Strijbos, P.; Rowles, A.; Facci, L.; Moore, S. E. et al. Myelin-
associated glycoprotein interacts with ganglioside GT1b - A mechanism for
neurite outgrowth inhibition. Journal of Biological Chemistry 2001, 276,
20280-20285.
(74) McKerracher, L. Ganglioside rafts as MAG receptors that mediate blockade of
axon growth. Proc Natl Acad Sci U S A 2002, 99, 7811-7813.
(75) Hakomori, S. The glycosynapse (vol 99, pg 225, 2002). Proceedings of the
National Academy of Sciences of the United States of America 2002, 99, 3356-
3356.
(76) Liu, B. P.; Fournier, A.; GrandPre, T.; Strittmatter, S. M. Myelin-associated
glycoprotein as a functional ligand for the Nogo-66 receptor. Science 2002,
297, 1190-1193.
(77) Domeniconi, M.; Cao, Z.; Spencer, T.; Sivasankaran, R.; Wang, K. C. et al.
Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit
neurite outgrowth. Neuron 2002, 35, 283-290.
(78) Yang, L. J. S.; Lorenzini, I.; Vajn, K.; Mountney, A.; Schramm, L. P. et al.
Sialidase enhances spinal axon outgrowth in vivo. Proceedings of the National
Academy of Sciences of the United States of America 2006, 103, 11057-11062.
LITERATURE
206
(79) Pan, B. H.; Fromholt, S. E.; Hess, E. J.; Crawford, T. O.; Griffin, J. W. et al.
Myelin-associated glycoprotein and complementary axonal ligands,
gangliosides, mediate axon stability in the CNS and PINS: Neuropathology
and behavioral deficits in single- and double-null mice. Experimental
Neurology 2005, 195, 208-217.
(80) Collins, B. E.; Kiso, M.; Hasegawa, A.; Tropak, M. B.; Roder, J. C. et al.
Binding specificities of the sialoadhesin family of I-type lectins. Sialic acid
linkage and substructure requirements for binding of myelin-associated
glycoprotein, Schwann cell myelin protein, and sialoadhesin. J Biol Chem
1997, 272, 16889-16895.
(81) Derrington, E. A.; Masco, D.; Whittaker, V. P. Confirmation of the
Cholinergic Specificity of the Chol-1 Gangliosides in Mammalian Brain Using
Affinity-Purified Antisera and Lesions Affecting the Cholinergic Input to the
Hippocampus. Journal of Neurochemistry 1989, 53, 1686-1692.
(82) Hirabayashi, Y.; Nakao, T.; Irie, F.; Whittaker, V. P.; Kon, K. et al. Structural
Characterization of a Novel Cholinergic Neuron-Specific Ganglioside in
Bovine Brain. Journal of Biological Chemistry 1992, 267, 12973-12978.
(83) Sawada, N.; Ishida, H.; Collins, B. E.; Schnaar, R. L.; Kiso, M. Ganglioside
GD1 alpha analogues as high-affinity ligands for myelin-associated
glycoprotein (MAG). Carbohydr Res 1999, 316, 1-5.
(84) Strenge, K.; Schauer, R.; Bovin, N.; Hasegawa, A.; Ishida, H. et al. Glycan
specificity of myelin-associated glycoprotein and sialoadhesin deduced from
interactions with synthetic oligosaccharides. Eur J Biochem 1998, 258, 677-
685.
(85) Collins, B. E.; Ito, H.; Sawada, N.; Ishida, H.; Kiso, M. et al. Enhanced
binding of the neural siglecs, myelin-associated glycoprotein and Schwann
cell myelin protein, to Chol-1 (alpha-series) gangliosides and novel sulfated
Chol-1 analogs. J Biol Chem 1999, 274, 37637-37643.
(86) Vyas, A. A.; Blixt, O.; Paulson, J. C.; Schnaar, R. L. Potent glycan inhibitors
of myelin-associated glycoprotein enhance axon outgrowth in vitro. J Biol
Chem 2005, 280, 16305-16310.
(87) Thompson, H. J.; Marklund, N.; LeBold, D. G.; Morales, D. M.; Keck, C. A.
et al. Tissue sparing and functional recovery following experimental traumatic
brain injury is provided by treatment with an anti-myelin-associated
glycoprotein antibody. European Journal of Neuroscience 2006, 24, 3063-
3072.
(88) Irving, E. A.; Vinson, M.; Rosin, C.; Roberts, J. C.; Chapman, D. M. et al.
Identification of neuroprotective properties of anti-MAG antibody: a novel
approach for the treatment of stroke? Journal of Cerebral Blood Flow and
Metabolism 2005, 25, 98-107.
(89) Schnell, L.; Schwab, M. E. Sprouting and Regeneration of Lesioned
Corticospinal Tract Fibers in the Adult-Rat Spinal-Cord. European Journal of
Neuroscience 1993, 5, 1156-1171.
(90) Bregman, B. S.; Kunkelbagden, E.; Schnell, L.; Dai, H. N.; Gao, D. et al.
Recovery from Spinal-Cord Injury Mediated by Antibodies to Neurite
Growth-Inhibitors. Nature 1995, 378, 498-501.
LITERATURE
207
(91) Li, W. W.; Walus, L.; Rabacchi, S. A.; Jirik, A.; Chang, E. et al. A
neutralizing anti-Nogo66 receptor monoclonal antibody reverses inhibition of
neurite outgrowth by central nervous system myelin. Journal of Biological
Chemistry 2004, 279, 43780-43788.
(92) Nikulina, E.; Tidwell, J. L.; Dai, H. N.; Bregman, B. S.; Filbin, M. T. The
phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion
promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S
A 2004, 101, 8786-8790.
(93) Stryer, L. Biochemistry. 1999.
(94) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Advanced Drug Delivery Reviews 2001,
46, 3-26.
(95) Hann, M. M.; Oprea, T. I. Pursuing the leadlikeness concept in pharmaceutical
research. Current Opinion in Chemical Biology 2004, 8, 255-263.
(96) Chapman, T. Drug discovery - The leading edge. Nature 2004, 430, 109-+.
(97) Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact
on the probability of finding leads for drug discovery. Journal of Chemical
Information and Computer Sciences 2001, 41, 856-864.
(98) Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference
between leads and drugs? A historical perspective. Journal of Chemical
Information and Computer Sciences 2001, 41, 1308-1315.
(99) Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike
combinatorial libraries. Angewandte Chemie-International Edition 1999, 38,
3743-3748.
(100) Kubinyi, H. Structure-based design of enzyme inhibitors and receptor ligands.
Current Opinion in Drug Discovery and Development 1998, 1.
(101) Swinney, D. C. Biochemical mechanisms of drug action: what does it take for
success? Nat Rev Drug Discov 2004, 3, 801-808.
(102) Berezov, A.; Zhang, H. T.; Greene, M. I.; Murali, R. Disabling erbB receptors
with rationally designed exocyclic mimetics of antibodies: structure-function
analysis. J Med Chem 2001, 44, 2565-2574.
(103) Markgren, P. O.; Hamalainen, M.; Danielson, U. H. Kinetic analysis of the
interaction between HIV-1 protease and inhibitors using optical biosensor
technology. Anal Biochem 2000, 279, 71-78.
(104) Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Opinion - Drug-target
residence time and its implications for lead optimization. Nature Reviews
Drug Discovery 2006, 5, 730-739.
(105) Billheimer, J. T.; Dicker, I. B.; Wynn, R.; Bradley, J. D.; Cromley, D. A. et al.
Evidence that thrombocytopenia observed in humans treated with orally
bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood
2002, 99, 3540-3546.
(106) Seiffert, D.; Stern, A. M.; Ebling, W.; Rossi, R. J.; Barrett, Y. C. et al.
Prospective testing for drug-dependent antibodies reduces the incidence of
thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa
LITERATURE
208
antagonist roxifiban: implications for the etiology of thrombocytopenia. Blood
2003, 101, 58-63.
(107) Kapur, S.; Seeman, P. Antipsychotic agents differ in how fast they come off
the dopamine D-2 receptors. Implications for atypical antipsychotic action.
Journal of Psychiatry & Neuroscience 2000, 25, 161-166.
(108) Huber, W. A new strategy for improved secondary screening and lead
optimization using high-resolution SPR characterization of compound-target
interactions. Journal of Molecular Recognition 2005, 18, 273-281.
(109) Myszka, D. G.; He, X.; Dembo, M.; Morton, T. A.; Goldstein, B. Extending
the range of rate constants available from BIACORE: Interpreting mass
transport-influenced binding data. Biophysical Journal 1998, 75, 583-594.
(110) Myszka, D. G.; Abdiche, Y. N.; Arisaka, F.; Byron, O.; Eisenstein, E. et al.
The ABRF-MIRG'02 study: assembly state, thermodynamic, and kinetic
analysis of an enzyme/inhibitor interaction. J Biomol Tech 2003, 14, 247-269.
(111) Day, Y. S.; Baird, C. L.; Rich, R. L.; Myszka, D. G. Direct comparison of
binding equilibrium, thermodynamic, and rate constants determined by
surface- and solution-based biophysical methods. Protein Sci 2002, 11, 1017-
1025.
(112) Papalia, G. A.; Leavitt, S.; Bynum, M. A.; Katsamba, P. S.; Wilton, R. et al.
Comparative analysis of 10 small molecules binding to carbonic anhydrase II
by different investigators using Biacore technology. Analytical Biochemistry
2006, 359, 94-105.
(113) Cannon, M. J.; Papalia, G. A.; Navratilova, I.; Fisher, R. J.; Roberts, L. R. et
al. Comparative analyses of a small molecule/enzyme interaction by multiple
users of Biacore technology. Anal Biochem 2004, 330, 98-113.
(114) Markgren, P. O.; Schaal, W.; Hamalainen, M.; Karlen, A.; Hallberg, A. et al.
Relationships between structure and interaction kinetics for HIV-1 protease
inhibitors. J Med Chem 2002, 45, 5430-5439.
(115) Shuman, C. F.; Vrang, L.; Danielson, U. H. Improved structure-activity
relationship analysis of HIV-1 protease inhibitors using interaction kinetic
data. J Med Chem 2004, 47, 5953-5961.
(116) Markgren, P. O.; Lindgren, M. T.; Gertow, K.; Karlsson, R.; Hamalainen, M.
et al. Determination of interaction kinetic constants for HIV-1 protease
inhibitors using optical biosensor technology. Anal Biochem 2001, 291, 207-
218.
(117) Markgren, P. O.; Hamalainen, M.; Danielson, U. H. Screening of compounds
interacting with HIV-1 proteinase using optical biosensor technology. Anal
Biochem 1998, 265, 340-350.
(118) Shuman, C. F.; Hamalainen, M. D.; Danielson, U. H. Kinetic and
thermodynamic characterization of HIV-1 protease inhibitors. J Mol Recognit
2004, 17, 106-119.
(119) Maschera, B.; Darby, G.; Palu, G.; Wright, L. L.; Tisdale, M. et al. Human
immunodeficiency virus - Mutations in the viral protease that confer resistance
to saquinavir increase the dissociation rate constant of the protease-saquinavir
complex. Journal of Biological Chemistry 1996, 271, 33231-33235.
LITERATURE
209
(120) Shuman, C. F.; Markgren, P. O.; Hamalainen, M.; Danielson, U. H.
Elucidation of HIV-1 protease resistance by characterization of interaction
kinetics between inhibitors and enzyme variants. Antiviral Res 2003, 58, 235-
242.
(121) Gossas, T.; Danielson, U. H. Analysis of the pH-dependencies of the
association and dissociation kinetics of HIV-1 protease inhibitors. Journal of
Molecular Recognition 2003, 16, 203-212.
(122) May, L. M.; Russell, D. A. The characterization of biomolecular secondary
structures by surface plasmon resonance. Analyst 2002, 127, 1589-1595.
(123) Zako, T.; Harada, K.; Mannen, T.; Yamaguchi, S.; Kitayama, A. et al.
Monitoring of the refolding process for immobilized firefly luciferase with a
biosensor based on surface plasmon resonance. Journal of Biochemistry 2001,
129, 1-4.
(124) Geitmann, M.; Danielson, U. H. Studies of substrate-induced conformational
changes in human cytomegalovirus protease using optical biosensor
technology. Analytical Biochemistry 2004, 332, 203-214.
(125) Gestwicki, J. E.; Hsieh, H. V.; Pitner, J. B. Using receptor conformational
change to detect low molecular weight analytes by surface plasmon resonance.
Anal Chem 2001, 73, 5732-5737.
(126) Turbadar, T. Complete Absorption of Light by Thin Metal Films. Proceedings
of the Physical Society of London 1959, 73, 40-44.
(127) Kaambhampati, D. Protein Microarray Technology; Wiley-VCH Verlag,
2003.
(128) Surface Plasmon Resonance (Technology Note 1); Biacore AB, 2001; 1-4.
(129) Jonsson, U.; Fagerstam, L.; Ivarsson, B.; Johnsson, B.; Karlsson, R. et al.
Real-time biospecific interaction analysis using surface plasmon resonance
and a sensor chip technology. Biotechniques 1991, 11, 620-627.
(130) Nagata, K. H., H. Real-Time Analysis of Biomolecular Interactions:
Applications of BIACORE; Springer: Japan, 2000.
(131) Stenberg, E.; Persson, B.; Roos, H.; Urbaniczky, C. Quantitative determination
of surface concentration of protein with surface plasmon resonance using
radiolabeled proteins. J Colloid Interface Sci 1991, 143, 513-526.
(132) Mannen, T.; Yamaguchi, S.; Honda, J.; Sugimoto, S.; Kitayama, A. et al.
Observation of charge state and conformational change in immobilized protein
using surface plasmon resonance sensor. Anal Biochem 2001, 293, 185-193.
(133) Lofas, S.; Johnson, B. A novel hydrogel matrix on gold surfaces in surface
plasmon resonance sensors for fast and efficient covalent immobilization of
ligands. J Chem Soc Chem Commun 1990, 1526-1528.
(134) Myszka, D. G. Analysis of small-molecule interactions using Biacore S51
technology. Anal Biochem 2004, 329, 316-323.
(135) Halkes, K. M.; St Hilaire, P. M.; Crocker, P. R.; Meldal, M. Glycopeptides as
oligosaccharide mimics: high affinity sialopeptide ligands for sialoadhesin
from combinatorial libraries. J Comb Chem 2003, 5, 18-27.
(136) Kaila, N.; Somers, W. S.; Thomas, B. E.; Thakker, P.; Janz, K. et al. Quinic
acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: Design,
LITERATURE
210
synthesis, and crystal structure in complex with E-selectin. Journal of
Medicinal Chemistry 2005, 48, 4346-4357.
(137) Myszka, D. G.; Morton, T. A.; Doyle, M. L.; Chaiken, I. M. Kinetic analysis
of a protein antigen-antibody interaction limited by mass transport on an
optical biosensor. Biophysical Chemistry 1997, 64, 127-137.
(138) Glaser, R. W. Antigen-antibody binding and mass transport by convection and
diffusion to a surface: a two-dimensional computer model of binding and
dissociation kinetics. Anal Biochem 1993, 213, 152-161.
(139) Schuck, P. Kinetics of ligand binding to receptor immobilized in a polymer
matrix, as detected with an evanescent wave biosensor. I. A computer
simulation of the influence of mass transport. Biophys J 1996, 70, 1230-1249.
(140) Myszka, D. G. Kinetic analysis of macromolecular interactions using surface
plasmon resonance biosensors. Curr Opin Biotechnol 1997, 8, 50-57.
(141) Frostell-Karlsson, A.; Remaeus, A.; Roos, H.; Andersson, K.; Borg, P. et al.
Biosensor analysis of the interaction between immobilized human serum
albumin and drug compounds for prediction of human serum albumin binding
levels. J Med Chem 2000, 43, 1986-1992.
(142) Myszka, D. G. Improving biosensor analysis. J Mol Recognit 1999, 12, 279-
284.
(143) Biacore® 3000 Instrument Handbook; March 1999 ed.; Biacore AB: Uppsala,
1999.
(144) Andersson, K.; Hamalainen, M.; Malmqvist, M. Identification and
optimization of regeneration conditions for affinity- based biosensor assays. A
multivariate cocktail approach. Anal Chem 1999, 71, 2475-2481.
(145) Rich, R. L.; Myszka, D. G. Survey of the year 2005 commercial optical
biosensor literature. Journal of Molecular Recognition 2006, 19, 478-534.
(146) Karlsson, R.; Michaelsson, A.; Mattsson, L. Kinetic analysis of monoclonal
antibody-antigen interactions with a new biosensor based analytical system. J
Immunol Methods 1991, 145, 229-240.
(147) O'Shannessy, D. J.; Brigham-Burke, M.; Soneson, K. K.; Hensley, P.; Brooks,
I. Determination of rate and equilibrium binding constants for macromolecular
interactions using surface plasmon resonance: use of nonlinear least squares
analysis methods. Anal Biochem 1993, 212, 457-468.
(148) Roden, L. D.; Myszka, D. G. Global analysis of a macromolecular interaction
measured on BIAcore. Biochem Biophys Res Commun 1996, 225, 1073-1077.
(149) Myszka, D. G.; Morton, T. A. CLAMP: a biosensor kinetic data analysis
program. Trends Biochem Sci 1998, 23, 149-150.
(150) Tomizaki, K. Y.; Usui, K.; Mihara, H. Protein-detecting microarrays: Current
accomplishments and requirements. Chembiochem 2005, 6, 783-799.
(151) Austin, R. P.; Barton, P.; Mohmed, S.; Riley, R. J. The binding of drugs to
hepatocytes and its relationship to physicochemical properties. Drug
Metabolism and Disposition 2005, 33, 419-425.
(152) Johnsson, B.; Lofas, S.; Lindquist, G. Immobilization of proteins to a
carboxymethyldextran-modified gold surface for biospecific interaction
analysis in surface plasmon resonance sensors. Anal Biochem 1991, 198, 268-
277.
LITERATURE
211
(153) Kortt, A. A.; Oddie, G. W.; Iliades, P.; Gruen, L. C.; Hudson, P. J.
Nonspecific amine immobilization of ligand can Be a potential source of error
in BIAcore binding experiments and may reduce binding affinities. Anal
Biochem 1997, 253, 103-111.
(154) Yoshitani, N.; Satou, K.; Saito, K.; Suzuki, S.; Hatanaka, H. et al. A structure-
based strategy for discovery of small ligands binding to functionally unknown
proteins: combination of in silico screening and surface plasmon resonance
measurements. Proteomics 2005, 5, 1472-1480.
(155) Canziani, G. A.; Klakamp, S.; Myszka, D. G. Kinetic screening of antibodies
from crude hybridoma samples using Biacore. Anal Biochem 2004, 325, 301-
307.
(156) Biacore Sensor Surface Handbook; Biacore AB: Uppsala, 2003.
(157) Kindermann, M.; George, N.; Johnsson, N.; Johnsson, K. Covalent and
selective immobilization of fusion proteins. J Am Chem Soc 2003, 125, 7810-
7811.
(158) Huber, W.; Perspicace, S.; Kohler, J.; Muller, F.; Schlatter, D. SPR-based
interaction studies with small molecular weight ligands using hAGT fusion
proteins. Anal Biochem 2004, 333, 280-288.
(159) Kwon, Y.; Coleman, M. A.; Camarero, J. A. Selective immobilization of
proteins onto solid supports through split-intein-mediated protein trans-
splicing. Angewandte Chemie-International Edition 2006, 45, 1726-1729.
(160) Cohen, N. S.; Chang, A. C. Y.; Boyer, H. W.; B., H. R. Construction of
Biologically Functional Bacterial Plasmids In Vitro. PNAS 1973, 70, 3240-
3244.
(161) Glick, B.; Pasternack, J. Molecular Biotechnology; American Society for
Microbiology, 1998.
(162) Liguori, L.; Marques, B.; Villegas-Mendez, A.; Rothe, R.; Lenormond, J. L.
Production of membrane proteins using cell-free expression systems. Expert
Review of Proteomics 2007, 4, 79-90.
(163) O'Reilly, D.; Miller, L.; Luckow, V. Baculovirus Expression Vectors; Oxford
University Press, 1994.
(164) Kost, T. A.; Condreay, J. P.; Jarvis, D. L. Baculovirus as versatile vectors for
protein expression in insect and mammalian cells. Nature Biotechnology 2005,
23, 567-575.
(165) Rich, R. L.; Myszka, D. G. Advances in surface plasmon resonance biosensor
analysis. Curr Opin Biotechnol 2000, 11, 54-61.
(166) Herfurth, L.; Ernst, B.; Wagner, B.; Ricklin, D.; Strasser, D. S. et al.
Comparative epitope mapping with saturation transfer difference NMR of
sialyl Lewis(a) compounds and derivatives bound to a monoclonal antibody.
Journal of Medicinal Chemistry 2005, 48, 6879-6886.
(167) Sachin, S. Exploring the carbohydrate-binding properties of myelin-associated
glycoprotein (MAG) and its ligands by a dynamic integrated approach. In
Institute for Molecular Pharmacy; University of Basel: Basel, 2006.
(168) Cline, J.; Braman, J. C.; Hogrefe, H. H. PCR fidelity of Pfu DNA polymerase
and other thermostable DNA polymerases. Nucleic Acids Research 1996, 24,
3546-3551.
LITERATURE
212
(169) Sambrook, J.; Frisch, E.; Maniatis, T. Molecular Cloning: A Laboratory
Manual; Cold Spring Harbor Press: New York, 1989.
(170) Invitrogen Bac-to-Bac Baculovirus Expression System Instruction Manual.
2002.
(171) Kang, D. H.; Gho, Y. S.; Suh, M. K.; Kang, C. H. Highly sensitive and fast
protein detection with coomassie brilliant blue in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Bulletin of the Korean Chemical Society
2002, 23, 1511-1512.
(172) Malmqvist, M. Biospecific interaction analysis using biosensor technology.
Nature 1993, 361, 186-187.
(173) (www.researchandmarkets.com/reportinfo.asp?report_id=75046).
(174) Rye, P. D.; Bovin, N. V.; Vlasova, E. V.; Molodyk, A. A.; Baryshnikov, A. et
al. Summary report on the ISOBM TD-6 workshop: Analysis of 20
monoclonal antibodies against Sialyl Lewis(a) and related antigens -
Montreux, Switzerland, September 19-24, 1997. Tumor Biology 1998, 19,
390-420.
(175) Geffen, I.; Spiess, M. Asialoglycoprotein receptor. Int Rev Cytol 1992, 137B,
181-219.
(176) Wragg, S.; Drickamer, K. Identification of amino acid residues that determine
pH dependence of ligand binding to the asialoglycoprotein receptor during
endocytosis. Journal of Biological Chemistry 1999, 274, 35400-35406.
(177) Toone, E. J. Structure and Energetics of Protein Carbohydrate Complexes.
Current Opinion in Structural Biology 1994, 4, 719-728.
(178) Mehta, P.; Cummings, R. D.; McEver, R. P. Affinity and kinetic analysis of P-
selectin binding to P-selectin glycoprotein ligand-1. J Biol Chem 1998, 273,
32506-32513.
(179) Ricklin, D. Surface plamon resonance applications in drug discovery. In
Institute for Molecular Pharmacy; University of Basel: Basel, 2005.
(180) Miura, Y.; Kim, S.; Etchison, J. R.; Ding, Y. L.; Hindsgaul, O. et al. Aglycone
structure influences alpha-fucosyltransferase III activity using N-
acetyllactosamine glycoside acceptors. Glycoconjugate Journal 1999, 16, 725-
730.
(181) Zaccai, N. R.; Maenaka, K.; Maenaka, T.; Crocker, P. R.; Brossmer, R. et al.
Structure-guided design of sialic acid-based Siglec inhibitors and
crystallographic analysis in complex with sialoadhesin. Structure (Camb)
2003, 11, 557-567.
(182) Davis, T. M.; Wilson, W. D. Determination of the refractive index increments
of small molecules for correction of surface plasmon resonance data.
Analytical Biochemistry 2000, 284, 348-353.
(183) Catimel, B.; Nerrie, M.; Lee, F. T.; Scott, A. M.; Ritter, G. et al. Kinetic
analysis of the interaction between the monoclonal antibody A33 and its
colonic epithelial antigen by the use of an optical biosensor. A comparison of
immobilisation strategies. J Chromatogr A 1997, 776, 15-30.
(184) Darling, R. J.; Kuchibhotla, U.; Glaesner, W.; Micanovic, R.; Witcher, D. R.
et al. Glycosylation of erythropoietin affects receptor binding kinetics: role of
electrostatic interactions. Biochemistry 2002, 41, 14524-14531.
LITERATURE
213
(185) Rich, R. L.; Myszka, D. G. BIACORE J: a new platform for routine
biomolecular interaction analysis. J Mol Recognit 2001, 14, 223-228.
(186) Catimel, B.; Scott, A. M.; Lee, F. T.; Hanai, N.; Ritter, G. et al. Direct
immobilization of gangliosides onto gold-carboxymethyldextran sensor
surfaces by hydrophobic interaction: applications to antibody characterization.
Glycobiology 1998, 8, 927-938.
(187) Terada, T.; Nishikawa, M.; Yamashita, F.; Hashida, M. Analysis of the
molecular interaction of glycosylated proteins with rabbit liver
asialoglycoprotein receptors using surface plasmon resonance spectroscopy.
Journal of Pharmaceutical and Biomedical Analysis 2006, 41, 966-972.
(188) Bohm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B. et al. Fluorine in
medicinal chemistry. Chembiochem 2004, 5, 637-643.
(189) Sinnokrot, M. O.; Sherrill, C. D. Substituent effects in pi-pi interactions:
Sandwich and T-shaped configurations. Journal of the American Chemical
Society 2004, 126, 7690-7697.
(190) Myszka, D. G.; Sweet, R. W.; Hensley, P.; Brigham-Burke, M.; Kwong, P. D.
et al. Energetics of the HIV gp120-CD4 binding reaction. Proceedings of the
National Academy of Sciences of the United States of America 2000, 97, 9026-
9031.
(191) Ruben, A. J.; Kiso, Y.; Freire, E. Overcoming roadblocks in lead optimization:
A thermodynamic perspective. Chemical Biology & Drug Design 2006, 67, 2-
4.
(192) Ringer, A. L.; Sinnokrot, M. O.; Lively, R. P.; Sherrill, C. D. The effect of
multiple substituents on sandwich and T-Shaped pi-pi interactions. Chemistry-
a European Journal 2006, 12, 3821-3828.
(193) Hajduk, P. J.; Olejniczak, E. T.; Fesik, S. W. One-dimensional relaxation- and
diffusion-edited NMR methods for screening compounds that bind to
macromolecules. Journal of the American Chemical Society 1997, 119, 12257-
12261.
(194) Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay et al. The SHAPES
strategy: an NMR-based approach for lead generation in drug discovery.
Chemistry & Biology 1999, 6, 755-769.
(195) Meyer, B.; Weimar, T.; Peters, T. Screening mixtures for biological activity by
NMR. European Journal of Biochemistry 1997, 246, 705-709.
(196) Jahnke, W.; Perez, L. B.; Paris, C. G.; Strauss, A.; Fendrich, G. et al. Second-
site NMR screening with a spin-labeled first ligand. Journal of the American
Chemical Society 2000, 122, 7394-7395.
(197) Geiser, M.; Cebe, R.; Drewello, D.; Schmitz, R. Integration of PCR fragments
at any specific site within cloning vectors without the use of restriction
enzymes and DNA ligase. Biotechniques 2001, 31, 88-90, 92.
APPENDIX I
214
APPENDIX
SH-019
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
SH-164
O
CO2Na
O
H
N
AcHN
HO
OH
OH
CH3
O
SH-081
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
Cl
SH-082
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
Cl
Cl
SH-035
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
APPENDIX I
215
SH-140
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
O2N
SH-141
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
Cl
Cl
SH-142
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
F3C
SH-143
O
CO2Na
O
H
N
AcHN
HO
OH
OH
O
Cl
SM-I3
OO
H
N
AcHN
HO
OH
OH CO2Na
O
Cl
Cl
Cl
SM-I4
OO
H
N
AcHN
HO
OH
OH CO2Na
O
Cl
F
F
APPENDIX I
216
SH-264
OO
H
N
AcHN
HO
OH
OH CO2Na
O
SH-218
OO
H
N
AcHN
HO
OH
OH CO2Na
O
SH-192
OO
H
N
AcHN
HO
OH
OH CO2Na
O
SH-246
SH-2-6
OAcHN
HO
CO2H
H
N
OH
OH
OO
N N
NH
SH-272
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N N
N
H
N
NO2
OO
H
N
AcHN
HO
OH
OH CO2Na
O
APPENDIX I
217
SH-281
OO
H
N
AcHN
HO
OH
OH CO2Na
O
N N
N
H
N
NO2
SH-267
N
H
NO2
N3
SM-m5
H
N
HO
O
COONa
O
OH
OHHN
O
O
F
F
O
Cl
SM-m6
H
N
HO
O
COONa
O
OH
OHHN
F
O
F
F
O
Cl
BG-PEG3
N
NN
N
H
O
O
NH2
O
NH2
3
BG-PEG12
N
NN
N
H
O
O
NH2
O
NH2
12
APPENDIX I
218
Carboxy-BG
N
NN
N
H
O
NH2
NH2
O
HO
Sulfo-BG
N
NN
N
H
O
NH2
NH2HO2S
Gluco-BG
N
NN
N
H
O
NH2
NH2
NN
N
N
H
O
HO O
OH
OH
HO
APPENDIX II
219
pSS26b
APPENDIX II
220
SNAP expressed in insect cells
  1 ATGCTACTAG TAAATCAGTC ACACCAAGGC TTCAATAAGG AACACACAAG CAAGATGGTA
 61 AGCGCTATTG TTTTATATGT GCTTTTGGCG GCGGCGGCGC ATTCTGCCTT TGCGTCTAGA
121 ATGGACAAAG ATTGCGAAAT GAAACGTACC ACCCTGGATA GCCCGCTGGG CAAACTGGAA
181 CTGAGCGGCT GCGAACAGGG CCTGCATGAA ATTAAACTGC TGGGTAAAGG CACCAGCGCG
241 GCCGATGCGG TTGAAGTTCC GGCCCCGGCC GCCGTGCTGG GTGGTCCGGA ACCGCTGATG
301 CAGGCGACCG CGTGGCTGAA CGCGTATTTT CATCAGCCGG AAGCGATTGA AGAATTTCCG
361 GTTCCGGCGC TGCATCATCC GGTGTTTCAG CAGGAGAGCT TTACCCGTCA GGTGCTGTGG
421 AAACTGCTGA AAGTGGTTAA ATTTGGCGAA GTGATTAGCT ATCAGCAGCT GGCGGCCCTG
481 GCGGGTAATC CGGCGGCCAC CGCCGCCGTT AAAACCGCGC TGAGCGGTAA CCCGGTGCCG
541 ATTCTGATTC CGTGCCATCG TGTGGTTAGC TCTAGCGGTG CGGTTGGCGG TTATGAAGGT
601 GGTCTGGCGG TGAAAGAGTG GCTGCTGGCC CATGAAGGTC ATCGTCTGGG TAAACCGGGT
661 CTGGGAGACT ACAAGGACGA TGACGATAAG TAATAGCTCG AG
Signal sequence
SNAP
FLAG
Stop
Restriction sites
  1 SRMDKDCEMK RTTLDSPLGK LELSGCEQGL HEIKLLGKGT SAADAVEVPA
 51 PAAVLGGPEP LMQATAWLNA YFHQPEAIEE FPVPALHHPV FQQESFTRQV
101 LWKLLKVVKF GEVISYQQLA ALAGNPAATA AVKTALSGNP VPILIPCHRV
151 VSSSGAVGGY EGGLAVKEWL LAHEGHRLGK PGLGDYKDDD DK
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MAG(d1-3)-SNAP expressed in insect cells
   1 ATGCTACTAG TAAATCAGTC ACACCAAGGC TTCAATAAGG AACACACAAG CAAGATGGTA
  61 AGCGCTATTG TTTTATATGT GCTTTTGGCG GCGGCGGCGC ATTCTGCCTT TGCGTCTAGA
 121 GGCCACTGGG GTGCCTGGAT GCCCTCGACC ATCTCAGCCT TCGAGGGCAC GTGTGTCTCC
 181 ATTCCCTGCC GTTTCGACTT CCCCGATGAG CTCAGACCGG CTGTGGTACA TGGCGTCTGG
 241 TATTTCAATA GTCCCTACCC CAAGAACTAC CCACCGGTGG TCTTCAAGTC CCGCACACAA
 301 GTGGTCCATG AGAGTTTCCA GGGCCGCAGC CGCCTATTGG GAGACCTGGG CCTACGAAAC
 361 TGTACCCTGC TTCTCAGCAC ACTGAGCCCC GAGCTGGGAG GCAAATACTA TTTCCGAGGC
 421 GACCTGGGTG GCTACAACCA GTACACCTTC TCGGAGCACA GCGTCCTGGA CATCGTCAAC
 481 ACCCCCAACA TTGTGGTTCC CCCGGAAGTG GTGGCAGGAA CGGAAGTGGA GGTCAGTTGT
 541 ATGGTGCCGG ACAACTGCCC AGAGCTGCGG CCAGAGCTGA GCTGGCTGGG CCACGAGGGG
 601 CTGGGAGAGC CCACTGTGCT GGGTCGGCTG CGTGAGGATG AAGGCACCTG GGTGCAGGTG
 661 TCGCTGCTAC ACTTCGTGCC TACTAGAGAG GCCAACGGCC ACCGTCTGGG CTGTCAGGCT
 721 GCCTTCCCCA ACACCACCTT GCAGTTCGAG GGTTACGCCA GTTTGGACGT CAAGTACCCC
 781 CCAGTGATTG TGGAGATGAA TTCCTCTGTG GAGGCCATTG AGGGCTCCCA TGTCAGCCTG
 841 CTCTGTGGGG CTGACAGCAA CCCGCCGCCG CTGCTGACTT GGATGCGGGA TGGGATGGTG
 901 TTGAGGGAGG CAGTTGCCAA GAGCCTGTAC CTGGATCTGG AGGAGGTGAC CCCAGGAGAG
 961 GACGGCGTCT ATGCTTGCCT AGCAGAGAAC GCCTATGGCC AGGACAACCG CACGGTGGAG
1021 CTGAGTGTCA TGTATGCAAA GCTTGATATC GAATTCCCCA TGGACAAAGA TTGCGAAATG
1081 AAACGTACCA CCCTGGATAG CCCGCTGGGC AAACTGGAAC TGAGCGGCTG CGAACAGGGC
1141 CTGCATGAAA TTAAACTGCT GGGTAAAGGC ACCAGCGCGG CCGATGCGGT TGAAGTTCCG
1201 GCCCCGGCCG CCGTGCTGGG TGGTCCGGAA CCGCTGATGC AGGCGACCGC GTGGCTGAAC
1261 GCGTATTTTC ATCAGCCGGA AGCGATTGAA GAATTTCCGG TTCCGGCGCT GCATCATCCG
1321 GTGTTTCAGC AGGAGAGCTT TACCCGTCAG GTGCTGTGGA AACTGCTGAA AGTGGTTAAA
1381 TTTGGCGAAG TGATTAGCTA TCAGCAGCTG GCGGCCCTGG CGGGTAATCC GGCGGCCACC
1441 GCCGCCGTTA AAACCGCGCT GAGCGGTAAC CCGGTGCCGA TTCTGATTCC GTGCCATCGT
1501 GTGGTTAGCT CTAGCGGTGC GGTTGGCGGT TATGAAGGTG GTCTGGCGGT GAAAGAGTGG
1561 CTGCTGGCCC ATGAAGGTCA TCGTCTGGGT AAACCGGGTC TGGGAGACTA CAAGGACGAT
1621 GACGATAAGT AATAGCTCGA G
Signal sequence
MAG
SNAP
Flag
Stop
Restriction sites
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Proposed amino acids forming the active site are indicated in yellow (ref) and
distribution of lysine within the v-domaine are highlighted in green.
1 SRGHWGAWMP STISAFEGTC VSIPCRFDFP DELRPAVVHG VWYFNSPYPK
51 NYPPVVFKSR TQVVHESFQG RSRLLGDLGL RNCTLLLSTL SPELGGKYYF
101 RGDLGGYNQY TFSEHSVLDI VNTPNIVVPP EVVAGTEVEV SCMVPDNCPE
151 LRPELSWLGH EGLGEPTVLG RLREDEGTWV QVSLLHFVPT REANGHRLGC
201 QAAFPNTTLQ FEGYASLDVK YPPVIVEMNS SVEAIEGSHV SLLCGADSNP
251 PPLLTWMRDG MVLREAVAKS LYLDLEEVTP GEDGVYACLA ENAYGQDNRT
301 VELSVMYAKL DIEFPMDKDC EMKRTTLDSP LGKLELSGCE QGLHEIKLLG
351 KGTSAADAVE VPAPAAVLGG PEPLMQATAW LNAYFHQPEA IEEFPVPALH
401 HPVFQQESFT RQVLWKLLKV VKFGEVISYQ QLAALAGNPA ATAAVKTALS
451 GNPVPILIPC HRVVSSSGAV GGYEGGLAVK EWLLAHEGHR LGKPGLGDYK
501 DDDDK
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MAG(d1-3)-SNAP expressed in mammalian cells
       M  I   F  L  A   T  L  P   L  F  W  I   M  I  S ·
       1 TCTAGAATGA TATTCCTCGC CACCCTGCCG CTGTTTTGGA TAATGATTTC
· A  S  R   G  G  H  W   G  A  W   M  P  S   T  I  S  A ·
      51 AGCTTCTCGA GGGGGCCACT GGGGTGCCTG GATGCCCTCG ACCATCTCAG
·  F  E  G   T  C  V   S  I  P  C   R  F  D   F  P  D
     101 CCTTCGAGGG CACGTGTGTC TCCATTCCCT GCCGTTTCGA CTTCCCCGAT
 E  L  R  P   A  V  V   H  G  V   W  Y  F  N   S  P  Y ·
     151 GAGCTCAGAC CGGCTGTGGT ACATGGCGTC TGGTATTTCA ATAGTCCCTA
· P  K  N   Y  P  P  V   V  F  K   S  R  T   Q  V  V  H ·
     201 CCCCAAGAAC TACCCACCGG TGGTCTTCAA GTCCCGCACA CAAGTGGTCC
·  E  S  F   Q  G  R   S  R  L  L   G  D  L   G  L  R
     251 ATGAGAGTTT CCAGGGCCGC AGCCGCCTAT TGGGAGACCT GGGCCTACGA
 N  C  T  L   L  L  S   T  L  S   P  E  L  G   G  K  Y ·
     301 AACTGTACCC TGCTTCTCAG CACACTGAGC CCCGAGCTGG GAGGCAAATA
· Y  F  R   G  D  L  G   G  Y  N   Q  Y  T   F  S  E  H ·
     351 CTATTTCCGA GGCGACCTGG GTGGCTACAA CCAGTACACC TTCTCGGAGC
·  S  V  L   D  I  V   N  T  P  N   I  V  V   P  P  E
     401 ACAGCGTCCT GGACATCGTC AACACCCCCA ACATTGTGGT TCCCCCGGAA
 V  V  A  G   T  E  V   E  V  S   C  M  V  P   D  N  C ·
     451 GTGGTGGCAG GAACGGAAGT GGAGGTCAGT TGTATGGTGC CGGACAACTG
· P  E  L   R  P  E  L   S  W  L   G  H  E   G  L  G  E ·
     501 CCCAGAGCTG CGGCCAGAGC TGAGCTGGCT GGGCCACGAG GGGCTGGGAG
·  P  T  V   L  G  R   L  R  E  D   E  G  T   W  V  Q
     551 AGCCCACTGT GCTGGGTCGG CTGCGTGAGG ATGAAGGCAC CTGGGTGCAG
 V  S  L  L   H  F  V   P  T  R   E  A  N  G   H  R  L ·
     601 GTGTCGCTGC TACACTTCGT GCCTACTAGA GAGGCCAACG GCCACCGTCT
· G  C  Q   A  A  F  P   N  T  T   L  Q  F   E  G  Y  A ·
     651 GGGCTGTCAG GCTGCCTTCC CCAACACCAC CTTGCAGTTC GAGGGTTACG
·  S  L  D   V  K  Y   P  P  V  I   V  E  M   N  S  S
     701 CCAGTTTGGA CGTCAAGTAC CCCCCAGTGA TTGTGGAGAT GAATTCCTCT
 V  E  A  I   E  G  S   H  V  S   L  L  C  G   A  D  S ·
     751 GTGGAGGCCA TTGAGGGCTC CCATGTCAGC CTGCTCTGTG GGGCTGACAG
· N  P  P   P  L  L  T   W  M  R   D  G  M   V  L  R  E ·
     801 CAACCCGCCG CCGCTGCTGA CTTGGATGCG GGATGGGATG GTGTTGAGGG
·  A  V  A   K  S  L   Y  L  D  L   E  E  V   T  P  G
     851 AGGCAGTTGC CAAGAGCCTC TACCTGGATC TGGAGGAGGT GACCCCAGGA
 E  D  G  V   Y  A  C   L  A  E   N  A  Y  G   Q  D  N ·
     901 GAGGACGGCG TCTATGCTTG CCTAGCAGAG AACGCCTATG GCCAGGACAA
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· R  T  V   E  L  S  V   M  Y  A         L   E  V  L  F ·
     951 CCGCACGGTG GAGCTGAGTG TCATGTATGC AGGATCCCTG GAGGTGCTGT
·  Q  G  P   M  D  K   D  C  E  M   K  R  T   T  L  D
    1001 TCCAGGGCCC CATGGACAAA GATTGCGAAA TGAAACGTAC CACCCTGGAT
 S  P  L  G   K  L  E   L  S  G   C  E  Q  G   L  H  E ·
    1051 AGCCCGCTGG GCAAACTGGA ACTGAGCGGC TGCGAACAGG GCCTGCATGA
· I  K  L   L  G  K  G   T  S  A   A  D  A   V  E  V  P ·
    1101 AATTAAACTG CTGGGTAAAG GCACCAGCGC GGCCGATGCG GTTGAAGTTC
·  A  P  A   A  V  L   G  G  P  E   P  L  M   Q  A  T
    1151 CGGCCCCGGC CGCCGTGCTG GGTGGTCCGG AACCGCTGAT GCAGGCGACC
 A  W  L  N   A  Y  F   H  Q  P   E  A  I  E   E  F  P ·
    1201 GCGTGGCTGA ACGCGTATTT TCATCAGCCG GAAGCGATTG AAGAATTTCC
· V  P  A   L  H  H  P   V  F  Q   Q  E  S   F  T  R  Q ·
    1251 GGTTCCGGCG CTGCATCATC CGGTGTTTCA GCAGGAGAGC TTTACCCGTC
·  V  L  W   K  L  L   K  V  V  K   F  G  E   V  I  S
    1301 AGGTGCTGTG GAAACTGCTG AAAGTGGTTA AATTTGGCGA AGTGATTAGC
 Y  Q  Q  L   A  A  L   A  G  N   P  A  A  T   A  A  V ·
    1351 TATCAGCAGC TGGCGGCCCT GGCGGGTAAT CCGGCGGCCA CCGCCGCCGT
· K  T  A   L  S  G  N   P  V  P   I  L  I   P  C  H  R ·
    1401 TAAAACCGCG CTGAGCGGTA ACCCGGTGCC GATTCTGATT CCGTGCCATC
·  V  V  S   S  S  G   A  V  G  G   Y  E  G   G  L  A
    1451 GTGTGGTTAG CTCTAGCGGT GCGGTTGGCG GTTATGAAGG TGGTCTGGCG
 V  K  E  W   L  L  A   H  E  G   H  R  L  G   K  P  G ·
    1501 GTGAAAGAGT GGCTGCTGGC CCATGAAGGT CATCGTCTGG GTAAACCGGG
· L  G                      W  S   H  P  Q   F  E  K
    1551 TCTGGGAGAA TTCGATATCG GTACCTGGAG CCACCCGCAG TTCGAAAAAT
    1601 AACCCGGG
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